 
 
 
 
 
TITLE PAGE  
 
Divisio n:  Worldwide De velopment 
Informat ion Type: Clinical P rotocol CONF IDENTIAL  
 
 
 
 
 
Title:  [A Pha se II Open-Labe l, Two-Arm Study of the MEK  Inhibi tor, 
Trametin ib, To  Investigate the  Safety a nd Anti -Can cer Activit y 
in Subjects with  Melanoma with BRAF  non-V600 Mut ations] 
 
 
Compo und 
Number(s): GSK1120212 
 
Vanderbilt -Ingram   
Cancer Center (VICC)    
Coordinating Center 
Protocol Number :  VICC MEL 1457  
 
Deve lopment Ph ase: II 
 
 
Description: This stu dy is a Pha se II, open- label, multi-site two -arm stu dy de signed to 
determine the activity an d safety of orally a dministered MEK inhibit or trametin ib 
(GSK1120212), in subj ects with melanoma  harboring  mutations in  BRAF a t locations 
other  than c odon 600 (BRA FnonV600MUT) or BR AF fusion s.  The  study will a lso 
evaluate  the effect of th erapy on tumor biomarkers.  All patients will r eceive tr ametinib 
2mg orally a dminist ered once daily. Cohort A will  consist of subj ects with melanoma 
harbouring mu tations which have high or  interme diate in trinsic cata lytic activity a nd/or 
which previous ly been described sensitive to M EK inhib itors in pr e-clinical and/or 
clinical studies (L597, K601E, G469A, E586K, F595L) a s well as B RAF f usion s. Cohort 
B will  consist of subj ects with melanoma  harbouri ng mutations tha t have  previous ly bee n 
shown to have  low af finity  for MEK phosphory lation a nd low  intrinsic ca talytic activit y 
and/or low s ensitivity to MEK inh ibitors from p revious studie s (D594V, G466V, G496R 
etc), or fo r which the  catalytic activity a nd eff ects on se nsitizati on to MEK  inhibitors is 
unknown . The  primary endpoint is obje ctive response rate to trameti nib for patie nts in 
Cohort A ; secondary end points include objective response rates in  Cohort B, safety, 
progression free survival a nd ov erall surviva l in both treatme nt arms. 
 
Subj
ect: MEK inhib itor, tr ametin ib, GSK1120212, B RAFV600 wild type, B RAF  non- 
V600 mutant, NRAS wild type, c utaneous m elanoma 
 
Autho r(s):  Johnson, Dou glas B; Flaherty Keit h T; Sosman  Jeffrey A; Davies, Mich ael 
A. 
 Copyright Novartis, 2015. All rights reserve d. Un authori zed copying or use of this infor mation is prohibi ted. 
 
  
 
  
Versi on Date: February 12, 2016 1 
CONFIDENTIAL 
Version Date: February 12, 2016  2  
  
 
 
 
COORDINATING CENTER / MEDI CAL MONIT OR INFORMATI ON PAGE 
 
Medical Mon itor and Sp onsor Contact Inform ation: 
 
Role Name Day Time 
Phone  
Number After-hours  
Phone/Cell
/ Pager 
Number  Fax Number  Address  
Primary 
Medical 
Mon itor Douglas B 
Johnson, 
MD     Vanderbilt -Ingram Cancer 
Center  
2220 Pierce Ave. 777 PRB  
Nashville, TN 37232  
Seconda ry 
Medical 
Mon itor     Novartis  
One Health Plaza,  
East Hanover, NJ 07936  
 
 
Supporter      National Compr ehensive  Can cer Ne twork  (NCCN) 
275 Commerce Dr ive, S uite 300 
     Fort Washington, P A  19034 
 
    
   Novartis  
   One Health Plaza,  
   East Hanover, NJ 07936 
 Coordinating Center   Vanderbilt -Ingram Cancer Center (VICC)  
    Multi -Institutional Coordinating Office  
Phone: (615) 936 -5770 
Facsimile:  (615) 875-0040 
 Protocol Chair    Douglas B Johnson, MD 
     Vanderbilt -Ingram Cancer Center  
2220 Pierce Ave. 777 PRB Nashville, TN 37232 
 
CONFIDENTIAL 
Version Date: February 12, 2016  3  
  
 
Regulato ry Agenc y Identifying Numb er(s): 
 
Compoun d Number IND Numb er EudraCT Numb er 
GSK1120212 Exempt   
CONFIDENTIAL 
Version Date: February 12, 2016  4  
  
 
INVESTIGAT OR P ROTOCOL AGREEMEN T PAGE 
 
Title:  [A Pha se II Open-Labe l, Two-Arm Study of the MEK  Inhibi tor, 
Trametin ib, To  Investigate the  Safety a nd Anti -Can cer Activit y in 
Subjects with  Melanoma with BRAF  non-V600 Mut ations] 
Vanderbilt -Ingram   
Cancer Center (VICC)    
Coordinating Center 
Protocol Number :  VICC MEL 1457  
 
 
• I c onfirm agreement to conduc t the study in com pliance with t he proto col. 
 
• I ac knowl edge that I a m responsi ble for overa ll study conduc t. I agree to 
personally conduc t or s upervise  the d escribed cli nical study. 
 
• I ag ree to ensu re that a ll associ ates, c olleagues and employee s assis ting in the 
conduc t of the  study are infor med about the ir obligati ons. M echanisms are in 
place to ensure that site s taff receives the appropriate information throughout t he 
study. 
 
Investigator Name:  
Investigator Address:  
Investigator Phone  Number:  
  
Investigator S ignature Date 
CONFIDENTIAL 
Version Date: February 12, 2016  5  
  
 
TABL E OF CONTENTS  
 
PAGE  
 
LIST  OF ABBREVIAT IONS ........................................................................................... 9 
 
1. INTRO DUCTI ON............................... ................................................................. .... 12 
1.1. B ackground ............................................................................................... . 12 
1.2. Trametinib ............................................................................................... .... 13 
 1.2.1. Trametinib Background............................................................... . 13 
1.2.2. Pharmacokinetics of Trametinib in Humans ............................... .. 14 
1.2.3. Clinical Safety of Trametinib ....................................................... . 14 
1.2.4. Clinical Activity of Trametinib ...................................................... . 14 
1.3. Ration 
1.3.1. ale in p opulation .............................................................................. . 15 
Rationale for targeted therapy  in BRAF non V600EMUT 
  melanoma................................................................................... . 15 
 1.3.2. Rationale for study cohorts ......................................................... . 15 
 
2. OBJ ECTIVES AN D ENDP OINTS ............................................................... ........... . 16 
 
3. INVESTIGA TIONAL PLAN .................................................................................... . 17 
3.1. Discussi on of Study D esign an d Study S chematic ................................ ...... 17 
3.2. Treatmen t Schedule .................................................................................. . 19 
3.3. Gen etic Analysis ........................................................................................ . 19 
3.4. Prod uct Dosing/A dministration................................................................ .... 19 
3.5. R ationale ............................... ................................................................. .... 20 
3.5.1. R ationale for Study ............................................................... ....... 20 
3.5.2. R ationale for Popul ation.............................................................. . 20 
3.5.3. R ationale for Dose ................................................................ ....... 20 
3.5.4. R ationale for Endp oints............................................................... . 20 
3.6. Study Treatment ........................................................................................ . 21 
3.7. D osage an d Administration of Study Trea tment ............................... ........... 21 
3.7.1. Meals an d Dietary R estrictions ................................................... . 21 
3.7.2. Blindin g....................................................................................... . 21 
3.8. Safety Manag ement Guid elines ............................................................... ... 21 
3.8.1. D ose L evels of trametinib ............................................................ 22 
3.8.2. Gen eral Guid elines for C linically Significant Toxic ities ................. 22 
3.9. D ose Modification Guid elines f or Trametini b Adv erse Events of 
Speci al Interest .......................................................................................... . 23 
3.9.1. Guid elines f or Cardiov ascul ar Adverse Events ........................... . 23 
3.9.1. 1. Lef t Ventricular Ejecti on Fraction (L VEF)  .................... 23 
3.9.1.2. Hype rtension .............................................................. 24 
3.9.2. Guid elines f or Visual Chang es ..................................................... 27 
3.9.3. Pne umon itis Manag ement Guid elines............................... .......... . 29 
3.10.  Dose M odifications for Trametini b and  supportiv e care ............................... 31 
3.10.1. Liv er Chemis try Stoppin g Crite ria ............................................... . 31 
3.9.1. 1. Liv er Chemis try Follow-u p Procedur es ....................... 31 
3.10.2. Guid elines f or Prolong ed QTc ..................................................... . 33 
3.10.3. Guid elines f or Rash ............................................................... ...... 34 
3.10.4. Guid elines f or Diarrhea ............................................................... . 35 
CONFIDENTIAL 
Version Date: February 12, 2016  6  
  
 
 
 
 
4. INVESTIGA TIONAL PRODUCT(S)  ................................................................ ........ 37 
4.1. Descripti on of Investigation al Prod uct and/or Compar ators/Placebo ........... 37 
4.1.1. Trametinib ................................................................................... . 37 
4.2. Prep aration/Hand ling/St orage of Trametinib .............................................. . 37 
4.3. Prod uct Accou ntabili ty ............................................................................... . 37 
4.4. Treatmen t Compliance............................................................................... . 38 
4.5. Treatmen t of Inv estigational Prod uct Overdose ............................... ........... 38 
 
5. ST UDY POPULATION .......................................................................................... . 38 
5.1. N umber  of Subjects ................................................................................... . 38 
5.2. Subj ect Selection Criteria............................................................... ............. 39 
5.2.1. I nclusion Criteria ............................................................... .......... . 39 
5.2.2. Excl usion Criteria ............................................................... ......... . 40 
 
6. CO MPLETION OR WITHDR AWAL OF SUBJECTS .............................................. . 42 
 6.1. Screen and  Baseline Fa ilures ............................................................... ...... 42 
 6.2. Subject Completion Criteria ............................................................... ......... 42 
 6.3. Permanent Discontinuation from Study Treatment ............................... ....... 42 
 6.4. Study Completion ...................................................................................... . 43 
 6.5. Treatment after the End of the Study ......................................................... . 43 
 
7. ST UDY ASSESSM ENTS AND PROCEDURE S................................................... 44 
7.1. Time an d Events Ta ble .............................................................................. . 44 
7.2. D emograph ic/Medical History and Bas eline Assessments ......................... . 48 
7.3. Safety Evaluations ..................................................................................... . 49 
7.3.1. Physi cal Examinations ............................................................... .. 49 
7.3.2. ECOG Performan ce Status ......................................................... . 49 
7.3.3. Vital Signs................................................................................... . 49 
7.3.4. Electrocardiogra m (ECG )............................................................ . 49 
7.3.5. E chocardiogr am (ECHO ) and/or Mul ti-gated Acquisiti on 
(MUGA) S cans............................................................... ............. . 49 
7.3.6. Brai n MRI an d/or CT Scan .......................................................... . 50 
7.3.7. Labor atory Assessments ............................................................ . 50 
7.3.8. Ophthalmic Ex amination ............................................................. . 51 
7.3.9 Pregna ncy Testi ng and Reporting ................................................ 52 
7.4. B aselin e documen tation of target and non-target l esions ........................... . 52 
7.5. E fficacy ................................ ............................................................... ........ 53 
7.5.1. Assessmen t Guid elines .............................................................. . 54 
7.5.2. Mea surab le and Non-me asura ble Definitions......................................55  
7.5.3. R esponse Crit eria ................................................................ ........ 56 
7.5.3. 1. Targe t Lesions ............................................................ 56 
7.5.3. 2. Non-Targ et Lesions .................................................... 57 
7.5.3. 3. N ew Lesions ............................................................... 57 
7.5.3. 4. Evaluati on of  overall respo nse................................ .... 58 
7.5.3. 5. Evaluati on of  best overal l response ............................ 58 
CONFIDENTIAL 
Version Date: February 12, 2016  7  
  
  
 
  
 
7.6. Tra nslational Research .............................................................................. . 59 
7.6.1. Tum or Tissue  for Genetic an d Protein Biomarker Analysis .......... 60 
7.6.2. Blood Biomarkers ................................................................ ........ 61 
 
8. ADVERSE EVENT S AN D SERIOUS ADVERSE EVENTS ................................ ..... 61 
8.1. Definiti on of an AE ..................................................................................... . 61 
8.2. Definiti on of an SAE................................................................................... . 62 
8.2.1. Sentine l Events ............................................................... ............ . 63 
8.3. Labor atory and Other Saf ety Assessmen t Abno rmalities Reported 
as AEs and SAEs ...................................................................................... . 64 
8.3.1. C ardiovascular Events ............................................................... .. 64 
8.4. Disease-Related Events an d/or Disease-Rel ated O utcomes Not 
Qualifying as SAEs .................................................................................... . 64 
8.5. Time P eriod and  Fre quency of D etecting AEs and SAEs ........................... . 65 
8.5.1. Pr ompt Reporting of SAEs and Other Events to Vanderbilt  
.................. 65 
8.5.2. Regul atory reporti ng requirements f or SAEs ................................ 67 
 
9. LIVER CHE MISTR Y FOLLOW-UP PROCEDURE S .............................................. . 67 
9.1. Liv er Chemis try Testing Pr ocedures .......................................................... . 67 
9.2. Liv er Chemis try Mo nitoring Crite ria ............................................................ . 69 
9.3. Dr ug Restart/R echallenge Following Liver Events tha t are Possibly 
Related to Study Dru g(s) ............................................................... ............. 69 
9.4. Dr ug Restart Following Trans ient, Resolving Liver Events N ot 
Related to Study Dru g(s) ............................................................... ............. 70 
 
10.  CONCOMITANT M EDICATIONS AN D NON- DRUG THERAPI ES ......................... 71 
10.1. Permitted Medication(s) ................................................................ .............. 71 
10.2. Pro hibited Medications and N on-Drug Thera pies............................... ......... 71 
 
11.  LIFESTYLE AND /OR DIETARY RESTRICTIONS ................................................. . 72 
11.1. Con traception ............................................................................................ . 72 
11.1.1. Femal e Subjects ............................................................... .......... . 72 
11.1.2. Mal e Subjects ............................................................... .............. . 73 
11.2. Lact ation Restrictions................................................................................. . 73 
 
12.  DATA MANAGEMENT ........................................................................................... 73 
 
13.  DATA ANALYSIS AND STATIS TICAL CON SIDERATIONS ............................... .... 74 
13.1. Hypothe ses............................................................................................... .. 74 
13.2. Sample Size Assump tions ............................................................... ........... 74 
13.3. Data An alysis Consider ations ................................................................ ..... 75 
13.3.1. I nterim An alysi s ............................................................... ........... . 75 
13.3.2. Fina l Analysis ............................................................... .............. . 75 
13.3.2.1. Prim ary Analysis......................................................... 75 
13.3.2.2. Secondary An alyses ................................................... 75 
13.3.2.2.1.Cohort B ............................... ............................ 75 
13.3.2.2.2.Survival ................................ ............................. 76 
13.3.2.2.3. Saf ety ................................ .............................. 76 
CONFIDENTIAL 
Version Date: February 12, 2016  8  
 13.4.1. Pharma odynamic Analyses....................................................... . 78 
 13.4.1. Translational Research Analyses .............................. . 78 
 13.4.2. Novel Biomarker Assays ............................... ............ . 78 
  
 
13.3.2.2.2. Biomar kers a nd Pharm acodynamic 
Analysis ................................ ................................ ............... 76 
13.3.3. Accrua l Considerations ............................................................... . 77 
13.3.4. Missi ng D ata ............................................................................... . 77 
13.3.5. Pr otocol Violations ............................................................... ........ 77 
13.3.6. D erived and Transforme d Data .................................................... 77 
13.3.7. Assessment Windows ............................................................... ... 77 
13.3.8. Other Issues ............................................................................... . 77 
13.4. Other Elements of An alysis Plan............................................................... .. 77 
c 
 
 
 
 
14.  STUDY CONDUCT C ONS IDERA TION S ............................................................... 78 
14.1. Posting of Informati on on  Clinicaltrials.gov................................................. . 78 
14.2. Regul atory an d Ethical Consider ations, Including the Inform ed 
Consent Pro ces s ....................................................................................... .78 
14.3. Urgent Saf ety Mea sures  ................................................................ ............. 79 
14.4. Qu ality Con trol (Study Mo nitoring) ............................................................. . 80 
14.5. Qu ality Assuranc e...................................................................................... . 80 
14.6. Study and Site Closure .............................................................................. . 81 
14.7. Records Retenti on ..................................................................................... . 81 
14.8. Provisi on of  Study R esults to Inv estigator s, Posting of Inform ation 
on Publicly Availa ble Clinical Trials Regist ers and Publicati on .................... 82 
 
15.  REFERENC ES................................ ............................................................... ........ 83 
 
APPEND ICES ................................ ............................................................................... 85 
Appendix 1:   BRAF Mutations by  Cohort .............................................................. . 85 
Appendix 2 :  NYH A Function al Classificati on System ............................... ............ . 86 
Appendix 3 :  COCKCR OFT-G AULT FORMULA ................................................... . 87 
Appendix 4:  E COG Perf ormance Status ............................................................... . 88 
Appendix 5 :  Liver Safety Dr ug Restart Guid elines ............................................... . 89 
Appendix 6 :  QT interval on e lectrocardiogr am corrected using the Baz ett’s 
formul a (QTcB) .......................................................................................... . 92 
Appendix 7 :  Medication Diary ................ . 93 
CONFIDENTIAL 
Version Date: February 12, 2016  9  
  
 
LIST OF  ABBREVIATIONS 
 
AE(s)  Adverse Event(s) 
AJCC American Joint Com mittee on C ancer 
ALT Alanine aminotransferase 
ANCOVA Analysis of covariance 
ANOVA  Analysis of Variance 
AST  Aspa rtate aminotransferase 
AUC(0-∞) Area under the concentration-time curve from time zero (pre-dose)  
extrapolat ed to infinite time 
AUC(0-x) Area under the concentration-time curve from zero (pre-dose) to some  
fixed nominal time x 
AUC(0-t) Area under the concentration-time curve from time zero (pre-dose)  to 
last t ime of  quantifiable concentration withi n a subject across a ll 
treatments 
AUC(0-τ) Area under the concentration-time curve over the dosing  interval 
β-HCG  Beta-Hum an Chorionic  Gonadotropin  
BP Blood pr essure 
BPM Beats per minute 
BUN Blood ur ea nitrogen 
CBC Comp lete blood count 
CfDNA Circulating  cell free DNA 
CI Confid ence Interval 
CL Systemic  clearance of parent drug 
CL/F Apparent clearance following  oral dos ing 
Cmax  Maximum obs erved concentration 
Cmin Mini mum obs erved concentration 
Cτ Pre-dose (trough) concentration at the end of  the dosing  interval 
CO2 Carbon dioxide 
CPK Creatine phosphokin ase 
CPMS Clinical Pharmacokinetic  Mod eling and Simulation 
CPSR Clinical Pharmacology Study Report 
CR Comp lete response  
CRO  Contr act Research Organization 
CRU  Clinical Research Unit  
CSR Clinical Study Report 
CTA  Clinical Trial Authori zation 
CTR  Clinical Trial Registry 
CV Coefficient of variance 
DBP Diastolic blood p ressure  
DILI Drug Induced Liver Injury 
DLT Dose-limiting toxicity 
DMPK  Drug Metabolism and Ph armacokinetics  
DNA  Deoxyribonu cleic acid 
ECG(s)  Electrocardiogram(s) 
ECHO  Echocardiog ram 
CONFIDENTIAL 
Version Date: February 12, 2016  10  
  
 
ECOG  Eastern Coop erative Oncology Group 
eCRF  Electronic case report form 
EDC  Electronic  data capture 
FDA Food and Drug Admin istration 
FTIH First time in hu mans 
GCP  Good Cl inical Practice 
GCSP Glob al Clinical Safety and Pharmacovigilance 
GGT  Gamma glutamyltransferase 
HBsAg Hepatitis B surface antigen 
HIV Hum an Immunod eficiency Virus  
h/hr Hour(s) 
HR Heart rate 
HRT  Hormone replacement therapy 
IB Investigator’s Brochure 
ICH International Confer ence on H armoni zation 
IDMC  Independent Data Moni toring Com mittee 
IDSL International Data Standards Library 
IgM Immunoglobulin M  
IHC Immunohistoch emistry 
IMP Investigational Medicin al Product 
IND Investigational New Drug 
INR International norm alization ratio 
IP Investigational Product 
IRB Institutional R eview  Board 
IRC Independent Review Comm ittee 
IU International Unit  
IV Intravenous  
IVRS  Interactive voice  respon se system  
Kg Kilogram 
L Liter 
LFTs Liver function tests  
LLN Lower limit  of normal 
Ln Naperian (natural) logarithm 
LOQ Limit of quantification 
LLQ Lower limit  of quantification 
LSLV Last subject’s last visit  
LVEF Left Ventricular Ejection Fraction 
µg Microgram 
µL Microliter  
MedDRA Medi cal Dictiona ry for Regulatory Activities 
Mg Milligrams 
mL Milliliter 
MRS Magnetic resonance spectroscopy 
MRT Mean residence time  
MSDS Material Safety Data Sh eet 
CONFIDENTIAL 
Version Date: February 12, 2016  11  
  
 
Msec Milliseconds  
MTD  Maximum tolerated dose  
MUGA Mult igated  (radionuclid e) angiogram 
NCI-CTCAE  National Cancer Institute - Com mon T erminolo gy Crite ria for Adverse 
Events 
NYHA  New York Heart Asso ciation 
PD Progressive disease or pharmacodynamic 
PFS Progression-free surviv al 
PGx Pharmacogenetics 
PK Pharmacokinetic  
PR Partial response  
QC Quality control  
QTc Corrected QT int erval duration 
QTcB QT interval corrected for heart rate by Bazett’s formula 
QTcF QT in terval corrected for heart rate by Fridericia’s formula 
RAM OS Registration and Medication O rdering System 
RAP  Reporting  and Analysis Plan 
RBC Red blood c ells 
RCR  Recommended Co mbination Regimen 
RNA  Ribonucl eic acid 
RPED Retinal Pigment Epith elial Detachment 
RVO  Retinal Vein Occlusion 
SAE Serious adverse event(s) 
SAS Statistical Analysis Software 
SD Standard deviation  or stable dis ease 
SOP Standard Operating Procedure 
T Time of  last obse rved quantifiable concentration 
t1/2 Termin al phase  half-life 
Τ Dosing  interval 
Tlag Lag time before observation of  drug concentrations in sampled mat rix 
Tmax  Time of  occurrence of Cmax 
ULN Upper limit  of normal 
UK United Kingdom 
UPC  Urine p rotein creatinine 
US/USA United S tates/United States of America 
Vd/F  Apparent vo lume of  distribution a fter extravascular (e.g., oral) 
administration 
VICC  Vanderbilt -Ingram Cancer Center  
WBC White blood c ells 
 
Trademark Inf ormation 
 
 
Trademarks of the Novartis  group of 
compani es 
 
Mekinist  
CONFIDENTIAL 
Version Date: February 12, 2016  12  
  
 
1. I NTRODUCTION  
 
1.1. Backg round  
 
Cutan eous me lanoma  is the most  aggressive form of  all skin cancers.  Wor ldwide, it is 
curre ntly exp ected th at approxima tely 132,000 people wil l be di agnosed wit h mel anoma 
each year a nd some  37,0 00 people are exp ected to  die of  the dis ease annua lly.  Untre ated, 
the medi an surviva l time for patie nts with S tage IV melanoma is approxima tely 6 mont hs 
with 26% of subj ects ali ve at 1-yea r (Ko rn 2008); the e stimated 5-yea r survival ra te is <  
10% ( Hunchare k 200 1).  Medi an progre ssion-free surviva l (PFS) is a lso short a t 1.7 
months and on ly 14.5%  of subj ects a re progre ssion-free a t 6 months (Ko rn 2008). 
 
Much ha s cha nged in t he treatme nt lands cape of cutaneous m elanoma  recently, but wi th 
the except ion of  ipilimu mab, si gnificant adv ancements h ave been made exclusively fo r 
patie nts with mutations i n a specific loc us of the  BRAF  protein (BRAFV600) tha t causes 
consti tutive activati on of  the RAS/RAF /MEK/ERK  (MAPK) pathway. BR AF is pa rt of 
the RAS/ RAF /MEK/ERK ( MAPK)  pathway, which is a c ritical proliferati on pathway in 
melanoma.  Nor mally, the MAPK p athway is activa ted by the binding  of extracellular 
growth f actors to membrane-bound gro wth fac tor receptors which th en recruit 
intracellular proteins to the cell memb rane, leading to t he activati on of  the small 
guanosine triphosphate ( GTP )-binding protein RAS.  As a  result, RAS  adopts an 
activa ted con formation wh ich in turn activa tes R AF, whi ch phosphory lates MEK on two 
regulato ry se rine res id ues.  Activa ted MEK  then phosphory lates threonine  and ty rosine 
residues on i ts only known subs trates, the  MAP kinas es ERK1 and ERK2. 
Phosphory lated ERK d imerizes and  translocates to t he nucleus, where it pl ays a critical 
role in cellular proli ferati on, nu clear transport, deoxy ribon ucleic acid (DNA ) repair, 
mess enger ribonuc leic acid pro cessing, a nd translation. 
 
Approxima tel y 40% of cutan eous m elanom as harbor a BRAF V600 mutat ion (BRA F 
V600MUT). The se mutations in crease the in trinsic s erine-threonine kina se activity of the 
BRAF  protein (Davie s 2002) . The  presence of a BRAF V600MUT in a me lanoma 
correla tes with inc reased activity of, and functi onal dep endence upon, the MAPK 
pathway. Most  importantly, the p resence of  BRAF  V600MUT also co rrelates with clin ical 
bene fit in p atients to treatment with s mall molecule inhibi tors of  the V600- mutant BRAF 
protein a nd MEK inhibi tors. V emurafenib (BRAF i, Gene ntech), dabrafe nib (BRAF i, 
GlaxoSmi thKline), a nd trametin ib (M EKi, GlaxoSmi thKline) have all gained regulato ry 
appro val for the tr eatmen t of stage  IV or unresecta ble stage I II melanoma  patie nts with 
BRAF  V600MUT melanoma. Ho wever, these agen ts are not approve d for  use in patients 
without  a mutation. As t hese patie nts represe nt > 50% of cutaneous me lanoma p atients, 
and a much highe r prop ortion of p atients with no n-cutaneous m elanomas, th ere is a 
critical need to ide ntify addit ional ef fective therape utic approa ches. 
 
Appr
oxima tely 5% of a ll melanomas h arbour mutations in B RAF  in loc i other than V600 
(BRAF nonV600 MUT).  Th ese mu tations are often not d etected by many te sting platfor ms 
which are commonly use d in clin ical practice that a ssess on ly codon 600.  However, they 
are detected by testing pla tforms that assess for other regions of t he BRAF gene that ar e 
known to be  affected by somatic  mutations, a s well as platforms that sequ ence the e ntire 
BRAF gene.  Many o f these BRAF nonV600 MUT result in increase d kina se activity of the  
CONFIDENTIAL 
Version Date: February 12, 2016  13  
  
 
BRAF  protein in vitro (“high activity g roup”  including L597V, K601E, G469A) (Wan 
2004). I n addit ion, other mutations tha t do not  increase the catalytic ac tivity of BRA F 
(“low ac tivity /unkno wn” group, inc luding G466E, D594V , G596R)  (Wa n 2004) appea r 
to be  able to inc rease MAPK p athway activity th rough protein-pr otein in teracti ons with 
other  components of this  pathway. Fu rthermore, BR AF fusions  have been recent ly 
identifie d in a  small p ercentage of me lanomas which activa te MAPK signali ng (B otton 
2013; Hutc hinson 2013) . MEK inhib itors h ave demonstr ated activity in vitro in 
melanomas with high act ivity non-V600 B RAF  mutations and indi vidual p atients with 
these  mutations ha ve demonstr ated si gnificant clin ical responses to tre atme nt wi th MEK 
inhibitors. Thus, MEK inhib itors m ay have va lue as a targeted th erapy in this populatio n. 
Althou gh the re is evide nce that low-activity BRAF mutations activa te MEK and ERK 
signali ng, the cli nical benefit of MEK  inhibition in mel anomas with such mu tations is 
poorly de fined. In addit ion, multiple som atic mutations i n BRAF  have b een identified 
that h ave yet to be fun ctionally charac terized (Wan 2004). 
 
1.2. Tramet inib 
 
1.2.1. Trametinib  Backgrou nd 
 
Trametin ib is a potent, hi ghly selective, all osteric inhibitor  of ME K1 and M EK2, is no n- 
competi tive tow ards ATP, and inhi bits both M EK activati on and kinase  activity. 
Trametin ib interfere s with cell ular signa l transduction and induce s apoptos is in human 
tumor cell lines both in vitro  and in xenogra ft mouse models. A ctivity wa s mo st 
extensive  in cell lines and  models  that c ontain ed activati ng BRAF  mutations (Gilmartin 
2011; J ing 2012). 
 
Trametin ib was first dos ed in hu mans in 2008 in MEK111054 (Infa nte 2 012). This fi rst- 
in-human stu dy identifi ed the recommende d monotherapy dose for trametinib (2 mg  once 
daily c ontinuous dos ing); established  the s afety, P K, and PD profile s; and  demonstrated 
clinical activity in seve ral tumor type s includi ng BRA FWT melanoma ( Falchook 2012). 
As of  23 June 2012, tra me tinib has been administered to more than 1700 s ubjects in 20 
studies, including  10 mono therapy studies [Novartis , 2016. T rametin ib was app roved by 
the U nited S tates Foo d and D rug a dministration on 29 M ay 2013, unde r the brand name 
Mekinist, as a monothe rapy in the setti ng of BRA FV600MUT melanoma. 
 
Trametin ib has also b een eva luate d in combinati on with dab rafenib in BRAFV600MUT 
melanoma.  In BRF113220 , this combin ation app eared mo re efficacious tha n dabra fenib 
alone, p rolonging prog ression-f ree surviva l and i ncreasing objective re sponse rates 
(Flaherty 2012) Altho ugh trametin ib has been most extensiv ely tested in BRA FV600MUT 
melanoma, studi es combining  trametin ib with othe r antineoplastic  molecules are ope ning 
in othe r melanoma  subtypes. The  study desc ribed he re is the first s tudy in which 
trametin ib or any mo lecularly targete d therapy will be eva luated sp ecifically in 
BRAFnonV600MUT melanoma.  
CONFIDENTIAL 
Version Date: February 12, 2016  14  
  
 
1.2.2. Pharmac okinetics of Trametinib  in Huma ns 
 
Peak plasma t rametin ib con centrations were observed 1.50 hour s followin g sin gle-dose 
administration of  trametin ib tabl ets und er fasted condit ions. The  absolute ora l 
bioav ailability of the  trametin ib 2.0 mg  table t is mod erate to h igh (72%) relative to a 
coadministered I V mi crodose [ Novartis,  2016] . Trametin ib is h ighly bound to p lasma 
proteins (97.4% ), has a high volu me of distribution ( Vd; 1060 L) and a lo ng te rmina l 
half-li fe (5.3 days), a nd acc umulates with repeat o nce dail y dosing. 
 
The metabolism of trameti nib has bee n investig ated using  a series of in vitr o and in viv o 
studies.  T rametin ib is metabolize d via d eacetylati on to fo rm M5 (deacetylati on alone) 
and deacetylation i n combination with mono-oxygenati on to fo rm M7  
(mono -oxygenati on and d eacetylati on). M5 c an be N-g lucuronida ted to form M6 
(N-glucuronidati on of  M5) w hile M7 undergoe s O-glucuronidation t o form M9  
(O-glucur onidati on of  M7), a mi nor pathway in humans. T rametin ib is metabolize d 
predomina ntly via dea cetylati on (non-CYP450 mediate d) alone o r with mon o- 
oxygenati on or  in combination wi th glucuronidat ion biotra nsformation pa thways. 
Althou gh the spec ific enzyme re sponsi ble h as not  been identified, deacetylati on is l ikely 
medi ated by hydrolytic e sterases, such  as carbo xyl-e sterases or amidases. 
 
1.2.3. Clinica l Safety of Tr ametinib  
 
The adverse events (AEs ) obse rved in t he pivotal, Phase III re gistration stu dy (F laherty 
2012) wa s consistent wi th that s een a cross tr ametinib monothe rapy studies and is 
summarized here .  The  Phase III stu dy de monstr ated that the 2 m g, continuous, on ce 
daily dose of trametin ib ha s an ac ceptab le safety profi le. Adverse eve nts occur ring in 
≥15% of  su bj ects that received a t least o ne dose of tr ametinib (N=211) were ra sh (57%), 
diarrhea (43 %), peripheral edema (26%), fatigu e (26%) , dermatitis acneiform (19%), 
nausea (18%), a lopecia (17%), and hype rtension (15%). Le ss tha n 8%  of the subj ects had 
grade 3 or 4  rash (including only one patie nt wi th grade 4), a nd no gra de 3 or 4 diarrhea 
was obse rved.  D ecreased ejection fr action or  ventricula r dysfuncti on occur red in 7% of 
the subje cts, and < 1% (n=2) had gra de 3 cardiac-re lated eve nts that were consid ered 
trametin ib related and le d to pe rmane nt discontinuati on of  the stu dy treatment. O cular 
events, most  of w hich we re grade 1 or 2, o ccurred in 9%  of the subje cts.  Blurre d vis ion 
was the most  freque nt ocular event (4 %), and there wa s one  case  of reversi ble 
choriore tinopathy. Retina l vein o cclusion, a n AE  that ha s been associ ated with MEK 
inhibitors, wa s obse rved only ex tremely rarely.  Ra sh, di arrhea , visu al disorders, hepati c 
disord ers, ca rdiac-re lated AEs, a nd pn eumon itis are c onsid ered AEs of sp ecial in terest for 
trametin ib beca use th ey are eithe r known c lass eff ects (i.e.  were observed with o ther 
MEK inhib itors) or are potential ly life-threatenin g. 
 
 
1.2.4. Clinica l Activity of Trame tinib  
 
Trametin ib has demonst rated si gnificant clin ical activity with an a cceptable safety profile 
in Pha se I-III stu dies (Falchook 2012 ; Flaherty 2012; Infante 2012; Kim 2013). I n 
BRAFV600MUT melanoma, the Phase III stu dy of trametin ib demonstr ated improved 
rates of  prog ression-free surviva l and ov erall survival (F laherty 2012).  I n this study, 
CONFIDENTIAL 
Version Date: February 12, 2016  15  
  
 
trametin ib demonstr ated an overall response ra te of 22%  and a me dian P FS of 4.8 
months.  The  durati on of  response wa s 5.5 months.  
 
BRAFV600WT melanoma ha s been eva luated in t he trametin ib first-in-human stu dy 
(Infa nte 2012). This study en rolled 39 subj ects w ith BRAFV600WT cutaneous m elanom a, 
of whi ch 4 (10%) had conf irmed obje ctive responses (Falchook 2012). The medi an PFS 
for these  39 subjec ts was 2.0 mont hs (95%  CI 1.7- 3.7 mont hs; (Falchook 2012) ). 
Subjects who w ere both BRAFV600WT and NR ASWT (n=20) ha d a higher response ra te 
(20%) than those  who  were wild type only a t BRAF (n= 11; response ra te= 0%). 
Moreover, a highe r pro porti on of  patie nts that were wild type f or both gene s, comp ared to 
those th at were wild type for only BRAF , were on study treatme nt at w eek 24 (40% 
versus 18 %; p= 0.26) and a t 1 year (30% ve rsus 0 %; p=0.07 ).  Import antly, 2 patie nts 
with B RAFnonV600MUT melanoma (L597V and G469A ) were treated in t his study with 
one ac hieving a partial re sponse a nd the other with  tempo rary stabili zation of  melanoma 
growth (s ee section 1.3. 1). Th ese results demonstr ate that trametin ib has clinical activit y 
in sub groups other  than B RAFV600MUT melanoma. 
 
1.3 Rationale  in study p opulation  
 
1.3.1  Rationale  for targe ted ther apy i n BRAF nonV600MUT mela noma  
 
BRAF alterati ons in loci  other  than c odon V6 00 occur in 4 -6% of advance d mel anomas 
in severa l pub lished repo rts (Berger 2012; Da hlman 2012 ; Krauthamm er 2012 ; Botton 
2013). S ome of  these  recurre nt alte rations c onsti tutively activa te MAPK sign aling and 
may be explo ited th erape utically. Dir ect inhibition of mutant BRAF with v emurafenib or 
dabra fenib appea rs ine ffective in this population, although modest in vi tro activity a nd a 
brief partial re sponse have bee n reported for vemurafe nib (Dahlman 2012; Bahadoran 
2013). By c on trast, in the  precli nical sett ing a nd in  occasional p atients tr eated in clin ical 
trials, MEK inhib ition app ears to be  a more active therapeutic approach. Fo r exa mple, 
BRAF L597MUT and K6 01E MUT melanoma d emonstrated in  vitro sensit ivity to tra metin ib 
(Dahlman 2012). 
 
Clinical corrobora tion ha s been demonstr ated by severa l patie nts who ha ve achiev ed a 
response to MEK inhibitors. F or example, a pat ient wi th BRAF L597SMUT melanoma h ad 
a dra matic  response to an expe rimental M EK inhib itor (TAK-733) (Dahlman 2012). 
Furthermore , in the phase I trial of  trametin ib, a patie nt wi th BRAF L597V MUT 
melanoma expe rienced a prolonged partial response and rema ined on stu dy for more  than  
2 yea rs (Falchook 2012). An addit ional p atient wi th a BRAF G469A mutation had a be st 
response of  stable dise ase. F inally , in a tra metinib phase  II study, a patie nt with B RAF 
K601E  MUT melanoma expe rienced a prolo nged partial re sponse ( Kim 2013 ). MEK 
inhibition in this population ha s not b een studied i n a systematic fa shion an d has never 
been eva luated prosp ectively. The re is strong rationa le to sy stematically eva luate  MEK 
inhibition in the B RAF  nonV600EMUT melanoma  population a s this is a significant 
subgroup without  current approved targeted th erapy options. 
 
1.3.2  Ra
tionale  for study c ohor ts 
 
Subjects with  BRAF  nonV600EMUT melanoma m ay be further classifie d by the fun ctional 
effec ts of each pa rticular mu tation on B RAF  kina se activati on and subseque nt MEK  
CONFIDENTIAL 
Version Date: February 12, 2016  16  
  
 
phosphory lation. All well-char acterized B RAF  mutations  in the kinase  domain  activate 
MAPK si gnaling, althoug h the m echanisms vary. Many of the more  common mu tations, 
including  V600, L597, K601 (see appe ndix 1 for  full mutation list), robustly activa te 
MAPK si gnali ng through MEK phosphorylati on and a re predicted to be s ensitive to MEK 
inhib ition (Coh ort A, “ high activity” ) (Wan 2004) . However, oth er obse rved mu tations 
including G469E and D594G may signal throu gh othe r effectors which may confer 
resistance to MEK  inhibition, althou gh the cli nical experience wi th these mel anomas is 
extremely limi ted (Smalley 2009). Togethe r with addit ional  mutations of un clear 
significan ce, (including S467L and P731S), we have lab elled this group as cohort B , the 
“lo
w activity /unknown”  group. Addit ionally, B RAF  nonV6 00 mu tations m ay occur 
coincident ally with a ctivati ng NRAS or BR AF V600E mu tations. T he functi onal 
significance of these mutations i s not c lear. It is hypothesi zed that these  play a se condary 
role in the se tumors; there fore the se patie nts will  not be in cluded in our  study. 
 
Insight int
o the relative  frequenc ies of these groups c an be obtain ed from a  large group of 
melanomas which w ere subjected to whole  exon s equencin g as part of the melanoma 
TCGA effo rt. Among  the f irst 266 tumor s, all of w hich we re primaries or  metastase s of 
non-acral cutane ous m elanomas,  17 (6.3%)  harbored somatic  BRAF nonV600 
mutations and w ere NRASWT and BRAF V600WT. Of these, 10 (3.8%) could be classified 
as “hi gh activity,” with the addit ional 7 mel anomas (2.6%) in the  “low activity /unkno wn” 
group (3 wit h low ac tivity, 4 with unknown acti vity). Our primary study gr oup of  
interest is cohort A : the “high activity” group, a s there is known pre-cli nical and cli nical 
rationale to stu dy this population. How ever, there may be a dditional p atient s who wil l 
bene fit from trametin ib in t he “low ac tivity /unkno wn” group (c ohort B); the refore this 
group will  also be eligible to r eceive th erapy in an  explor atory fashion.  
 
Approxima tely 1% of m elanom as harbor fusions in the  BRAF gene. (B otton 2013 ; 
Hutchinson 2013) . These rearrangeme nts fu se the  BRAF  kina se domain wi th a partner 
gene whi ch leads to consti tutive ac tivati on of  the M APK pathway. BRAF f usions a re a 
frequent recurrent event in pilocytic a strocytomas a nd other  cance rs and we re recently 
identifie d in melanoma  and mel anocytic tumors ( Ciampi 2005; Jones 2008; Pa lanis amy 
2010).  BRAF f usion me lanoma a ppea rs to confer re sistance to vem urafe nib. By c ontrast, 
trametin ib stron gly inhibited MAPK  signaling in vitro  and is p redicte d to have clinical 
activity in BRAF f usions  (Hutchinson 2013) . Therefore, patie nts with ide ntified BRA F 
fusions will be in cluded in cohort A. 
 
2. OB JECTIVES AND END POINTS 
Table 1 l ists the obj ective s and  corresponding end points. 
Table 1  Objec tives an d Endpoi nts 
 
 Objectives Endpoints 
Primary 1. To determine the clinical efficacy of 
trametinib in advanced BRAF 
nonV 600MUT  melanoma (“hig h 
activity” group) 1. Overall response rate (primary  statistical 
endpoint ), dur ation of 
respons e, clinical benef it (CR+PR+SD)  
per RECIST v. 1.1. 
Secondary 1. To characterize the safety of 
trametinib 
2. To evaluate the  1. Safety and tolerability as measured by 
clinical assessments in cluding v ital sign s 
and physical examinations, 12-lead 
CONFIDENTIAL 
Version Date: February 12, 2016  17  
  
 
 time to progression (TTP) and overall 
survival 
(OS) of trametinib in advanced  
BRAF nonV 600MUT  melanoma electrocardiograms (ECG), 
echoc ardiogram (EC HO) or Mu lti Gated 
Acquisition ( MUGA) sca ns, chemistr y 
and hem atology laboratory valu es, an d 
adverse even ts (AEs). 
2. TTP and over all survival. 
Exploratory 1. To determine the clinical efficacy of 
trametinib in advanced BRAF 
nonV 600MUT  melanoma (“lo w 
activity/u nknown” g roup) 
2. Identify mechanisms of r esistance to 
trametinib in this patient populati on 1. Overall response rate, duration of 
respons e, clinical benef it (CR+PR+SD)  
per RECI ST v. 1.1. 
2. Assess mo lecular charac teristics of 
patient samp les, including archiva l 
samp les, pre-treatmen t, early wh ile on 
treatmen t, and/or at the time o f 
progression 
 
 
  
3. INVESTIGATIONA L PLAN 
 
3.1. Discu ssion of Study D esign and Study Sche matic  
 
This i s a Ph ase II, open- label, multi-center  study in subj ects with adv anced 
BRAFnonV600MUT melanoma str atified by activity of genetic al terations. Cohort A will 
be patie nts with “hi gh activity” BRAF mutations or BRAF f usion eve nts (see appe ndix 
A); cohort B is an explor atory gr oup with BRAF mutations of “low ac tivity/ unknown”  
significan ce. The stu dy is designed to ev aluate  the response ra te to tr ametin ib at the dose 
appro ved by the Food an d Drug Admin istration (FDA) for BRAF  V600 MUT melanoma in 
the B RAFnonV600MUT population. Safety will also be assesse d. 
 
Figure 1: Study Sche matic  
 
 
Subjects with adv anced mel anoma 
with no B RAF  V600 mu tations, 
and no mu tations in NRAS codons 
12, 13, and 61  
 
  
 
 
Scree n for BRAF nonV6 00 mu tation 
 
 
 
 
  
 
If mutation posit ive, scree n for 
enrollment  
CONFIDENTIAL 
Version Date: February 12, 2016  18  
  
  
 
  
 
Register with the Vanderbilt -Ingram Cancer Center (VICC)  
Multi- Institutional Coordinating Office  
 
 
  
 
 
 
Enroll in trial with trametin ib 2mg  once daily in either Cohort 
A (“high activity” ) or Cohor t B (“low activity /unknown ”) 
 
  Protocol waivers or exe mptions a re not allow ed.  Therefore, adherence to  the stu dy 
design requirements, in cluding  those sp ecified in the Time  and Ev ents Ta ble (see Se ction 
7.1), are essential.  
 
 
 Enrollment Procedures 
All patients MUST be registered with the Vanderbilt -Ingram Cancer Center (VICC) Multi -
Institutional Coordinating Office prior to the start of protocol treatment. Each participating 
site must also be registered with their own institution according to their institutional guidelines prior to start of protocol treatment.  Prior to the first patient registration, a copy of IRB approval at the respective sites will be requested and on file at the VICC Coordinating Center.   Patients will be centrally registered by sending the completed enrollment packet to the 
VICC Multi -Institutional Coordinating Office as outlined in the instruc tions provided on the 
enrollment f orm. The enrollment packet must include the following documents:    
 
• Copy of the patient’s signed and dated Informed Consent  
• Eligibility Checklist 
• Coordinating Center enrollment f orm 
  
 
 
 3.2. Treat ment Sc hedu le 
 
The dose and schedule of tr ametin ib is 2.0 mg adm inistered ora lly once daily. Alterations 
to the dose and schedule of tr ametin ib may be incorpora ted base d on toxicity for 
individual p atients. How ever, the  dose lev el and sche dule wil l not exceed 2.0 mg once 
daily. Dosing with sta rt with Tr eatme nt pe riod 1,  Day 1 and the subj ect may continue 
treatme nt wi th trametin ib unti l the Treatme nt Dis conti nuati on Cri teria are met (Section 
CONFIDENTIAL 
Version Date: February 12, 2016  19  
 6.3). 
 
3.3. Genetic Analysis  
 
Prior to en rolment, subje cts will  be required to pr ovide arc hived tumor tis sue or underg o 
tumor biop sy if arc hived  tumor tissue is not availa ble. Evaluation of BRAF mutational 
status may be perfo rmed at any laboratory with Cli nical La boratory Ce rtification 
Amendment (CLI A) certification st atus. Most  commonly per formed di agno stics of B RAF 
mutations a ssess on ly mu tations found a t codon 60 0. Th erefore, B RAF  nonV600 
mutations will likely be identified by eithe r next generati on sequencing me thods ( for 
example, Foundati onOn eTM assay which asse sses t he entire coding region o f BRAF a s 
well as functi onal rearrangeme nts in BRAF). T argeted po lymerase cha in reaction assays 
may a lso be per formed (f or exa mple, MD A nderson Can cer Center performs PCR-base d 
mutational analysis in codons 444, 464, 466, 469, 471, 581, 586, 587, 592, 594, 595, 596,  
597, 599, 600, 601, and 605 ).  Patie nts with detec ted alterati ons in BRAF at known or 
previous ly unknown l oci will be in cluded. P rior testing results from a CLIA-ce rtified 
laboratory that m eet molecular entry criteria (presence of a non-V600 BRAF mutation or 
BRAF g ene fusion; no mutation i n codon 600 of  BRAF; no mutation i n codons 12, 13, 
and 61 of  NRAS) wil l be sufficient for  patie nt en rolment in the stu dy without fur ther 
testin g. 
 
3.4. Product dosing /administration  
 
Produ ct name Trametinib 
Formulation 
descriptio n: The drug substance is blended wi th inert ingredients (mannitol, sodium 
lauryl sulfate, colloidal silicon dioxide, microcrystalline cellulose,  
hypromellose, croscarmellose sodium, and magnesium stearate), and 
compressed into tablets.  
The tablets are then coated with either a white or pink opaque film*  
(*Opadry  White or Pink, a titanium dioxid e-based formulation with iron 
oxide as colorant  as applicable)  
Dosage form :  Tablet   
Unit dose 
strength(s) / 
Dosage levels  
0.5mg    
2mg 
Physical 
Description: White, oval , 
biconvex film coated 
tablet, 4.8mm x 8.7 mm  Pink, round  
biconvex film 
coated-tablets 
8.0 mm in diameter. 
Route/Duration Oral/ Until treatment discontinuation criteria are met  
Dosing 
Instructions: Trametinib should be taken fasting, at least 1 hour before or 2 hours after a 
meal. Trame tinib wi ll be a dminister ed w ith approximately eight ounces of 
water. If a subje ct vom its after taking study medication, t he subject should 
be instructed not to retake the do se and  should take the next scheduled dose. 
CONFIDENTIAL 
Version Date: February 12, 2016  20  
  
 
 
 
 
3.5. Rationale  
 
3.5.1. Rationale  for Study  
 
Trametin ib has demonst rated cli nical activity in subjects with BRAF V600WT cutaneous 
melanoma (Falchook 2012). I n patie nts with BRAFnonV600MUT melanoma, several 
clinical responses have been desc ribed to MEK i nhibition, including  one lasting  over two 
years from tr ametin ib (Da hlman 2012; Fa lchook 2012). F inally, in v itro evidenc e 
supports tha t inhibiti on of MAPK signaling thro ugh MEK inhibiti on in 
BRAFnonV600MUT melanoma, including  those wi th BRAF  fusions,  is an ef fective 
treatme nt strategy. 
 
3.5.2. Rationale  for Popula tion 
 
Subjects with BRAFnonV600MUT melanoma m ay respond to targe ted the rapy althoug h as 
yet there have bee n no tr ial specifically en rolling  this group. This patient p opulation has 
an unmet medi cal need and trametin ib monothe rapy has achieved obje ctive re sponses in 
such subj ects. We a re subdividing  subjects bas ed on the p redicted activity of BRA F 
alterati ons into Cohort A (“high activity” B RAF  mutations  and B RAF fusion eve nts) and 
Cohort B (“low activity/ unknown” BRAF mutations) a s defined by Wan e t al publi shed 
in Ce ll 2 004; complete  list is in appe ndix 1. This  predetermin ed stratification will  allow 
for impr oved definition of  which subj ects a re likely to be nefit from trameti nib. 
 
3.5.3. Rationale  for Dose  
 
The starting re gimen of tra metin ib will  be 2 mg  conti nuous, on ce daily.  T his dose h as 
demonstr ated an acceptable safety profile (see Se ction 1.2.3 ), clinical activity, a nd a 
pharmacodynamic effect in subje cts with  BRAFV600MUTmelanoma ( Falchook 2012;  
Infante  2012). This dose is also the FDA approved dose for subjects with 
BRAFV600MUT melanoma.  
 
 
3.5.4. Rationale  for Endpoints  
 
The primary e ndpoint  is to determine the cli nical efficacy of tra metinib in 
BRAFnonV600MUT melanoma for Cohort A (“ high a ctivity” mutations and B RAF 
fusions). Response c riteria base d on RE CIST 1.1  will be used  to ass ess complete or p artial 
responses, stable dise ase, or prog ressive disease. Safet y for  both c ohorts is a s econdary 
endpoint and a s such  clinical assessments including vita l signs and physical examinati ons, 
12-lead ECG, ECHO, chemi stry and he matolo gy laboratory value s, retinal 
exam s as n eeded, and A Es will  be monitored and eva luate d. Progre ssion free surviva l and 
overall surviva l will be addit ional s econdary e ndpoints. 
 
The explor atory endpoint  is to det ermine  the cli nical efficacy of tra metin ib in Cohort B 
(“low ac tivity /unkno wn” group).  Response c riteria base d on RE CIST 1.1 wi ll be used  to 
assess c omplete or partial responses, stable  disease, or progre ssive disease ( Eisenh auer 
2009). PFS a nd OS for  this coho rt will be addit ional explor atory endpoint s. 
 
CONFIDENTIAL 
Version Date: February 12, 2016  21  
  
 
3.6. Study Tr eatment  
 
All patients will r eceive tra metin ib 2 mg orally once daily 
 
3.7. Dosage and Administration of Study Tr eatmen t 
 
Trametin ib should be  admi nistered once pe r day, continuously; a nd should  be taken at 
about t he same  time each day. The stu dy treatment should be  administered together with 
approxima tely eig ht ounces of wa ter. T rametinib should be t aken fasting, at least 1 hour 
before or 2 hours after a me al.  If a subjec t vomits after taking study medi cation, the 
subject should be instru cted not to r etake the dose and should take the n ext sch eduled 
dose.  A subject may take a dose within 12 hours of the scheduled time. If a dose is 
missed , a subject should not take a dose within 12 hours of their next scheduled dose of 
trametinib. Trametinib may not be crushed, chewed, or dissolved in water.  
 
3.7.1. M eals and Di etary Res trictions  
Study treatme nt(s) will be administered unde r fasting conditions (s ee Se ction 3. 7). 
Fasting will  consist of avoid ing the o ral inge stion of calor ie-containi ng produc ts; 
ingestion of  w ater is pe rmitted.  Any ong oing, usua l con comitant medi cations m ay be  
administered while fa sting. 
 
3.7.2. Blinding  
 
This i s an open- label study. 
 
3.8. Safe ty Manag ement Guidelin es 
 
The severity of adverse eve nts (AEs) will be grade d utilizing the Nati onal Can cer 
Institute- Com mon Toxici ty Crite ria for Adverse Even ts (N CI-CTCAE ), version 4. 0.  The 
severity of AEs will  be graded usi ng the CTCAE,  version 4.0.  The  secti on include s: 
 
• general g uidelines  for cli nically sig nificant toxici ties re lated to stu dy 
treatme nts and 
 
• specific guidelines fo r adve rse events of spec ial interest, whi ch include but  are 
not limited to eve nts that have  been obs erved with hi gher frequency o r severity 
in subj ects r eceiving trametinib. 
 
Subjects should be carefully evalua ted for e vidence of drug-rela ted to xicity.  The 
investi gator should use  clinical judgment to det ermine which drug may be contributing  
to the tr eatme nt em ergent tox icity and ma ke the app ropriate dosi ng adjustments.  Th is 
may include  interrupti on and/or reducing the do se of one  or both tr eatme nts.  
Guidelines f or toxicity and dose modi fications a re provided.  Investigators shoul d also 
refer to the tr ametin ib Inve stigator Bro chure [ Novartis , 2016]. 
 
CONFIDENTIAL 
Version Date: February 12, 2016  22  
  
 
3.8.1. Dose  Leve ls of tram etinib  
 
The dose lev els for this stu dy are pro vided in  Table 2.  
 
Table 2 Dos e Level Reduc tion G uidelines 
 
Dose Levels Tramet inib once daily 
Full dose 2 mg  
1st Dose red uction  1.5 mg  
2nd Dose redu ction 1.0 mg  
 
If an AE  resolves to  grade 1 or  baseli ne at the reduced dose  level, and no addit ional 
toxicities are seen after four wee ks of study treatment a t the reduce d dos e, the dose  of 
trametin ib may be inc reased to t he previous dose  level. If a dose reducti on be low 1.0 mg 
once daily for tra metin ib is r equired, then t rametin ib will  be permanently discontinued. 
 
3.8.2. Ge neral Guid elines for Clini cally S ignifica nt Toxic ities 
 
Genera l guideline s regarding man agement a nd dose reducti on for adverse events that are 
consid ered by the in vestigator to be related to study  treatme nt and which do  not have 
specific guidelines (se e Table 2) are provided in Ta ble 3.  
 
Table 3 Dos e Modificati on Guide lines f or Event s Considered Rel ated to  
Study T reatm ent 
 
CTCAE Grade Action and  Dose M odificati on 
Grade 1  • Continue study  treatment  at current d ose level 
• Monitor closely 
• Provide suppor tive care a ccording to institutional standards 
Grade 2  • Interrupt  study  treatment if clinically indicated 
• Monitor closely 
• Provide suppor tive care a ccording to institutional standards 
• When to xicity re solves to grade 1 or b aseline, restart s tudy treatment 
at current  dose level 
CONFIDENTIAL 
Version Date: February 12, 2016  23  
  
 
CTCAE Grade Action and  Dose M odificati on 
Grade 3  • Interrupt  study  treatment 
• Monitor closely 
• Provide suppor tive care a ccording to institutional standards 
• When to xicity re solves to grade 1 or b aseline, restart s tudy treatment  
reduced by one dose l evel 
• If the grad e 3 toxicity re curs, interrupt s tudy treatment 
• When to xicity re solves to grade 1 or b aseline, restart s tudy treatment  
reduced by anoth er dose lev el 
Grade 4  • Interrupt  study  treatment 
• Monitor closely 
• Provide suppor tive care a ccording to institutional standards 
• Discontinu e trametinib OR if the sub ject is clinically bene fiting, 
discu ss continuation of the study treatment  with the  me dical 
monitor once toxicity re solves to grade 1 or baseline. If continued, 
reduce by one d ose le vel. 
• If the grad e 4 toxicity re curs, pe rmanently di sconti nue study 
treatment  
Treatment with trametin ib may be delaye d for  up to 21 day s to allow re solution of  
toxicity, sch eduling difficulties, or  investi gator dis creti on. Approva l to restart a 
subje ct after >21 day delay will require  consultation wi th the  medi cal monitor. 
Labora tory abnorm alitie s that a re not cli nically sig nificant  (i.e. creati nine phosphokina se 
levels) but a re gra de 3 or 4 do not automatically re quire  dose re ducti on or  
discontinu ation of  study drug. They should be  discussed in de tail with the  medi cal 
monitor. 
 
3.9. Dose Modification Guidelin es for Tra metinib Adver se Events 
of Speci al Inte rest 
 
3.9.1. Guide lines for Cardi ovascul ar Adverse Events  
 
Cardiov ascular adverse eve nts have  been seen in s ubjects rece iving trametinib; (see the 
trametin ib IB [ GlaxoSmithKline,  2012] for addit ional infor mation). Guid eline s for 
LVEF d ecreases a nd hyperte nsion are provided in S ections 3.9.1.1 and 3.9.1.2, 
respectively. 
 
3.9.1.1. Left Ventricular Ejectio n Fracti on (L VEF)  
 
Decreases of the left-ven tricular-ej ection-fr action (L VEF) h ave been observe d in subje cts 
receiving tra metinib . Therefore, ECHOs  (prefer red) or MUGA ’s must  be perfor med to 
assess ca rdiac ejection fraction .  The  procedure perfor med a t baseli ne must  be perfo rmed 
at all subsequ ent visits as outl ined in t he Time  and Eve nts Table (see S ection 7.1). 
Electronic  copies o f all ECHO/MUGA scans will  be collected by Vanderbilt  for review.  
CONFIDENTIAL 
Version Date: February 12, 2016  24  
  
 
Dose  modification guidance and stopping c riteria for LVEF decrease are pr ovided (Ta ble 
4). 
 
Table 4 Dos e Modificati on Guide lines and Stop ping Cr iteria for L VEF 
Decrease 
 
Clinic LVEF-drop (%) or  
CTCAE grade Action and  Dose M odificati on 
 
Asymp tomat ic  
Absolute decrease of >1 0% in 
LVEF compared to baseli ne and 
ejecti on fraction  below the 
institution’s  LLN • Interrupt t rametinib and repeat ECHO/MUGA 
within 2 weeksa 
 
• If the LVE F recovers within 4 weeks (defined 
as LVEF ≥LLN and absolute decrease ≤10% 
compa red to basel ine) 
 
• Consult wit h the  me dical monitor and 
request ap proval for r estart 
 
• Restart trea tment  with trametinib at 
reduced  dose by one dose level 
 
• Repeat E CHO /MUGA 2  , 4 , 8 and 12 
weeks  after re -start; c ontinue in inter vals 
of 12  w eeks thereafter 
 
• If LVEF does not r ecover wit hin 4 wee ksc 
 
• Consult wit h cardiologist 
 
• Permanently dis continue t rametinib  
 
• Repeat E CHO after 2, 4, 8, 12, and 16 
weeks or until resolution 
Sympto maticb Grade 3:  resting LV EF 39-20% 
or >2 0% ab solute red uction from 
baseline • Permanently dis continue t rametinib.  
 
• Repor t as SAE 
 
• Consult w ith ca rdiologist  
 
•  Repeat E CHO /MUGA after 2, 4, 8, 12,  and 16 
weeks or u ntil resoluti on Grade 4:  resting LV EF <20% 
Abbreviations:  CTCAE = Common Te rminolo gy Crite ria for Adverse Events;  ECHO = echocar diogr am; ; LLN = lower  limit 
of normal; LVEF = left ventr icular ejection  fraction ; MUGA=Mu lti-gated  acquis ition a.  If ECHO/M UGA  does not show  
LVEF recovery after 2 weeks, repe at ECHO/M UGA  2 weeks  later. 
b. Sympt oms may include: dyspnea, or thopnea, and o ther signs  and symptoms of pulmonary congesti on and 
edem a. 
c.  If dose is delayed more than 21 days, discussion with the medical monitor is required to resume therapy.  
 
3.9.1.2. Hyperten sion 
 
Increases in blood pr essure have been obse rved in subj ects r eceiving trametinib. 
Recom mendati ons for  blood pre ssure  monitorin g and man ageme nt are provide d. 
 
Monitoring of Hypert ension 
All b lood p ressure  assess ments shou ld be performe d und er the following  optimal 
condit ions:  
CONFIDENTIAL 
Version Date: February 12, 2016  25  
  
 
• the subje ct has b een seated with ba ck support, ensur ing that legs a re uncrossed 
and flat on t he floor 
 
• the subje ct is relaxed comfortably for a t least 5 minutes 
 
• re strictive c lothing ha s been r emoved from  the cuff area and the approp riate 
cuff size ha s been selected 
 
• the subje cts arm is suppor ted so that the middle  of the cuf f is a t heart level 
 
• the subje ct remains qui et during the m easurement. 
 
In subj ects with an init ial blood pr essure  reading with in the hyperte nsive ra nge, a sec ond 
reading should be  taken at least 1 minute later, wit h the 2 rea dings averaged to ob tain a 
final blood pre ssure  measure ment. The  averaged va lue should be recorded in the eCRF. 
 
Persistent hype rtension is de fined as a n inc rease of sy stolic blood p ressure (S BP) > 140 
mm Hg and/or di astolic blood pr essure  (DBP) > 9 0 mm  Hg in th ree cons ecutive visits 
with b lood pre ssure  assessments f rom two rea dings collected a s desc ribed above . Visits 
to monitor increase d blood pre ssure  can be  sched uled ind epende ntly from the p er- 
protocol visi ts outl ined in the Time a nd Ev ents Ta ble (see S ection 7.1 ). Ideally, 
subseque nt blood pre ssure assessments shou ld be perfor med within one  week. 
 
Asymptomatic hype rtension is defined a s an in crease of SBP > 140 mm  Hg and/or DBP 
>90 mm  Hg in the absence of he adache, light-headedne ss, ve rtigo, ti nnitus, ep isodes of 
fainting or other symptoms indicative of hype rtension. 
 
Management  of Hypert ension 
For subj ects expe riencing a n increase in sy stolic and/or di astolic blood p ressure  that is 
persistent and m ay be associ ated with t he study treatme nt, recom mendati ons for  the 
clinical manage ment o f hype rtension are desc ribed in Table 5.  
CONFIDENTIAL 
Version Date: February 12, 2016  26  
  
 
Table 5 Manag ement and Dose Modificati on G uideline s for Hyperten sion 
 
Hypertension  Action and  Dose M odificati on 
(Scenario A)  
 
• Asymp tomat ic an d per sistenta SBP of ≥ 140 and 
<160 mmH g, or DB P ≥90 and  <100 mmH g, 
 
or 
 
• Clinically significant increase i n DB P of 20 
mmH g (but still be low 100 mmH g). • Continue trametinib at the current do se 
 
• Adjust current or  initiate n ew antihypertensiv e 
medic ation 
 
• Titrate a ntihyperten sive me dication(s)  during 
the ne xt 2 weeks as  indicated to achiev e well- 
control ledb BP 
 
• If BP is not well contro lled wi thin 2 weeks, 
consider refer ral to a sp ecialist and go t o 
scenar io (B). 
(Scenario B)  
 
• Asymp tomat ic SBP ≥ 160 mmHg, or DB P 
≥100 mmH g, 
 
or 
 
• Failure to achieve well-contr olled BP  within 2 
weeks in Scenar io A • Interrupt t rametinib if clinically indicated 
 
• Adjust current or  initiate n ew antihypertensiv e 
medic ation(s) 
 
• Titrate a ntihyperten sive me dication(s)  during 
the ne xt 2 weeks as  indicated to achiev e well- 
control led BP  
 
• Once BP is well co ntrolledb, restart s tudy 
treatment  reduced by  one do se level  
(Scenario C)  
 
• Sympto maticc hypertens ion 
or 
• Persistent SBP ≥ 160 mmH g, or DB P 
≥100 mmHg, desp ite an tihype rtens ive 
medic ation and dos e reduction of stu dy 
treatment  • Interrupt t rametinib  
 
• Adjust current or  initiate n ew antihypertensiv e 
medic ation(s) 
 
• Titrate a ntihyperten sive me dication du ring the 
next 2 wee ks as in dicated to a chieve well- 
control led BP  
 
• Referral to a specialist for fur ther e valuation 
and fo llow-up is re comme nded 
 
• Once BP is well co ntrolled, restart trame tinib 
reduced by one dose l evel 
(Scenario D)  
 
 
• Refractory  hypertension un responsi ve to  above 
interv entions or h ypert ensive crisis. • Permanently dis continue t rametinib  
 
• Continue follow- up per pro tocol. 
 
• If hype rtension resolves to ≤Gra de 1, 
trametinib may be restarted wi th 
perm ission from t he m edical mo nitor 
Abbreviations:  BP = blood  pressur e; DBP = diastolic  blood pressur e; mmHg  = millimetres mercury; SBP = systolic 
blood pressur e; 
a. Hyper tension det ected in two se parate rea dings d uring up to three consecutive visits 
b. Well-controlled blood pressure de fined  as SBP ≤140 mm Hg and DBP ≤90 mm Hg in two separ ate rea dings 
during up to three consecutive visits.  
c. S ympt omatic hyper tension def ined as hypertension aggr avated by sympt oms (e.g., heada che, light-headednes s, 
vertigo, tinnitus,  episo des of fa inting) th at resolve af ter the b lood pressure is controlled  within the no rmal range. 
CONFIDENTIAL 
Version Date: February 12, 2016  27  
  
 
3.9.2. Guide lines for Visual Changes  
 
Episodes of  visual change s have bee n obs erved in subj ects r eceiving trameti nib. The 
causal re lationship betw een a change in v ision and  the stu dy treatme nt should be 
careful ly explor ed and an ophthalmolog ist should be  consulted. Spe cial at tention should 
be give n to r etina l (e.g., RP ED) or  retinal vein abnormalitie s (e.g., RVO ). 
 
Guid eline s regarding  manage ment a nd dose  reducti on for visu al changes c onsid ered to be 
related to stu dy treatme nt are provided (s ee Ta ble 6 and 7). 
CONFIDENTIAL 
Version Date: February 12, 2016  28  
  
 
Table 6 Manag ement and Dose Modificati on G uideline s for Visual Chang es 
and/or Ophth almic Examina tion Findings  
 
 CTCAE 
Gradea Adverse Event Ma nagement  Action and  Dose M odificati on  
  
Grade 1b • Consult ophthalmologist wi thin 
7 days of onset 
 
• • If dilated fundus examination cannot 
be pe rformed within 7 days of onse t, 
interrupt trametinib until RPED and 
RVO  can be e xcluded b y retina 
specialist/ ophthalmo logist. 
 
• If RPED and RVO e xcluded, 
continue (or restart) trame tinib at 
same dose level 
 
• If RPED  suspe cted or diagnos ed: 
see R PED dose modification tab le 7 
below;  report as S AE if diagnosed.  
 
• If RVO  diagnosed:  Permanent ly 
discontinue trametinib  and re port 
as SAE.   
  
Grade 2 and 
Grade 3  • Consult ophthalmologist 
immediately 
 
• Interrup t tram etinib 
 
• • If RPED and RVO excluded, restart 
trametinib at same dose level 
 
• If RPED  diagnosed, see RPED dose 
modifica tion tab le below;  report as 
SAE. 
 
• If RVO  diagnosed: Permanent ly 
discontinue trametinib  and re port 
as SAE 
 
•  
  
Grade 4  • Consult ophthalmologist 
immediately 
 
• Interrup t tram etinib 
 
• Report as SAE 
 
• 
 
• • If RPED and RVO excluded, may 
consider resta rting tramet inib at 
same or redu ced dose af ter 
discussion  with stud y me dical 
monitor 
 
• If RVO  or RPED dia gnose d, 
permanently  discontinue 
trametinib   
Abbreviations:  RPED = r etinal  pigment e pithelial  detachm ent; CTCAE = Common Terminolo gy Criteria for Adverse 
Events; 
RVO= r etinal  vein occlusion; SAE = ser ious adverse e vent 
CONFIDENTIAL 
Version Date: February 12, 2016  29  
  
 
a. Refe rs to CTCAE Vers ion 4.0 ‘Eye disord ers – Other, specify’ 
b. If visual  changes are cle arly unrel ated to study treatment ( e.g., allergic  conjunctivi tis), mon itor closely  but 
ophthalmic exam ination is not required. 
 
Table 7 Recomme nded  dose mod ifications for trametinib  for retinal pigment 
epithelial detachments (R PED)a 
 
CTCAE Grade Action a nd Dose  Modification 
Grade 1 RPED (Asymptomatic; 
clinical or diagnostic obse rvations onl y) • Continue treatment with retinal 
evaluation monthly until resolution. If 
RPED worse ns follow instructi ons 
below 
Grade 2-3 RPED (Symptomatic with 
mild to moderate decrease in visual 
acuity; limiting  instrum ental ADL) • Interrupt tram etinib 
• Retinal eva luation month ly 
• If imp roved to ≤ Grade 1, restar t 
trametinib at lower dose (reduced by 
0.5 mg) or discontinue in patients 
taking trametinib 1 mg daily 
c. Refe rs to CTCAE Vers ion 4.0 ‘R etinopa thy’ 
 
 
3.9.3. Pneumonitis Manageme nt Guidelines  
 
Pneumon itis has b een obs erved in subje cts receiv ing trameti nib. To r educe the r isk of 
pneumon itis, sub jects wi ll be moni tored closely for symptoms, eva luated wit h imaging 
and functi onal tests. Dose modification and suppo rtive care g uidelines  for pne umon itis 
are desc ribed (see Table 8). 
CONFIDENTIAL 
Version Date: February 12, 2016  30  
  
 
Table 8 Pne umo nitis Guidelines for Trametinib 
 
CTCAE 
Grade Adverse Event Ma nagement  Action and  Dose M odificati on 
Grade 1  • CT scan (high-resolution with lung 
windows) recommended  
 
• Clinical evaluation a nd la boratory wo rk-up 
for inf ection  
 
• Monitor ing of oxy gena tion via pulse- 
oxime try re commend ed 
 
• Consultat ion with pulmono logist 
recommended  • Continue trametinib at current dose 
Grade 2  • CT scan (high-resolution with lung 
windows) 
 
• Clinical evaluation a nd la boratory wo rk-up 
for inf ection  
 
• Consult p ulmonologist 
 
• Pulmonary fun ction  tests - if < normal, 
repeat e very 8  weeks until ≥ normal  
 
• Broncho scopy with b iopsy an d/or BAL 
recommended  
 
• Sympto matic therapy in cluding 
corticostero ids if clinically indicated • Interrupt t rametinib until recovery 
to grade  ≤1 
 
• Restart treat ment  with tra metinib 
reduced by one dose l evel 
 
• Escala tion to prev ious dose level 
after 4 w eeks an d con sultation with 
medic al monitor possible 
 
• If no re covery to grade ≤1 within 4 
weeks, permanently di scont inue 
trametinib  
Grade 3  • CT scan (high-resolution with lung 
windows) 
 
• Clinical evaluation a nd labo ratory wo rk-up 
for inf ection  
 
• Consult p ulmonologist 
 
• Pulmonary fun ction  tests- if < norma l, repeat 
every 8  weeks until ≥ norm al 
 
• Broncho scopy with b iopsy an d/or BAL if 
possible 
 
• Sympto matic therapy in cluding 
corticostero ids as clinical ly indicated • Interrupt t rametinib until recovery 
to grade  ≤1 
 
• After con sulta tion wit h me dical 
moni tor, treatment with trame tinib 
may be restar ted reduc ed by one 
dose level  
 
• If no recov ery to grade ≤1 within 21 
days , permanently di scont inue 
trametinib  
Grade 4  • Same as grade 3  • Permanently dis continue 
trametinib  
Abbreviations:  BAL= bronchioalveo lar lavag e; CT = compu ted tomography; CTCAE = Common Terminolo gy Crite ria 
for Adverse Events  
CONFIDENTIAL 
Version Date: February 12, 2016  31  
  
 
3.10.  Dose Modifications for Trametinib and supportive ca re 
 
3.10.1. Liver Chemistry Stop ping Criteria  
 
Liver chemi stry threshol d stopping  criteria ha ve been designe d to ass ure subject safety 
and to ev aluate  liver eve nt etio logy during a dministration of  study treatment(s) and the 
follow -up period.  S tudy treatme nt(s) will be stopped if any of the  following  liver 
chemistry stoppi ng criteria is/a re met:  
 
1. Alanine ami notransferase (AL T) ≥3 X (times) u pper limit  of normal (ULN) and 
bilirubin ≥ 2 Xs UL N (or ALT ≥ 3 X UL N and inte rnational normal ization ratio 
[INR] >1.5) 
 
NOTE: Se rum bilirubin f ractionati on should be  perfor med i f testing is availa ble.  I f 
fractionati on is unavailab le, urinary bilirubin is to be  measured via  dipstick (a 
measurement of  direc t bilirubin, w hich w ould sug gest liver injury). 
 
2. AL T ≥5
 X ULN. 
 
3. AL T ≥3 X ULN if associated wit h the appearance or wo rsening of rash or hepatiti s 
symptoms ( fatigue, na usea, vom iting, rig ht upper quadra nt pain or  tenderne ss, or 
jaundi ce) or  hype rsensitivity ( such  as fever, ra sh or eosinophil ia). 
 
4. AL T ≥3 X ULN persists for ≥4 weeks. 
 
5. AL T ≥3 X ULN and cannot be moni tored weekly for 4 weeks. 
 
Subjects with ALT ≥3 X ULN and < 5 Xs UL N and bi lirubin < 2 X ULN, w ho do not 
exhib it hep atitis symptoms or rash, can conti nue study treatme nt(s) a s long as they can be 
monitored weekly for 4 w eeks. As with other causes of dose holding, discussion with the 
medical monitor is required if trametinib is held for >21 days.   See following  secti on for 
details on w eekly follo w-up pro cedures for these sub jects. 
 
3.10.1. 1. Liver Chemist ry Follow- up Procedures 
 
Refer to the  diagram in Appendix 5 for a visual pr esentation of the  procedure s listed 
below. 
 
The procedure s listed b elow a re to be  follow ed if a subj ect meets the liver chemi stry 
stopping  criteria de fined in S ection 3.10.1:  
 
• Imme diately a nd pe rmanently withdr aw the subj ect fr om stu dy treatme nt. 
 
• Notify the Me dical Monitor wit hin 24 hours of  learning of the  abnormality to 
confir m the subj ect’s st udy treatme nt(s) cessation  and follow- up. 
 
• Comp lete the  “Safety F ollow-Up Pro cedures” listed below. 
 
• Comp lete the  liver eve nt electronic  case  report forms (e CRFs).  I f the event also 
meets the criteria of a ser ious adv erse event (SAE) (see Section 8.2 ), the S AE data 
collection tool  will be completed separa tely with the relevant det ails. 
 
• Upon c ompletion of  the safety f ollow-up permanently withdr aw the  subj ect from the 
study and do not rechallenge with study treatment( s). 
CONFIDENTIAL 
Version Date: February 12, 2016  32  
  
 
Safety Follow-Up Proc edures for subjec ts with ALT ≥3 times ULN:  
 
• Monitor subje cts weekly until liver chemi stries (AL T, aspartate ami notransferas e 
[AST ], alkaline phosphata se [ALP], a nd bi lirubin) re solve, stabil ize or return to 
within baseli ne values. 
 
Safety Follow-Up Proc edures for subjec ts with ALT ≥3 times ULN and  bilirubin ≥2 
times ULN (or ALT ≥3 times ULN a nd INR  >1.5 ): 
 
• This event is con sidered an  SAE (see S ection 8.2 ).  Se rum bilirubin f ractionati on 
should be  performed if t esting is av ailable.  If fr actionation is unavaila ble, u rinary 
bilirubin is to be  measured via dipstick  (a measurement of  direct bilirubin, w hich 
would sug gest liver injury). 
 
• Make  every reasonab le attempt to have  subjects return to the cli nic within 24 hours 
for repeat liver chemi stries,  addit ional testin g, and c lose moni toring  (with specialist 
or hepa tology consultati on recommended ). 
 
• Monitor subje cts twice weekly until liver chemi stries (AL T, AS T, alkaline 
phospha tase, bil irubin) resolve, stabil ize or return to wit hin bas eline values. 
 
In addition, f or all subjects with A LT ≥3 times ULN, every attempt mu st be  made t o 
also ob tain t he following:  
 
• Viral hep atitis serology inc luding: 
 
• Hepatiti s A Imm unog lobulin M (Ig M) antibody. 
 
• Hepatiti s B surface a ntigen and Hepatiti s B Core Antibo dy (IgM ). 
 
• Hepatiti s C ribonucle ic acid (RNA ). 
 
• Cy tomega lovirus IgM anti body. 
 
• Epstein -Barr vir al capsid  antigen I gM a ntibody (o r if unavaila ble, obta in 
heterophile a ntibody or monospot te sting). 
 
• Hepatiti s E IgM a ntibody (if subject resides outsi de the U nited States (US) or 
Canada , or ha s travele d outside US or Cana da in past 3 months).  
 
• Se rum c reatine phosphokina se and la ctate dehydrogenase. 
 
• F ractionate bil irubin, if  total bi lirubin ≥ 2 times UL N. 
 
• Obtain complete  blood count wit h differential to assess eosinophil ia 
 
• R ecord the app earance or worsening of cli nical symptoms of hepatitis or 
hype rsensitivity, such as fatigue, na usea, vom iting, rig ht uppe r quadrant pa in or 
tenderness, feve r, rash or  eosinophilia , on the AE eCRF. 
 
• R ecord use  of conc omitant medication (s), ace taminophe n, herbal remedi es, other 
over-the-counter  medication(s), or putative h epatotoxins on  the Conc omitant 
Medications e CRF. 
 
• R ecord alcohol use  on the Live r Events eCRF. 
CONFIDENTIAL 
Version Date: February 12, 2016  33  
  
 
The following a re require d for  subj ects with ALT ≥3 times UL N and bilirubin  ≥2 times 
ULN but are optional for other  abnorma l liver chemi stries:  
 
• Anti-nuclear antibody, a nti-smooth muscle  antibody, a nd Type 1 a nti-liver kidney 
microsom al antibod ies. 
 
• L iver imaging (ultr asound,  magnetic re sonance imaging [MRI] or c ompu ted 
tomography [C T] scan) to eva luate  liver disease. 
 
• L iver Imaging a nd/or  Live r Biopsy eCRF s are also to be c ompleted if  these  tests a re 
perfor med.  
 
• Se rum ace taminophen adduc t HPLC assay (quantifies pote ntial acetaminophe n 
contribution t o liver injury  in subje cts with de finite or lik ely ace taminophe n use  in 
the p receding w eek [CTCAE,  2009] ). 
 
• Only in those with unde rlying chro nic h epatiti s B at study e ntry (identified by 
posit ive hepatiti s B surface a ntigen) :  quantitative h epatit is B DNA a nd hepatiti s delta 
antibody. NOT E:  If hepatiti s delta antibody assay ca nnot be perfor med, it  can be 
replaced with a P CR of h epatiti s D RNA virus (whe re needed) – a s outl ined in: 
http://www.nc bi.nlm.nih.gov/pmc/article s/PMC1153793.  
 
3.10.2. Guide lines for Prolo nged QTc 
 
Investigators should r eview concomitant medication usage for those that cause a 
prolonged QTc . Guid eline s for dose modification and stopping c riteria due to QT c-
prolongati on are provided (see Ta ble 9 ). 
 
Table 9 W ithholdi ng and Stoppi ng Criteria f or QTc-P rolongati on 
 
QTc-Prolon gationa Action and  Dose M odificati on 
• QTcB  ≥501 msec • Interrupt all study treatm ents until QTcB pr olonga tion 
resolves to grade 1 or ba seline 
 
• Test serum p otassium, calcium, pho sphor us and 
magn esium. If ab normal corr ect per ro utine clinical 
pract ice to wit hin n ormal  limits. 
 
• Review concomitant medication usage for a pr olonged 
QTc.  
 
• Restart at current dose levelb,c 
 
• If event recurs, permanently discontinue study 
treatments  
Abbreviations:  msec = milliseconds; QTcB = QT interval on elect rocar diogr am corrected using t he Bazett’s  formula 
a. B ased  on average QTc value  of triplicate  ECGs.  For example,  if an ECG demonstr ates a pr olonged QT interval, 
obtain two or more EC Gs over a br ief period, and then use the averaged QTc values of the thr ee EC Gs to 
determine if study treatmen ts should be interrupted or disco ntinued. 
b. If the QTc prolongation  resolves  to gr ade 1 or baseline,  the subject  may resume study  treatment if the investi gator 
and  medical mon itor agree that the su bject  will bene fit from further treatmen t. 
c.  If dose is delayed more than 21 days, discussion with the medical monitor is required to resume therapy.  
 
CONFIDENTIAL 
Version Date: February 12, 2016  34  
  
 
3.10.3. Guide lines fo r Rash 
 
Rash is a freque nt AE o bserved in subje cts receiv ing trameti nib (see the  Inve stigator’s 
Brochure s [GlaxoSmithKline,  2012] for  more  information). R ecommendations for  
supportive care and g uidel ines for dose modifications for rash are based on expe rience 
with other  MEK inhib itors and E GFR inh ibitors (Balag ula 201 1; Lac outure  2011) and 
are provided (s ee Ta ble  10  and Ta ble 11 ). 
 
The institutional standards for the m anage ment of  skin-re lated AEs can dif fer from the se 
guidelines.  In this case, best clinic al judgment sh ould be applie d and a consultation with 
the M edical Moni tor may be re quired. 
 
Table 10 G uidelines for Supportiv e Care of Rash  
 
Type of Care Action  
 
Preventi on/Pr ophylaxisa • Avoid u nnecessary exposure to sunlight 
 
• Apply broad-spectru m sun screen (cont aining tita nium dioxide or zinc 
oxide) wit h a skin protection fa ctor (SPF) ≥ 15 at l east twic e daily. 
 
• Use thick, alc ohol-free emollient c ream (e.g., glycerine and 
cetoma crogol cream) on  dry areas of the body at  least twice daily. 
 
• Topical ster oids and a ntibiotics sho uld be applied at lea st twice daily 
starting on D ay 1 of study  treatment, to body are as su ch as face, c hest, 
and upper  back. 
 
• Use m ild-strength to pical ste roid  (hyd rocortison e 1% cream)  
 
or 
• topical an tibiotic (e.g., cli ndamycin)  or oral  antibiotics (e .g., 
doxycycline 100 mg BID, minocycline 100 m g BID) 
 
Sympto matic Careb • Pruritic lesions: cool compre sses and oral antihistamine therapies 
 
• Fissuring lesi ons: Monsel’s solution, silver nit rate, or  zinc oxide c ream 
 
• Desquama tion: thick e mollients and mi ld soap  
 
• Paronyc hia: antise ptic bath,  local potent corticostero ids in addition t o 
oral ant ibiotics; if no improvement, con sult derm atologist or surgeon  
 
• Infected lesions: appr opriate  bacterial/fung al culture-driven systemic or 
topical ant ibiotics 
Abbreviations:  BID = twice d aily; SPF = s un protection factor  
a. Rash prophylaxis is reco mmended f or the f irst 6 weeks  of study treatment 
b. Sub jects who develop rash/skin toxicities sho uld be  seen by a qual ified physician a nd should  receive 
evalua tion for sympt omatic/sup portive care management 
 
 
Guid eline s for manageme nt and dose  reducti on for rash consid ered to be  relate d to stu dy 
treatme nt are pro vided (see Ta ble 1 1). Commented [d1]: Change to Novartis 2016?  
CONFIDENTIAL 
Version Date: February 12, 2016  35  
  
 
Table 11 Manag ement and Dose Modificati on G uideline s for Rash  
 
CTCAE Grade Adverse Event Ma nagement  Action and  Dose M odificati on 
 
Grade 1  • Initiate prophylactic and 
symp tomatic treatmen t measuresa 
 
• Use moder ate str ength t opical 
steroi db 
 
• Reassess after 2 w eeks • Continue study  treatment  
 
• If ras h does not recover to 
baseline within 2 wee ks despit e 
best suppor tive care,  reduc e 
trametinib by one  dose le velc 
 
Grade 2  • Initiate prophylactic and 
symp tomatic treatmen t measures 
 
• Use moder ate str ength t opical 
steroi db 
 
• Reassess after 2 w eeks • Reduce t rametinib by one dose 
level  
 
•   If rash re covers to ≤grade 1 
within 2 weeks, increase dos e 
to pre vious dose level 
 
•   If no recov ery to ≤grade 1 
within 2 weeks, interru pt study 
treatment  until rec overy to 
≤grade 1 
 
• Restart trametinib at  reduced 
dose levelc 
 
Grade  ≥3 • Use mode rate strength topical 
steroi dsb PLUS oral  methyl- 
prednis olone dose pack 
 
• Consult d ermat ologist • Interrupt tr ametinib until rash 
recovers to gr ade ≤1 
 
• Restartc  trametinib reduced by 
one do se le veld 
 
• If no re covery to grade ≤2 within 4 
weeks, pe rmanently d iscont inue 
trametinib  
Abbreviations:  CTCAE = Common Te rminolo gy Crite ria for Adverse Events  
a. Rash prophylaxis is reco mmended f or the f irst 6 weeks  of study treatment 
b. Moder ate-stren gth to pical steroids:  hydrocor tisone 2.5% cream or fluticasone  prioprionate 0.5% crea m 
c. Ap proval  of med ical monitor is required to restart study treatment a fter >21 days  of interruption. 
d. Escalation of study treatment to previous dose level may be consider ed if no rash is evident 4 weeks af ter 
restarting study  treatment 
 
3.10.4. Guide lines for Di arrhea  
 
Episodes of  diarrhea have o ccurred in subje cts rece iving trameti nib (see the  Inve stigator 
Brochure s [Novartis, 2016] for more  information). O ther, frequent causes fo r diarrhea 
includi ng conc omitant medications ( e.g., stool softene rs, la xative s, antac ids, etc.), 
infections by C. difficile or other  pathogens, pa rtial bow el obstru ction, e tc., should be 
clinically exc luded.  
 
Guid eline s regarding  manage ment a nd dose  reducti on for diarrhea c onsid ered to be 
related to tr ametin ib by t he investi gator are provided (s ee Ta ble 12 ). 
CONFIDENTIAL 
Version Date: February 12, 2016  36  
  
 
Table 12 Manag ement an d Dose Modificati on G uideline s for Diarrhea  
 
CTCAE Grade Adverse Event Ma nagement  Action and  Dose M odificati on 
 
Uncomplicated 
Diarrheaa 
 
Grade 1 or 2 • Diet: stop all lactose containing produ cts; eat 
small me als, BRAT-di et (ban ana, ric e, app les, 
toast) recommend ed 
 
• Hydration:  8-10 large g lasses of clear liquids per 
day (e.g., Gat orade or  broth)  
 
• Lopera midec: initially 4 mg, follow ed by  2 mg 
every four hours or a fter every unforme d stool; 
maximum  16 mg/ day. Co ntinue unt il diarrh ea 
free for 12  hours  
 
• Diarrhea > 24h: lo peramide 2  mg eve ry tw o 
hours; maximum  16 m g/day. Consider a dding 
oral ant ibiotics 
 
•  Diarrhea > 48h:  lo peramide 2 mg eve ry tw o 
hours; maximum  16 m g/day. Add bude sonide or 
other se cond-line therapies (otreotid e, or 
tincture of op ium) a nd or al anti biotics • Continue trametinib 
 
• If diarrhea is grade 2 for >  
48h,  interrupt  trametinib 
until diarrhea resolves to 
grade ≤1 
 
• Restart tram etinib at the 
same  dose leveld 
 
Uncomplicated 
Diarrheaa 
Grade 3 or 4 
 
Any Complicated 
Diarrheab • Clinical evaluation mandatory 
 
• Lopera midec: initially 4 mg, follow ed by  2 mg 
every four hours or a fter every unforme d stool; 
maximum  16 mg/ day. Co ntinue unt il diarrh ea 
free for 12  hours  
 
• Oral a ntibiotics and second-line therapi es if 
clinical ly indicated 
 
• Hydration:  intra venous flu ids if clinical ly 
indicated 
 
• Antibiotic s  (oral or  intravenous ) if cl inically 
indicated 
 
• Interven tion shou ld be continued unt il the 
subject is di arrhea free for ≥ 24 hours  
 
•  Interven tion may require hospitaliza tion f or 
subjects at risk of  life-thr eateni ng com plications • Interrupt tr ametinib until 
diarrhea r esolves to grade 
≤1 
 
• Restart w ith trametinib 
reduced by one do se 
leveld,e 
 
 
• If 3 dose red uctions of 
study  treatm ent are 
clinical ly indicated, 
permanently di sconti nue 
trametinib  
Abbreviation:  CTCAE = Common Te rminolo gy Crite ria for Adverse Events  
a. Uncomp licated diarrhea defined  by the absence of sym ptoms such as, cram ping, nausea/vom iting ≥grade 2 , 
decreased p erformance sta tus, pyrexia, sepsis, neutropen ia grade ≥3, frank bleeding, and /or dehydr ation  
requiring intraveno us fluid substi tution  
b. Complicated diarrhea defined  by the pr esence of sym ptom s such as, cram ping, nausea/vom iting ≥grade 2 , 
decreased p erformance sta tus, pyrexia, sepsis, neutropen ia grade ≥3, frank bleeding, and /or dehydr ation 
requiring intraveno us fluid substi tution  
c. Lop eramide should  be made avai lable pr ior to start of study treatment so loperam ide administration  can begin at 
the first signs  of diarrhea 
d.  If dose is delayed more than 21 days, discussion with the medical monitor is required to resume therapy.  
e
. Escalation o f trametinib  to previo us dose level is allowed  after con sulta tion with the med ical monitor and in the 
absence of ano ther ep isode of com plicat ed or sever e diarrhea in the 4 weeks  subseque nt to dose redu ction.  
CONFIDENTIAL 
Version Date: February 12, 2016  37  
  
 
4. INVESTIGATIONA L PRODUCT (S) 
 
The term ‘stu dy treatmen t’ is us ed throughout t he protocol to des cribe any c ombination 
of investi gational product( s) (IP) received  by the subject as p er the protocol design. 
Study treatme nt may therefore refe r to the  individual stu dy treatme nt or the  combination 
of those stu dy treatme nts. 
 
4.1. Descri ption of Investigation al Product( s) and/or 
Comparators /Placebo 
 
4.1.1. Trametinib  
 
Trametin ib will  be provided as 0.5 mg a nd 2.0 mg tablets.  E ach tabl et will cont ain 0.5 
mg or 2.0 mg of trametin ib pare nt (present as the  DMSO solvat e). 
 
Trametinib commercial available supply with auxiliary label will also be provided by 
Novartis. The study drug should be administered and stored according to the instructions 
specified on the drug labels (refer to label, PI, and IB for detailed information).  
 
Trametinib will be shipped to sites by the Clinical Research Management Group.  The 
contents of the  label will be in acc ordance with all applic able re gulato ry requirement s. 
 
4.2. Prepa ration/Handling/Stor age of Trametinib  
 
Handling 
 
Under nor mal conditions of handli ng and administration, investi gational product s (IPs ) 
are not e xpected to pose  significant s afety r isks to site sta ff.  A M aterial Safety Da ta 
Sheet (M SDS) d escribing the o ccupationa l hazar ds and recommende d handling 
preca utions will be pr ovided to si te sta ff if required by local laws or  will othe rwise be 
availa ble from Novartis  upon request. 
 
In the  case of un intentional occupati onal exposure  notify the stu dy monitor, the  
Medi cal Mon itor and/or t he study ma nage r. 
 
 
Storage  
 
Study treatme nts must  be stored in a s ecure area unde r the appropriate phys ical conditions 
for the p roduc t.  Access t o and a dministration of  the study treatments  will be limited to the 
investigator and authorize d site staff. S tudy treatme nts must  be dispens ed or administered 
only to subje cts enrolled in t he study a nd in accordance wi th the protocol.  S tudy 
medi cation is to be refrigerated and stor ed at the temp erature spe cified on t he label. 
Mainten ance o f a temperature log ( manual or automated) is require d. 
4.3. Product Accountability 
 
In accordance with lo cal regulato ry requirements,  the inv estigator, designate d site sta ff, 
or head of t he medi cal institution (where appli cable ) must docum ent the amount of stud y 
treatme nts dispens ed and /or administered to stu dy subj ects, the amount  returned by study 
CONFIDENTIAL 
Version Date: February 12, 2016  38  
  
 
subjects, and the  amount  received fr om and  returned to Novartis , when appl icable.  
Produc t accountabil ity records must be m aintained th roughout t he course of the  study.  
See Appendix 8 for medication diary.  
 
4.4. Treat ment Complia nce 
 
Treatment c ompliance will  be asse ssed th rough querying the subj ect duri ng the site  visits 
and do cument ed in t he source doc uments , electronic case  report fo rm (eCRF), and the 
medication diary .  A r ecord of  the numb er of tra metinib ta blets capsul es disp ensed to and 
taken by eac h subj ect must be  maintain ed and r econcile d with stu dy treatmen t and 
compliance records.  T reatment sta rt and stop dat es, inclu ding dates for treatme nt delays 
and/or dose  reduct ions will  also be  recorded in t he eCRF.  Inve stigators must make every 
effort to bring  non-c ompliant subj ects into compl iance. 
 
4.5. Treat ment of Inves tigational Prod uct Ove rdose 
 
In the  event of  an overdose defined as administr ation of  more  than 3.0 mg once daily for 
trametin ib (the  maximum tolerated dose  defined in the MEK111054 Study),  the 
investi gator should:  
 
• c ontact the Medical Monitor immedi ately 
 
• c losely monitor the  subj ect for adve rse events (AEs) /serious a dverse eve nts 
(SAEs)  and labora tory abnormalities 
 
• obtain a  plasma  sample f or ph armacokinetic (P K) analy sis if reque sted by the 
Medical Moni tor (determine d on a  case-by-ca se basis) 
 
• doc ument the qu antity of the excess dose  as well as the du ration of  the 
overdosing  in the electronic case  report fo rm (eCRF). 
 
Decisions r egarding dose in terrupti ons or modific ations will be  made  by the investi gator 
in consult ation with the Me dical Moni tor base d on the clinical evaluati on of  the subj ect. 
 
5. STUD Y POPULATION  
 
5.1. Number of Su bjects  
 
The number  of subjec ts enr olled will  be depende nt on the early re sponse ra te. In stage I, 
15 subj ects will be enrolled in cohor t A and if le ss than one response is  confirmed, t he 
trial will be te rmin ated. If one or  more  responses a re obse rved, an addit ional 10 subj ects 
will be enrolled. Fo r cohor t B, we will enroll patie nts con curre ntly.  In stage I we  will 
enroll up to 15 patients.  If no re sponses a re seen, t his arm will be terminate d. If one or 
more  responses o ccur, we will  accrue up to 10 a dditional p atients. How ever, this 
explor atory study arm wi ll close a t the completion  of cohort A accrual .  
CONFIDENTIAL 
Version Date: February 12, 2016  39  
  
 
5.2. Subject  Selection C riteria  
 
5.2.1. Inclusion Crite ria 
 
Specific in formation regarding  warnings, pre cautions, contra indications, adve rse events 
(AEs), and othe r pertinent infor mation on the study tr eatment s that m ay imp act sub ject 
eligibility is provided in t he Investigator Brochures and  Suppleme nts [Novartis, 2016 ]. 
 
Deviations from inclusion c riteria are not allo wed b ecause t hey can pote ntially jeopardize 
the scientific  integrity of the stu dy, re gulato ry acce ptabil ity or subj ect safety.  Therefore, 
adherence to t he criteria as spe cified in the protocol is essential. 
 
Subjects eli gible for enrolme nt in the stu dy must  meet all of the f ollowing criteria: 
 
1. ≥18 years old.  
 
2. Signe d written in formed consent. 
 
3. Histolo gically or cytologically confir med di agnosis of mel anoma.  
 
4.   B RAF  mutation in loc i other than V600 (BRAF nonV6 00 MUT)  or BRAF f usion 
detected by genet ic testing of the  primary tumor or regional/d istant m etastasis. 
 
5. Subjects must  provide eithe r a fresh or  archived tumor sample for cor relative stu dy 
analyses. 
 
6.   F or subj ects with me lanoma, ar chived o r freshly biopsied tumor tissue (preferred) 
must  be obtain ed prior  to en rollment.  Tissue shipm ent tracking info rmation should be 
provided be fore administration of  study treatment is initiated. However, if shipping 
will be delayed  and  tissue shipment tracking information  is unavailable , study drug 
may be administered prior to tissue receipt pending discussion with principal 
investigator. 
 
7.   Me asurable di sease (i.e., pre sent with at le ast one  measurable le sion pe r RECIS T, 
version 1.1 ( Eisenh auer 2009). 
 
8.   All prior a nti-cancer treatment-related toxicities (except alop ecia and lab oratory 
values a s listed on T able 12) must be ≤  grade 1 accordi ng to the Com mon 
Terminolo gy Crite ria for Adverse Events ve rsion 4 (CTCAE v ersion 4.0;  
CTCAE, 2009) a t the time of ra ndom ization. Subjects with endocrinopathies 
(e.g. hypopituitarism, hypothyroidism, hypoadrenalism) caused by immune therapies currently on adequate hormone replacement WILL be permitted.  
 
9.   Able  to sw allow a nd retain or al medication and m ust not have  any cli nically 
significant  gastroin testinal abno rmalities th at may alte r absorption such a s 
malabsorption sy ndrome or major  resection of  the stomach or bow els. 
 
10.  W omen of  childbea ring potential must have a negative se rum pr egnancy te st with in 
14 days prior to randomizati on and agree to use  effecti ve contrace ption as de fined 
(see Section 7.3.9).  
 
11.  Men with a fe male pa rtner of childbea ring potent ial must have  eithe r had a prior 
vasectomy or ag ree to u se effecti ve contraception as des cribed in Se ction 11.1.2.  
 
12. An Eastern Cooperati ve Oncology Group (ECOG ) performance status of 0  or 1. 
Refer to App endix for de tails.  
CONFIDENTIAL 
Version Date: February 12, 2016  40  
  
13.  Adequa te baseli ne organ function as defined in Table 13.
CONFIDENTIAL 
Version Date: February 12, 2016  41  
 Table 13 D efinitions for Adequ ate Bas eline O rgan Func tion 
 
System  Labo ratory Values  
Hematolo gic 
ANC ≥ 1.0 × 109/L 
Hemoglo bin ≥ 9 g/dL 
Platelet count  ≥ 75 x 109/L 
PT/INRa and PTT  ≤ 1.3 x ULN 
Hepatic  
Album in ≥ 2.5 g/dL 
Total  bilirubin ≤ 1.5 x ULN 
ALT ≤ 2.5 x ULN 
Renal 
Creatinine  or ≤ 1.5 ULN 
Calcula ted creatinine cleara nceb ≥50 mL/min 
Cardiac 
Left Ventr icular Ejection fr action (LVEF) ≥ LLN by ECH O, >50% if not specified  
Abbreviations:  ALT = alanine  transam inase; ANC = ab solute ne utrophil count;  INR = international no rmalized  ratio; 
LLN = lower  limit of no rmal; PT = prothrombin time;  PTT = p artial thrombo plastin  time; ULN = upper lim it of normal. 
a. Sub jects receiving anticoag ulation treatment m ay be a llowed  to participate  with INR estab lished  within the 
therapeu tic range pr ior to random ization.  PT an d PTT > 1.3 x ULN are pe rmitted in these su bjects.  
b. Calculate  crea tinine  clearance usi ng standard Cockcr oft-Gault formula (Appen dix ). Crea tinine  clearance m ust be 
≥50 m L/min to be eligible.  
 
 
5.2.2. E xclus ion Criter ia 
 
Deviations from exc lusion criteria are not allo wed b ecause t hey can pote ntially 
jeopardize the scientific  integrity of the stu dy, regulato ry acceptabil ity or subject safety. 
Therefore, adherence to t he criteria as spec ified in the p rotocol is e ssential.  
 
Sub
jects meeting any o f the following c riteria mu st not be enrolled in t he study: 
 
1. No p rior th erapy with inhibitors af fecting the M APK pathways at any level (BRAF, 
MEK, N RAS, E RK inhib itors) for unres ectable  stage IIIC of Stage I V (me tastatic) 
melanoma. N o limit to othe r therapies (im munotherapy or chemotherapy ). Prior 
systemic  treatme nt in the  adjuvant s etting is allo wed. (Note: I pilimumab t reatme nt 
must  end at least 8 w eeks prior to S tudy Day 1 ). 
 
2. BRAFV600 mutation posit ive. 
 
3. NRAS c odon 12, 13, or  61 mu tation. 
 
4. Any maj or surgery, ex tensive  radiotherapy, chemo therapy with del ayed toxicity, 
biologic therapy , or immunothe rapy within 21 days prior  to Study Day 1, or daily o r 
weekly che motherapy wi thout  the pot ential for delaye d toxicity within 14 d ays prior 
to Study Day 1. 
 
5. Take n an invest igational dr ug with in 28 day s or 5 half-live s (min imum  14 days), 
whicheve r is shor ter, prio r to Stu dy Day 1. 
 
6. Current use of  a prohibite d medi cation as described (see Section 10). 
CONFIDENTIAL 
Version Date: February 12, 2016  42  
  
 
7. Histo ry of another  malignancy 
 
Exception: Subjects who h ave been dise ase-free for 3 years, o r subj ects w ith a 
history of completely res ected, non- melanoma sk in cancer, or subj ects with indolent 
second mali gnanc ies are eligible. T1a  melanoma a nd mel anoma in situ a re pe rmitted. 
Consult M edical Moni tor if unsu re wh ether second mali gnanc ies meet requirements 
specified above.  
 
8. Any se rious or  unsta ble p re-existing medi cal conditions ( aside from m alignanc y 
except ions spe cified above), psyc hiatric disor ders, or o ther condit ions tha t could 
interfere with t he subj ect’s safety , obtaini ng info rmed c onsent, or c ompliance with 
study procedure s. 
 
9. Known Hum an Imm unode ficiency Virus (HIV), Hepatiti s B Virus (HBV), or 
Hepatiti s C Virus (HCV) infection (s ubjects with labora tory eviden ce of cleare d 
HBV a nd HCV inf ection will  be permitted). 
 
10.  Histo ry of leptomeninge al disease or spina l cord compr ession secondary to 
metastasis.  
 
11.  Bra in meta stasis, unless p revious ly treated wit h surgery or stereotactic ra diosur gery 
and the dis ease has been confir med stable  (i.e., no increase in le sion size ) for a t least 
6 weeks with two consecutive MRI sca ns us ing contrast prior to S tudy Day 1 
(the first MRI may be prior to surgical resection or radiation ).  
 
12.  A his tory or eviden ce of cardiov ascular risk inclu ding any o f the following: 
 
a.   A QT inte rval correc ted for h eart rate using the Bazett’s for mula (QTc; Ap pendix 
6 ) ≥480 ms ec; 
b.   A histo ry or eviden ce of curre nt clinically sig nificant un controlle d arrhythmia s; 
Except ion:  S ubjects wi th atrial f ibrillation controlled for  > 30 days p rior to Study 
Day 1; 
 
c.   Histo ry of acute  coron ary syndrom es (including myoca rdial infarcti on an d unst able 
angina), coron ary ang ioplasty, or ste nting with in 6 mon ths prior to  Study Day 1; 
CONFID ENTI AL 
Ver s ion Dat e:  Feb rua ry  12 ,  2016 43  
  
 
 
  
d .    A h i s t or y  o r e v i d e n c e o f  c u r re n t  C la s s  I  c ong e s t i v e  he a r t  f a i l ur e  a s  de f i n e d  by  t he  
Ne w Yo rk  He a r t  As s o c i a t i on  ( NYHA)  g u i d e l i n e s  ( A p pe n d i x  2  ) ;  
 
e .    Tr e a t me n t  r e f r a c t o r y  hy pe r t e n s i o n  de f i n e d  a s  a  b l oo d  p r e s s u r e  of  s y s t o l i c > 14 0  
mmHg a nd / o r  d i a s t o l i c  > 9 0  mm  Hg w h ic h c a n n o t  b e  c o n t r o l l e d  by  a n t i -  hy pe r t e n s i v e  t he r a py ;  
 
f .  Pa t i e n t s  w i t h  i n t r a - c a rd i a c  de f i b r i l l a t o r s  o r  pe rm a ne n t  p a c e ma k e r s ;  
 
g .    K nown  c a r d i a c  m e ta s t a s e s ;  
 
1 3 .   A  h i s t or y  o r c u r r e n t  e v i de nc e  o f RVO  i n c l ud i ng :  
 
a .    H i st or y  o f  RVO  or  
 
b .    V i s i b l e  r e t i na l  p a t ho l o gy  a s  a s s e s s e d  by  op h t h a lm i c  e x a mi na t i on  t h a t  i s  
c o n s i de r e d  a  r i sk  f a c t o r  f o r RVO s u c h  a s :  
 
•  E v i de nc e  o f  ne w  o p t i c  di s c  c u p p i ng ;  
 
•  E v i d e nc e  o f  ne w  v i sua l  f i e l d  d e f e c t s ;  
 
•  I n t r a oc u l a r  p r e s s ur e  >2 1 mmHg a s  m e a su r e d  by  t on og r a p hy .  
 
1 4 .   K n own  imm e d ia t e  o r  de l a y e d  hy pe r s e n s i t iv i t y  r e a c t i on  o r  i d i os y nc r a s y  t o  dr u g s  
c he mi c a l l y  r e l a t e d  t o  t h e  s t u dy  t r e a t me n t s ,  t he i r  e xc i p i e n t s ,  a nd / o r d ime t hy l  su l f o x i d e  ( DMSO) .  
 
1 5 .   H i s t or y  o f  i n t e r s t i t i a l  l ung  d i s e a s e  o r  p ne um on i t i s .  
 
1 6 .   F em a le s  w ho  a r e  p r e g na n t  o r  n u r s i ng  ( s e e  S ec t i on 1 1 . 2 ) .  
 
 
 
6 . COMPLETI ON OR WI THDRAWAL  OF SUBJECTS 
 
6 .1 . Sc reen and Base lin e Fa i lur es 
 
Da t a  f o r  s c r e e n  a n d  ba s e l i n e  f a i l ur e s  w i l l  b e  c o l l e c t e d  i n  so u r c e  d oc ume n t at i on  a t  t h e  s i t e  
b u t  w il l  no t  b e  t r a n sm i t t e d  t o  t h e  C oo rd i n a t i ng  C en t e r.  
 
6 .2 . Sub jec t Compl e t ion C r i te r ia 
 
A  c om pl e t e d  sub j e c t  i s  on e  w h o ha s  d i s c o n t i nue d  s t u dy  t r e a t me n t  fo r r e a s on s  l i st e d  i n  Se c t i on  6 . 3  a n d  c om pl e t e d  a  p o st - t r e a t me n t  fo l l ow- up  v i s i t o r  ha s  d i e d  w h i l e  r e c e iv i ng  s t u dy  t r e a t me n t . 
 
6 .3 . Pe rmanen t Di scon ti nua t ion f r om St udy T rea tmen t 
 
Su b j e c t s  w i l l  r e c e i v e  s t udy  t r e a t me n t  unt i l  d i s e a s e  p rog r e s s i on ,  de a t h  o r  u na c c e p t a b l e  t o xi c i t y ,  i n c l ud i ng  me e t i ng  s t op p i ng  c r i t e r i a  f o r l i v e r  c he mi s t r y  de f i n e d  i n Se c t i on 3 . 1 0 . 1 .  I n a d d i t i o n,  s t u dy  t r e a t me n t  m ay  be  pe r ma ne n t l y  d i s c o n t i nue d  f o r a ny  o f  t h e  f o l l ow i ng  r e a so n s :  
 
•  de v i a t i on ( s )  f r om  t h e  pr o t o c o l  
CONFIDENTIAL 
Version Date: February 12, 2016  44  
  
 
• reque st of the subjec t or proxy (withdrawa l of conse nt by subject or p roxy) 
 
• investi gator’s discretion 
 
• a dose delay o f > 21 days unless the inv estigator or Medical Moni tor agree that 
further treatme nt may bene fit the  subj ect 
 
• intercurre nt illne ss tha t prevents fu rther administration of  study treatme nt(s) 
 
• subj ect is lost to follo w-up or  study is closed or termina ted. 
 
The primary r eason s tudy treatme nt was permanently discontinu ed must be doc ument ed 
in the subj ect’s medi cal records and electronic case re port fo rm (eCRF ). 
 
If the subje ct voluntarily discontinu es from treatme nt due to to xicity, ‘a dverse event 
(AE) ’ will be reco rded as the pri mary rea son for  permanently discontinuati on on the 
electronic  case  report form (eCRF) . 
 
Once a
 subj ect has p ermanently discontinu ed from trametin ib, the subj ect will not be re- 
administered with t he discontinu ed stu dy treatmen t. 
 
All subje cts who dis continue from both stu dy treatments will  have sa fety asse ssments at 
the ti me of dis conti nuation a nd during post- study treatme nt follo w-up as specified  in 
Time a nd Ev ents Table (see S ection 7.1 ). 
 
6.4. Study Completion  
 
Study will be completed having met the stu dy objective s, approxima tely 24 month s a fter 
last sub ject first visi t, or wh en all subj ects have withdra wn from the stu dy, whicheve r 
occurs first.  
 
6.5. Treat ment aft er the End  of the Study 
 
The investig ator is r esponsible for e nsuri ng that consid eration ha s been give n for  the 
post- study ca re of the s ubject’s medical condit ion wh ether or not the Coordinating 
Center  is providing spe cific pos t-study treatme nt. 
 
After 
study pa rticipati on is completed or  terminated, subj ects may eithe r: 
 
• T ransition to a future  rollover stu dy if elig ible and conti nue rece iving their 
curre nt treatme nt wi th trametin ib 
 
OR 
 
• Comp lete a f ollow-up visit  within approximately 28 day s of the last dose of  study 
treatment s if the  subj ect: 
 
• choose s not to ent er the roll-over study, or 
 
• is withdr awn due  to an a dverse event (AE)  considere d related to stu dy treatme nt, 
or 
 
• is conside red inel igible to ent er the rollover study. 
CONFIDENTIAL 
Version Date: February 12, 2016  45  
  
  
 
7. STUD Y ASSESSMENT S AN D PROCEDURES  
 
A signed, written in forme d consen t form must be  obtain ed from the subj ect pr ior to an y 
study-specific pro cedures or a ssessments being perfor med.  
 
The timing o f each a ssessment is l isted in the  Time a nd Ev ents Table (S ection 7.1).  The 
timing and number  of the plann ed stu dy assessm ents may be altere d during t he course of 
the stu dy base d on newly availa ble d ata (e.g. to o btain d ata closer  to the time of p eak 
plasma  conce ntrati ons) t o ensure  appropriate monitor ing for  the following assessment s: 
safety, pharm acokinetic  (PK), pharmacodynamics  (PD)/biomarker or other assessment s. 
The chan ge in tim ing or addit ion of time points for any of the plan ned study asse ssments 
listed a bove  must  be appr oved and do cumen ted by the Coordinating Center , but t his will  
not c onsti tute a p rotocol a mendm ent.  T he institutional review  board (IRB) or e thics 
committee (EC) will be  informed of  any safety issues that re quire  alteration of the s afety 
monitoring scheme. No more  than 100 ml of  blood will be collected ove r  the durati on of  
the stu dy, includi ng any ex tra assessments th at may be require d. 
 
 
7.1. Time and Events Table 
 
This s ection consists  of the  Time  and Ev ents Table (Ta ble 1 4) and suppleme ntal 
footnotes to d escribe assessment windows and sequencing of stu dy-specific a ssessments 
and pro cedures.
2013N166559_00 CONFIDENTIAL 
200344 
46 
Version Date: July 1, 2015  
  
 Table 14         Time and Events  
 
STUDY PHASES1 SCR2 TREATMENT -One Cycle=28 days  Follow up3 
D1 D1521 Continuation EOT Post EOT FU 
Visit Window (Days)                                       -28 N/A ±3 ±3 ± 3 ±7 
CLINICAL ASSESSMENTS  
Informed Consent4                                                    X      
Baseline  demographics                                   X      
Medical History                                                X      
Interim Medical History                                                                                                                          Day 1 of each cycle    
Disease Characteristics X      
Prior Anti-Cancer  Therapy X      
ECOG  Performance Status                             X X5  Day 1 of each cycle  X  
SAFETY ASSESSMENTS  
Physical  Exam, Weight, Height17 X X5  Day 1 of each cycle  X  
Ophthalmologic Exam6 X 
(≤35 days)  
   As clinically warranted As clinically warranted  
Vital Signs7 X X X Day 1 of each cycle  X X 
12-lead ECG8 
X   Cycle 2 day 1, cycle 4 day 1 , then every 12 
weeks thereafter; more frequently if clinically 
warranted   X 
ECHO or MUGA9 X 
(≤35 days)    Cycle 2 day 1, cycle 4 day 1 , then every 12 
weeks thereafter; more frequently if clinically 
warranted   X18 
Adverse Even ts10     X Continu ous X 
Conco mitant Medications                                X Continu ous X 
LABORATO RY ASSESSMENTS 
Hematology/ Chemistry22 X 
(≤14 days)  X5 X Day 1 of each cycle  or more often  as 
clinically warranted X X 
Coagulation/ Urinalysis X   As clinically warranted  X 
Serum Pregnancy Test11 X 
(≤14 days)    Cycle 3, day 1, then e very 8 weeks   X 
Hepatitis B and Hepatitis C16 X      
EFFICACY ASSESSMENTS 
Disease assessment/imaging 
studies  X14   Every 8 weeks through week 56 then 
every 12 weeks thereafter (+/ - 7 days)   X15 
2013N166559_00 CONFIDENTIAL 
200344 
47 
Version Date: July 1, 2015  
  
  
STUDY PHASES1 SCR2 TREATMENT-One Cycle=28 days Follow up3 
D1 D15 Continuation EOT Post EOT FU 
Visit Window (Days) -28 N/A ±3 ±3 ± 3 ±7 
       
EXPLORAT ORY ASSESSMENTS 
Archival t umor tissue  19 X      
Option al Pre-Dose /Post-Dose  
Biopsie s12 X 
(≤28 days)   
X20    
Blood Biomarkers X  X    
Option al Post-Progression  Tumor 
Biopsy13      
X  
SCR=Scree ning, D=Day 
1. All assessmen ts manda ted throughout the study should be performed on the visit day prior to adm inistration of study treatmen ts unless o therwise in dicat ed. Dose  mod ifications  of 
any na ture for either study  treatment must not a lter the pre-planned sched ule of vis its star ting with the first dose of stu dy treatment on Cycle  1, day 1. T he start of a Cycle is 
defined  as the day when tram etinib administration beg ins. If a cycl e is delayed by one week or less, assessmen ts need n ot be repeat ed if results  were not clinically significant.  
2. Assessmen ts within  28 days pr ior to the f irst dose of stu dy treatment u nless  otherwise n oted. 
3. For subjec ts mee ting permanent stu dy treatment withd rawal cr iteria (S ection 6.3), per form fo llow-up visit approxim ately 28 days after withd rawal from study treatmen t. For 
subjects  eligib le to co ntinue study  treatmen ts in a rollover  protocol at study  end (S ection 6.5), per form fo llow-up visit just prior to the start of d osing in the rollover  trial. 
Assessments com pleted at this end of study  follow- up visit may be used as base line values for the rollover trial , provided th at these assessmen ts are co llected within  
14 days of the first dose of study  treatmen t. 
4. Informed con sent may be o btained at any time prior to commencement of scree ning pr ocedures  and does not expir e. 
5. If completed within  72 hrs prior to the first dose  of study  treatmen t, this assessment need n ot be repea ted unless clinically indicate d. If labs are obtained, inclusion criteria remain the 
same and subjects may not begin therapy if laboratory parameters have changed outside study limits .  
6. An oph thalmic exam ination will be p erformed as descr ibed (see S ection 7.3.8).  
7. Vital signs include temp erature,  respiratory rate, blood pressur e, and p ulse rate (see S ection 7.3.3). 
8. For ECG collect ion, the sub ject should rest in a semi-recumbe nt or su pine position  for at least  5 min utes pr ior to digital ECG acquisit ion (see S ection  7.3.4). 
9. LVEF is measur ed with either ECHO (preferr ed) or MUGA. T he m ethod used to initially document t he sub ject’s  basel ine status  must be used consisten tly throughout t he study  
(see Sec tion 7.3.5 ). 
10.  From the time of consent  until first dose of study  treatmen t: only collect SAEs r elated to study p articipation or a Novartis concom itant medi catio n. From Day 1 of study  treatment to 
28 days after the last dose:  colle ct all AEs and S AEs regar dless of causality.  From 29 days post treatment a nd on ward, if available:  only collect  SAEs r elated to study  participation,  
study treatmen t, or a Novartis concom itant med ication.  
11.  Perform on ly in women of childb earing potential. Serum testing  is req uired at scree ning; ser um or urine pregnancy test m ay be used at subsequent time p oints  (see Se ction  
7.3.9). 
12.  If available  and with their consent, subjects  may choose to provide fresh t umor  tissue sam ples at th e times indicated (see Se ction  0). Sam ples co llected on Day 15 should be 
collected prior to dosing.  Tissue may be obtained through excisional, incisional, core needle, or punch biopsies (or by other methods after discussion with medical monitor. ) 
13.  Post-progressi on tumor  tissue col lection  is optional  and should  be performed  on all con senting subjects within  28 days of disease pro gression.  
2013N166559_00 CONFIDENTIAL 
200344 
48 
Version Date: July 1, 2015  
  
  
14.  Baseline CT with contrast ( or MRI if CT is contraindicate d) sho uld be per formed within  28 days of th e first dose of study  treatmen t. The m ethod (CT or MRI) used to document the 
subject’s  baseli ne status  must be used co nsiste ntly throughout the study. Sub jects with melanoma must also have he ad M RI to fulfil eligibility cr iteria. (See Section 7.3.6  details.)  
15.  Required only if previous as sessment was more than 8 weeks  prior to follow-up visit. 
16.  Subjects must be negat ive for Hepa titis B surface an tigen and Hepatitis C an tibody  at the scree ning visit. False positive p atients  may be cleared for e nrollme nt based on RNA- 
based assays (see Se ction  7.3.7).  
17.  Height  w ill be collected  at scree ning only. 
18.  ECHO/M UGA  not requ ired at Follow-up visit if all other on-study LVEF assessmen ts were no rmal and treating physician feels it is not indicated. 
19.  Archival  tumor  tissue (10 unstained slides, 5 micron thickness ) will be collected if available for further research if a baseline biopsy is not performed. Efforts should be made to obtain 
the archival tissue prior to receiving drug; if a plan to receive the tumor tissue is in place, however, day 1 should not be delayed. 
20.  Optional early on-tre atment b iopsy m ay occur on day 15 +/- 3 d ays. 
21. Day 15 visit  only for cycle 1; thereafter patients will be seen every 28 days (+/ - 3 days).  
22. See Table 15 for required laboratory tests.
CONFIDENTIAL 
Version Date: February 12 , 201 6 48  
  
 
 
 
 
7.2. Demographic/M edical History and B aseline As sessmen ts 
 
The following  demograp hic p arameters wil l be captur ed during Sc reening: da te of birth, 
gender, race and e thnicity. 
 
Medi cal/medi cation histo ry assessed a s related to t he eligibility c riteria lis ted in Section 
5.2. 
 
Baseli ne (Screening) asse ssments obtain ed will  includ e: 
 
• Comp lete physical examinati on, including  heig ht (in cm) a nd w eight (in kg). 
 
• Vital si gns:  blood pr essure, temp erature, respiratory ra te, pulse  rate 
 
• Ea stern Cooperative On cology Group ( ECOG)  perfor mance status  
 
• Clinical laboratory tests:  hematolo gy, cli nical chemistry and urinalysis 
 
• Se rum b eta-human  chori onic gona dotropin (β-HCG) pregnancy test f or female 
subjects of c hildbea ring potential on ly 
 
• 12- lead elec trocardiogram (ECG)  
 
• Echoca rdiog ram (ECH O) or multi-gate d acquis ition ( MUGA) scan 
 
• Bra in magnetic re sonance imaging (MRI) with c ontrast or a c ompu ted tomograph y 
(CT) scan (with/without c ontrast) if M RI is contraindicated for  all subj ects with 
cutaneous m elanoma  
 
• Ophth almic exa m by an ophthalmolog ist 
 
• Re view  of conc omitant medica tions 
 
Procedures conduc ted as pa rt of the subje ct’s routi ne clinical manage ment (e.g., blood 
count, i maging study) and obtain ed prior to signing of informe d conse nt ma y be ut ilized 
for Sc reening or  baseli ne purposes p rovided the  procedure m eets the proto col-de fined 
criteria and ha s been performed in the ti meframe o f the study. 
 
 
 
7.2.1. Critical Ba seline Assessments  
 
Critic al baseline assess ments inc lude heig ht, w eight, bl ood pre ssure, smoking  history, 
medi cal condit ions and family history of cardiov ascular disease and risk fa ctors, and 
stage of disease a t screening. 
 
CONFIDENTIAL 
Version Date: February 12 , 201 6 49  
  
 
7.3. Safety Ev aluations  
 
Planned time points for a ll safety assessments are pr ovided in t he Time  and Events Table  
(Section 7.1 ). 
 
7.3.1. Physi cal Exa minatio ns 
 
A complete physical examinati on will  include  assessments of the  head, eyes, ears, nose, 
throat, skin, thy roid, neur ological, lungs, ca rdiov ascular, abdomen (liver and spl een), 
lymph nodes and extr emities.  Heig ht and weig ht will also be m easur ed an d recorde d. 
 
A brief physical examinati on will  include  assessments of the  skin, lun gs, ca rdiov ascular 
system, a nd abdomen (live r and spl een). 
 
7.3.2. ECOG  Performa nce Status  
 
The perfo rmance status  will be assesse d usi ng the Eastern Cooperati ve Onc ology Group 
(ECO G) sca le (Appendix 4) a s spe cified in t he Time a nd Ev ents Table  (see S ection 7.1). 
 
7.3.3. Vit
al Signs 
 
Vital si gn me asurements  will include (i.e., sy stolic and diastolic blood p ressure, 
temp erature, respiration ra te and pulse  rate).  Vital  signs shoul d be measured a fter resting 
for at least 5 minutes in a  semi-supine  posit ion.  Vital si gns will be m easured more 
frequently if warra nted by cli nical condi tion of the  subj ect.  On d ays where vita l signs are 
measured mu ltiple ti mes, temp erature doe s not n eed to be re peated unl ess cli nically 
indicated.   
 
7.3.4. Electro cardiogr am (ECG)  
 
A sin gle 12 -lead ECG w ill be obtain ed at designated time  points during the study using 
an ECG ma chine th at automatically ca lculates the heart rate and m easures PR, QRS, QT, 
and corr ected  QT (QTc) intervals.  At eac h assess ment a  12-lead ECG will be performed 
by quali fied personnel a t the site after the sub ject has a t least a 5 minute re st and is  in a 
semi-rec umbent or supine positi on. 
 
The QT 
interval should be corr ected for heart rate by Bazette ’s formula  (QT cB; see 
Appendix 6). Refe r to S ection 3.10.2  for QTc stopping  criteria and addit ional 
information.  
 
7.3.5. Ec hocardiog ram (ECHO) and/or  Multi-gated Ac quisition (MUGA ) 
Scans  
 
An E CHO  (preferred) or a MU GA scan will  be perfor med a t baseli ne to as sess cardi ac 
ejection fraction and cardiac  valve mo rphology for the pu rpose of study eli gibility, a s 
specified in the Time  and Events Table (see S ection 7.1). Additi onal ECHO or  MUGA 
assessments m ay be perfor med if  clinically warra nted.  The  procedure use d to docum ent 
the subje ct’s baseline LVEF status shou ld be used consistent ly throughout t he study.  I f 
possi ble, the in terpretation of LVEF  status  should be  perfo rmed consistent ly by the sa me 
reviewer throughout t he study.  The evaluati on of  the echoca rdiographe r should inc lude 
CONFIDENTIAL 
Version Date: February 12 , 201 6 50  
 an eva luation f or left ventricula r ejecti on fraction (LVEF)  and both r ight and left-sided 
valvular lesions. 
 
Copies of  all ECHO or  MUGA scans perfo rmed on subj ects who expe rience an a bsolute 
decrease >10% in  LVEF c ompa red to ba seline concurre nt wi th LVEF < institutional 
lower limit of n ormal (LLN) may be required by the Coordinating Center  for review. 
 
7.3.6. Brain MRI and/or CT S can 
 
A ma gnetic re sonance imaging (MRI) with cont rast will be p erfor med at Scree ning (see 
Time a nd Ev ents Table,  Section 7.1) to r ule out any ne w unt reate d brain metastase s and  
to ve rify stability of b rain met astases if p resent for all subjects with cutane ous m elanom a. 
A compu ted tomography (C T) scan with and without  contrast may be perfo rmed if a  MRI 
is contr aindicated.  
 
7.3.7. Labor a
tory A ssess ments  
 
All proto col required laboratory asse ssments should be perfor med accor ding to t he 
Time  and Ev ents Ta ble (see S ection 
7.1).   
 
Prior to admin istration of  the f irst dose  of stu dy treatme nt, results of l aborator y 
assessments shou ld be reviewed.  Any laboratory test with a  value outside the no rmal 
range may be repeated  (prior  to the first dos e) at the discreti on of  the inv estigator. 
 
If laboratory assessments for screening are completed within 72 hours of the first dose, they do not have to be repeated on cycle 1, day 1. If labs are obtained on the first day, values are still required to meet inclusion criteria (Table 13).  
 
If additional non -protocol specified labo ratory asse ssments are perfo rmed at the 
institution’s local labora tory and result in a chan ge in patient man agement  or are 
consid ered cli nical significant by the I nvestigator (for exa mple SAE or AE or dose 
modification) the  results must  be recorded in t he subject’s C RF. 
 
All l
abora tory tests wi th abnorma l values that a re consid ered cli nically sign ificant duri ng 
particip ation in t he study or with in 30 days a fter the last dose of  study treatment should 
be repeated until  the v alues return to norm al or baseline.  I f such values do  not r eturn to 
norma l within a pe riod j udged rea sonable by the inve stigator, the possi ble et iology 
should be  identifie d and t he Coordinating Center notifie d. 
 
Hematolo gy, cli nical chemistry, urin alysis and addi tional p arameters to be  tested are 
listed in T able 15:  
CONFIDENTIAL 
Version Date: February 12 , 201 6 51  
  
 
 
Table 15 List of  Clinical Labor atory Tests  
 
Hematology  
Platelet Count RBC Indices: Automated  WBC Different ial: 
Red blood cell (RBC) Count MCV Neutroph ils 
White b lood cell (WBC) Count 
(absol ute) MCH Lymphocytes 
 MCHC Mono cytes 
Hemoglo bin  Eosinophils 
Hemato crit  Basophils 
Internat ional Normalized Ratio (INR; at s creening only)a 
Prothromb in time (PT; at screening only)a 
Partial  thrombop lastin time (PTT; at s creen ing only)a 
Clinical C hemist ry 
Blood urea  nitrogen 
(BUN ) Potassium Aspartate aminotran sferase  
(AST) Total  and direct bilirubin 
Creatinin eb Chloride  Alanine  aminotran sferase  
(ALT)  
Glucose, (rando m) Total  carbon 
dioxide (CO2)  Album in 
Sodium Calcium Alkaline ph ospha tase  
Lactate 
Dehydrogenase 
(LDH)  Potassium  
Routine Ur inalysis  
Specific gravity 
pH, glucose, p rotein, bl ood and keto nes by d ipstick 
Microscopic examination (if  blood or pro tein is ab norm al) 
Other  screening tests  
Human I mmuno deficiency virus (HI V) c 
Hepatitis B ( HBsAg) 
Hepatitis C (H ep C  antibody -- if second g enerat ion H epatitis C anti body po sitive, a hepat itis C antib ody 
Chiron RI BA®  immuno blot assay should b e refl exively perfor med  on the same s ample  to confirm the 
result) 
Follicle stimulating ho rmone (F SH) and es tradiol (as needed in women of n on-chil d bearing potent ial only) 
a. Coag ulation  panel to be do ne at Scree ning on ly 
b. If serum  crea tinine  is > 1.5 m g/dL, crea tinine  clearance shou ld be calculated  using  the standard Cockroft-Gault 
formula (Appen dix ) 
c. HIV testing is optional  
 
 
7.3.8. Opht halmic Examination 
 
Subjects are required to have a stan dard ophthalm ic examinati on perfor med by a n 
ophthalmolog ist at the times d escribed (Section 7.1). At certa in time point s in t he trial 
and if visual change s develop, an eye exa m is ind icated. (Refe r to Table 6  for visual 
change s stopping criteria).  T he exam wi ll include b est corrected visu al acuity, 
tonometry, sli t lamp b iomicroscopic examination, visua l field examination, a nd di lated 
indirect fundoscopy with special atte ntion to r etina l abno rmalities.  O ptical coherenc e 
tomography is strongly r ecom mended a t schedule d vis its, and if retinal abnormalities are 
suspe cted. Other types of ancil lary testing including  color fundu s phot ography and 
CONFIDENTIAL 
Version Date: February 12 , 201 6 52  
 fluorescein angiography a re also recommende d if clinically indicated. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 53  
  
7.3.9. Pregnancy Testing and Reporting 
 
The need for  a screening p regnancy te st dep ends o n wh ether a female subj ect is of 
childbea ring potential or  non-c hildbeari ng potent ial. 
 
If a fe male  subjec t is of c hildbea ring pote ntial, she  must  have a serum β-HCG p regnanc y 
test p erfor med within 14 day s prior to the first do se of stu dy treatment(s).  S ubjects with 
posit ive pregnancy test re sult must  be excluded from the study.  S ubjects with neg ative 
pregnancy te st result must  agree to use  an effective contraception method as des cribed 
(Section 11.1.1)  during the stu dy until four mon ths following  the la st do se of stu dy 
treatment (s). 
 
Any p regnancy that o ccurs dur ing study pa rticip ation must be re porte d usi ng a cli nical 
trial p regnancy for m.  To  ensure  subj ect safety, each pre gnancy must  be reporte d to the 
Coordinating Center within two w eeks of l earning of its oc currence.  T he pregnancy must  
be followed up t o determine outcome  (including prema ture termin ation) and sta tus of 
mother and c hild. Pr egnancy c omplicati ons and e lective te rmin ations for  medi cal reasons 
must be re porte d as an adve rse event (A E) or se rious a dverse event (SAE).  Spontaneous 
abortions must be r eported a s an SAE.  
 
Any S AE 
occurring in associ ation with a p regnancy b rought to the inv estigator’s 
attention after the subj ect ha s complet ed the stu dy and c onsid ered by the inve stigator as 
possibly re lated to t he study treatment (s), must be  promptly repo rted to the  
Coordinating Center . 
 
In addit ion, t he investi gator must  attempt to colle ct pregnancy in formation on any fe male 
partners of male stu dy su bjects who bec ome p regnant whi le the subje ct is enr olled in t he 
study.  P regnancy informati on must be re ported to  the Coordinating Center a s described 
above. 
 
7.4. Baseline Ass essment of Targ et and non-target l esions 
 
All ba seline lesion asse ssmen ts must be pe rformed w ithin 28 days of enrol lmen t. 
• Lymph node s that ha ve a s hort ax is of <10mm a re considered non- 
pathological and should not be recorded or follow ed. 
• Patho logica l lymph nodes with <15mm and but ≥10mm s hort ax is are 
consid ered non measu rable. 
• Patho logical l ymph nodes with ≥15mm s hort axis are consid ered measurable and 
can be se lected a s target le sions; howeve r lymph nodes 
shou ld not be se lected a s target lesions w hen othe r suitab le target le sions 
are avail able.  
• Measurable lesions up to a maximum of two le sions per organ an d five lesi ons in 
total, representative of a ll involved org ans, shou ld be iden tified as target lesi ons, 
and reco rded and measured at ba seline. These lesions shou ld be se lected on the 
basis of the ir size (lesions with the longe st diamet er) and t heir suitability for 
accurate repeated measurements (either by i maging technique s or clinically). 
 
Note: Cystic le sions thought to re present cyst ic metastase s shou ld not b e selected 
as target lesions when other suitable target lesions a re avail able. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 54  
  
 
 
 
Note: Measurable le sions that have be en prev iously irradiated and have not be en shown to 
be pro gressing fo llowing irradiation shou ld not be c onsidered as target lesions.  
 
 
• Lytic bone lesi ons or mixed ly tic-blastic lesion s, with identifiable soft  tissue 
components, that can be eva luated by CT  or M RI can be con sidered measurable. 
Bone sc ans, FDG-PET scans or X-ray s are not c onsidered adequa te imaging 
techniq ues to measu re bone le sions. 
• All ot her lesions (or si tes of d isease) should be id entified as non-targe t and should 
also be recorded at ba seline. Non-target lesions wil l be g roup by org an. 
Measuremen ts of the se lesions are not re quired, but th e presen ce or absen ce of 
each should  be noted th roughout follow- up. 
 
7.5. Efficacy A ssessments 
 
Disease progression  and response eva luations will be determined a ccording  to the 
definition s established in the Response Eva luation Criteria in Solid T umors (RECIST  
version 1.1 ) [Eise nhauer,  2009 ]. 
 
See the Time and Ev ents Table (S ection 7.1 ) for the sc hedule of effica cy 
assessme nts. As sessments must be pe rformed on a ca lendar schedu le and should not 
be af fected by dose interr uption s/delays. 
 
The follow ing are required at ba seline: 
• Computed to mography (CT) scan  with contrast (e.g., c hest, abdomen, and /or 
pelvis as appropria te for a given s ubject) for assessment o f baseline d isease 
burden w ithin four weeks of en rollment. All post- tre atment asse ssme nts require 
CT imaging of disease sit es identified b y these baseline sc ans. 
NOTE: A lthough CT is preferr ed, MRI may be used as an a lternative method of 
baseline d isease assessmen t, espe cially  for those subjects where CT is 
contraindicated (i.e ., allergy), p rovided tha t the method use d to docu ment 
baseline status is used c onsis tently throughout stud y treatment to facilitate dire ct 
comparison. 
• A ba s eline b rain scan is required fo r all s ubjects for assessme nt of CN S disease 
within four weeks of en rollment. He ad CT  with contrast or magnetic re sonance 
imaging (MRI) are both a cceptable methods of CNS disease assessmen t, but 
contrast en hanced M RI is preferr ed. For sub jects without CN S disease at baseline, 
subsequ ent brain scans should only b e performed a s clinic ally indicated (i.e ., 
symptoms sugge stive of CNS pro gressio n). Sub jects demonstrating brain 
metasta sis at ba seline mu st have the baseline scan com pared to an earlie r scan  
performed (prefe rably 6 weeks ea rlier) to de monstrate that the metastasi s is st able. 
Stable is defined as no incr ease in lesions between the two sc ans. The ra diologist 
reports and the pri mary inve stigator’ s analysi s for these scans must be sen t to the 
medical monitor fo r approval. Tim ing between the baseline sc an and or iginal scan 
is described above. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 55  
  
 
 
 
NOTE: For subjects with CNS d isease at ba seline, a brain scan  is 
required eve ry eight w eeks o r as clinically i ndica ted. 
 
NOTE: The method used to docu ment baseline statu s shou ld be use d 
consist ently throughout study treatment to facil itate direct com parison 
 
For s ubjec ts with palpable/superficial lesions, cl inical d isease assessme nts by 
physical examination should be performed at ba selin e and throughout st udy 
treatment as clinic ally i ndica ted. 
 
Confirma tion of CR an d PR are required per prot ocol. Confir mation assessme nts must be 
performed no less  than fou r weeks af ter the cr iteria for respon se have initi ally been met 
and ma y be pe rformed at the next p rotocol scheduled a ssessme nt. If a confir mation 
assessme nt is performed prior to  the next protocol schedule asse ssme nt, the ne xt protocol 
scheduled  evaluation is s till require d (e.g., eva luations must  occur at each protocol 
scheduled time po int rega rdless of un scheduled asse ssme nts). 
 
7.5.1 A ssess ment Guidelines 
 
Please note the following: 
 
• The same d iagnostic  method, includ ing use of contrast  when app licable, must 
be used thro ughout the study to eva luate a lesion. 
• All measure ments shou ld be ta ken an d recor ded in mill imeters (mm), u sing a 
ruler or cali pers. 
• Ultrasound is not a suit able modality of disease a ssessmen t. If ne w lesi ons a re 
identif ied by u ltrasound, confir mation by CT o r MRI is re quired. 
• FDG -PET is gene rally not suitable for ongoing a ssessments of disease. Ho wever 
FDG-PET c an be usefu l in confirm ing new sites of disease where a po sitive FDG -
PET scan corre lates with the new site of disease present on C T/MRI or when a 
baseline FDG -PET wa s previously negative for t he site of the new le sion.  
• If PET/CT is per formed then the CT comp onent can on ly be used for st andard 
response asse ssments if pe rformed to  diagnostic quality, 
which include s the required a natomical coverage and prescr ibed us e of 
contrast. The method of a ssessment should be noted a s CT on the electronic 
CRF. 
 
Clinical Examination: Cl inically detected lesi ons wil l only  be c onsidered mea surable 
when they a re superficial (e.g., s kin nodules). In the ca se of skin 
CONFIDENTIAL 
Version Date: February 12 , 201 6 56  
 lesions,  documenta tion by co lor photography, including  a rul er or calip ers to 
measure the si ze of the le sion, is required. 
 
CT and MR I: Contrast enhanced CT w ith 5mm con tiguous slices  is 
recomme nded. 
Minimum size of a measu rable baseline lesion shou ld be tw ice the sli ce thickness, with 
a minimum le sion si ze of 10 mm w hen the slice  thickness is 5 mm. M RI is acceptable, 
but w hen used, the tec hnical s pecif ication of th e scann ing sequence s shou ld be 
optimized for the eva luation of the type and si te of d isease and lesions must be 
measured in  the same anatom ic plane by u se of the same imaging exam inations. 
Whenever po ssible, the same scanner should be used ( Eisenhauer 2009). 
 
X-ray: S hould  not be used fo r target lesi on m easuremen ts owing to poor lesion 
definition. 
Lesions on c hest X-ray may be c onsidered measurab le if they are clearly defi ned an d 
surrounded by aerated lung; howeve r chest CT is preferred ove r chest X-ray. 
 
Brain  Scan: If b rain scans are required, then c ontrast en hanced MRI is prefer able to 
contrast en hanced CT. 
 
 
7.5.2 Measurable a nd Non-m easurable De finitions  
 
A me asurab le lesion is  a non-no dal lesion that can be a ccurately measu red in at least one 
dimension (longest dimen sion) of: 
 
• ≥10 mm w ith MRI o r CT when the scan slice  thickness is no gr eater than 
5mm. If the slice  thickness is g reater than 5mm, the m inimum si ze of a 
measurable lesi on must  be at lea st double the slice  thickness (e. g., if the slice 
thickness is 10 mm, a measurable lesion must  be ≥20 mm ). 
• ≥10 mm cali per/ruler measurement by clinical exam or med ical 
photog raphy. 
• ≥20 mm by c hest x-ray. 
 
Additiona lly ly mph node s can be con sidered pathologically  enlarged and 
measurable if: 
• ≥15 mm in the s hort axis when assessed by CT o r MRI (s lice thickness 
recomme nded to be no more  than 5 mm ). At baseline and follow- up, only t he 
short axis will be m easured ( Eisenhauer 2009). 
 
A non-measurab le lesion is:  
• All ot her lesions including le sions too s mall to be con sidered measurable 
(longe st diameter <10 mm o r patho logical ly mph node s with ≥10 mm and 
<15 mm short ax is) as we ll as truly non- measurable lesions, which include : 
ascites, pleura l or perica rdial effu sions, inflammato ry breast disease, 
lymphangitic in volvemen t of the skin  or lung, abdom inal 
CONFIDENTIAL 
Version Date: February 12 , 201 6 57  
  
 
masses/abdom inal organomegaly identified by physical exam that is not 
measurable by reproducible  imaging technique s (Eisenhauer 2009). 
 
Measurable disease: The  presence of at l east one me asurab le lesion. Pal pable lesi ons 
that are not measu rable by radiologic o r photog raphic evaluations ma y not be u tilized 
as the on ly measurab le lesion. 
 
Non-Measurab le only disease: The pres ence of on ly non-m easurable le sions. Note: 
non-measurab le only  disease is not al lowed pe r protoco l. 
 
 
7.5.3 Res ponse  Crit eria 
 
7.5.3 .1 Target Lesions 
 
Definitions for
 assessment of response for target lesion(s)  are as follow s: 
• Com plete Res ponse (CR ): Disappearance of a ll target lesions. Any 
pathological ly mph node s must  be <10  mm in the s hort axis. 
• Partial Response (PR ): At least a 30 % decrease in the sum of th e diamet ers of 
target lesions,  taking as a reference, the ba seline su m of the 
diamet ers (e.g. pe rcent change from baseline ). 
• Stab le Di sease (SD ): Neither sufficient shrinkage to qua lify fo r PR nor 
sufficient incre ase to q ualify for p rogressive disease. 
• Progres sive Di sease (PD ): At least a 20 % increase in the sum of th e diamet ers of 
target lesions,  taking as a reference, the s mallest su m of diamet ers reco rded since 
the treatment started (e .g. pe rcent change fro m nad ir, where nadir is de fined as the 
smal lest sum of diamete rs reco rded 
since  treatmen t start). In add ition, the su m must have an abso lute 
incre ase from nad ir of 5mm. 
• Not Applicable (NA ): No  target lesions at baseli ne. 
• Not Eva luable (NE ): Ca nnot be cl assified by one of the five p reced ing 
definition s. 
 
NOTE:  
• If lymph node s are documented as ta rget lesions the s hort axis is added into the 
sum of the dia meters (e.g. sum of dia meters is the sum of th e longest diamete rs for 
non-noda l lesion s and the short ax is for nodal lesi ons). W hen lymph nodes 
decrease to non-patholog ical si ze (sh ort ax is <10mm ) they s hould  still have a 
measurem ent reported in  order not t o ove rstate progressio n. 
• If at a given a sse ssment time po int all target le sions identified at baselin e are not 
assessed, sum of the d iamet ers cannot be ca lculated for purpose s of asse ssing  CR, 
PR, or SD,  or for use  as the nad ir for future a ssessme nts. Ho wever, the sum of the 
diamete rs of the a ssessed le sions and the pe rcent c hange from n adir shou ld be 
calculated to en sure that progression  has not be en documented. If an a ssessment of 
PD c annot b e made, the respon se asse ssment s hould be N E. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 58  
  
 
• All le sions (nodal and non-noda l) should  have the ir measuremen ts rec orded even 
when very small (e.g., 2 mm ). If lesions are present but too s mall to measure, 5 
mm should be re corded an d should con tribute to th e sum of the dia meters, unless  it 
is likely that the le sion has d isappea red in wh ich case 0 mm shou ld be repo rted. 
• If a lesion d isappears and reap pears  at a subsequen t time po int it should c ontinue to 
be measured. The re sponse at the time w hen the lesio n reappears wil l depend upon 
the status of the ot her lesions. For example, if the disease had reached a CR st atus 
then P D would be docu mented at 
the time of reap p earance. Ho weve r, if the re sponse status was PR or SD, t he 
diamet er of the rea ppearing le sion shou ld be ad ded to  the re maining d iamet ers 
and response determi ned based on percent ch ange fro m ba selin e and pe rcent 
change fro m nad ir. 
 
 
 
7.5.3 .2 Non-target lesions 
 
Definitions for as sessment of response for non-target lesion s are as follows: 
• Comp lete Respon se (CR): The dis appearan ce of a ll non-target lesion s. All 
lymph node s identified a s a site of disea se at ba seline must  be no n- pa thological 
(e.g. <10 mm s hort axis). 
• Non- CR /Non-PD: The pe rsistence of 1 or more non-target lesion(s)  or lymph 
node s iden tified a s a site of d isease at ba seline ≥  10 mm s hort ax is. 
• Prog ressive Dise ase (PD): Un equivoca l progression  of ex isting  non-targe t 
lesions.  
• Not Applicab le (NA ): No non-target lesion s at baseline.  
• Not Eval uable (NE): C annot be cl assified by one of the four preced ing 
definition s. 
 
NOTE:  
• In the p resence of measu rable disease, p rogression on the ba sis of so lely non-
target d isease re quire s subst antial worsening such that even in the presen ce of SD 
or PR in target dis ease, the ove rall tumor burden ha s incre ased suff iciently to merit  
discontinua tion of t herapy. 
• Sites of non-target lesions, which are not asse ssed at a pa rticular tim e point 
based on the asse ssment sc hedule, shou ld be ex cluded from the 
response determ ination (e.g. non-target res ponse does not have to be 
"Not Evaluable"). 
 
  
7.5.3 .3 New Le sions 
 
New  malignancies denoting disease p rogression must  be unequivoca l. Lesions 
identified in  follow-up in  an anatom ical loca tion not sc anned at baseline are consid ered 
new le sions. 
 
Any equivoca l new lesi ons s hould  continue to be follow ed. Treatment can continue at the 
discretion of the inve stigato r until the ne xt scheduled a ssessme nt. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 59  
  
 
If at the ne xt asse ssme nt the ne w lesion is consid ered to be une quivoca l, 
progression  shou ld be documented. 
 
 
7.5.3 .4          Eva luation of  overa ll res ponse  
 
Table 16 pre sents the ove rall response at an individ ual time point for a ll possible 
combinations of tu mor response s in target and non-target lesions with or without the 
appearan ce of ne w lesi ons for su bjects with measurable disease at baseline. 
 
Table 16 Eva luation of  Overa ll Response f or Subjects with Meas urable 
Disease a t Baseline 
Target Lesions Non-Target Lesions New Lesions Overall Response 
CR CR or NA No CR 
CR Non-CR/Non-PD or 
NE No PR 
PR Non-PD or NA or 
NE No PR 
SD Non-PD or NA or 
NE No SD 
NE Non-PD or NA or 
NE No NE 
PD Any Yes or No PD 
Any PD Yes or no  PD 
Any Any Yes PD 
CR=co mplete response, PR = partial respon se, SD=stable disease, PD=progressiv e disease, 
NA= Not appli cable, and N E=Not Evaluable 
 
NOTE: 
• Subjects with a glo bal deteriora tion of h ealth st atus requiring d iscontinuation of 
treatment without ob jective ev idence of disease progression  at that time shou ld be 
class ified a s having "symptoma tic de teriora tion." Ob jective res ponse statu s is 
determi ned by eva luations of disease burden . Eve ry effort should be made to 
docum ent the ob jective progression  even af ter discontinua tion of tr eatment. 
• In some circumst ances, it may  be difficu lt to distinguish resid ual disease fro m 
normal tissue. W hen the eva luation of CR dep ends on th is determination, it is 
recomme nded that the re sidual lesion be inve stigated (fine needle aspirate/bi opsy ) 
to confirm the C R. 
 
 
7.5.3 .5 Eva luation of  best overa ll response  
 
The be st overall res ponse is the be st respon se recorded fro m the sta rt of th e treatment 
until disease p rogressio n/recurrence and wil l be de termine d programma tically by the 
study investigator . 
• To be a ssigned a statu s of SD, the post- baseline d isease assessmen t must have 
met the SD cr iteria at least on ce af ter study Day 1. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 60  
  
 
• If the m inimum time  for S D is not me t, best response wil l depen d on th e subsequent 
assessmen ts. For ex ample if an a ssessme nt of PD  follows the assessme nt of SD and 
SD does not meet the m inimum time re quirement the be st respon se will be P D. 
Alternative subjects lost to  follow-up af ter an SD a ssess ment not m eeting the 
minimum t ime criteria wil l be c onsidered not eva luable. 
 
Confirma tion Cr iteria: 
To be a ssigned a statu s of PR o r CR, a confir matory disease assess ment should be 
performed no le ss than 28 days after the criteria for respon se are first met. Elec tronic 
scans wil l be re quired for i ndependent review. 
 
 
7.6. Transla tional Rese arch 
 
Perfor mance of th ese investi gations m ay be condit ional on t he results of the  clinical trial, 
and sa mples may be selected for analy sis on the ba sis of the  clinical outco me.  A table of 
samples to be  collected  for tr anslat ional research, whether the sa mples are mand atory or 
optional, and the  primary purpose for collection is provided (s ee Ta ble 17 ). 
 
Compa rative examinati on of  pre-dosing profiles of subj ects may uncover known or  nove l 
candidate  biomarke rs/profiles which co uld be us ed to predict re sponse to treatme nt wi th 
trametin ib or provide n ew insi ghts into cancer and medi cally re lated conditi ons. 
Compa rative examinati on of  post- dosing  profiles  in conjun ction with pre-d osing  profiles 
may yield known a nd nove l candidate bio markers/profiles and  new ins ights which re late 
to the action of tr ametin ib in t his patient population . 
 
All s
ample s may be re tained for  a maxim um of 15 years after the last subject’s last visit 
of the follow -up period. Future research may be performed on available sample with an 
IRB-approved protocol.  
 
Novel candida te bio marke rs and subseq uently discovered bio markers of the  biological 
response a ssociated with  cance r or medically re lated condit ions and/or the  action of 
trametin ib may be identif ied by a pplication of: 
 
• DN A/gene, RNA,  and protein analy sis of tumor t issue a nd blood /plasm a. 
 
Table 17 Tabl e of Samples for PD and Translation al Rese arch 
 
 
Samples  Mandatory/Optional Archived/Fresh 
tumor  tissue Primary Purpose 
Tumor 
tissue for 
geneti c 
analysis Mandatory1 Either For genetic analysis 
Pre-dose 
and pos t- Optional Fresh  For PD analysis of protein 
biomarkers via IHC 
CONFIDENTIAL 
Version Date: February 12 , 201 6 61  
  
 
dose tumor 
tissue 
biopsi es    or other analyses.  
Post- 
progr ession 
tumor 
biopsy Optional Fresh  For evaluation of DNA , RNA 
and protei ns relat ed to drug 
response and  resistan ce 
1Patients wi thout avail able tum or tissue w ith genetic analysis m ay be included if previ ous ne xt 
generati on sequenci ng panel s that hav e alre ady assessed g enetic biomarkers of 
intere st have been perform ed. Di scussi on w ith the principl e inve stigator is required. 
 
7.6.1. Tumor Ti ssue  for Ge netic  and Protein  Biomar ker A nalysis 
 
Molecu lar  inclusion f or the trial includ e: (1) The pre sence of a mu tation in  BRAF a t a 
codon other  than V600, o r a BRAF gene f usion eve nt; (2) The docume nted absence of a 
mutation at BRAFV600 (i.e., B RAFV60 0WT) in tumor  tissue; and (3) The  document ed 
absence of a mutation in c odons 12, 13, and 61 of  NRAS. Th ese molecular  criteria for 
inclusion m ay be met by pre vious ly perfo rmed mo lecular  testing per formed in a CLIA- 
certifie d lab oratory. Alte rnatively, arc hival or  fresh tissue must be  provided for testing  of 
BRAF a nd NRAS.  In addition to these  required mo lecular  tests, a rchival  specime ns are 
required to allow fo r testing of addit ional  molecular  alterati ons that may cor relate with 
sensitivity or resistance to treatme nt wi th trametinib. Suc h alterati ons inc lude, but are not 
limited to, ge ne mutations (ME K 1, MEK2, K RAS, HRAS, NF1, P TEN, PIK 3CA, A KT, 
TP53, CDKN2A, CDK4), gene de letions (PTEN, CD KN2A), gene a mplifications ( BRAF, 
CDK2, CCND1, MITF ), and/or change s in g ene or protein exp ression (growth factor  
receptors, p-ERK, p -AKT, PTEN, CDK N2A). 
 
During 
the sc reening peri od pr ior to enr ollment, al l sub jects with melanoma  will be 
required to provide  archived tumor t issue or  to unde rgo tumor biopsy if archived tumor 
tissue is not availa ble.  New biopsy  samples must  be ta ken from le sions not re quired 
for dise ase assessment . 
 
Optional tu mor biopsies may a lso be per formed to  allow for a ssessment o f the 
pharmacodynamic s effects of trametin ib treatment. Suc h biopsies m ay be perfor med 
within 28 day s of the  start of tr eatme nt, and on Cycle 1 Day 15 (+/- 3 day s to allow for 
scheduli ng conflic ts). A ssessment of these  sampl es will  includ e, but a re not limi ted to, 
change s in t he activati on st atus of  components of  the M APK pathway and other 
compens atory signalin g pathways implicated in  melanoma (i.e. PI3K-AK T pathway). 
 
Optional tu mor biopsies may a lso be c ollected afte r document ed disease progre ssion 
from subje cts  that have  provid ed approp riate consent. Sa mples will  be used  to investigate 
the mole cular mecha nisms of tr eatme nt resistance. Exac t methodolog ies and ma rkers 
examine d will  be determine d by the P rincipal I nvestigators a t the time the  samples are 
availa ble fo r analy sis, base d on existing knowl edge about re sistance and melanom a; the 
nature and a mount  of the  biop sy mat erial, and the  molecular  analy sis platfo rms availa ble 
at that time. Analyse s may includ e, but are not limite d to, change s in DN A, RN A, and/or 
protein, a nd the e stablis hment of cell  lines and/or xenogra fts. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 62  
  
 
Investigators are highly encouraged to collect tumor biopsies at baseline (in the 
absence of sufficient archival tissue) and day 15 (+/- 3 days) following initiation of 
therapy, with an optional tumor biopsy conducted at the time of disease progression.  The pre -treatment biopsy will be obtained within 28 days of starting therapy. As noted, 
archival tissue within one year of starting therapy of sufficient quantity will preclude 
the need for an initial biopsy.  Issues that would cause treatment delays should be discussed with the PI who may grant permission on a case -by-case basis to analyze 
tissue from a protocol pre -treatment biopsy that has occurred greater than 28 days prior 
to study treatment.  The post -treatment biopsy will be performed at day 1 5 ± 3 days 
prior to the morning dose of the study medications.  An optional third tumor biopsy will be requested of these patients at the t ime of tumor progression, with particular 
efforts made at obtaining such biopsies in patients who have developed progression after achieving a radiographic response to treatment or after prolonged disease control (i.e., greater than 4 months). All biopsies  may be obtained through excisional, 
incisional, core -needle, or punch biopsy methods. Up to eight core samples will be 
obtained with each biopsy  (in the case of a core biopsy) , providing sufficient tissue for 
the correlative studies.   
 
Tissue will be divided such that a portion (one core in the case of core needle biopsy 
procedures) is formalin fixed and designated for immunohistochemistry (IHC) and the 
remainder flash frozen in liquid nitrogen or embedded in optimal cutting temperature (OCT) compound. When limited tissue is available, flash frozen/OCT tissue will generally be prioritized.  
 Fresh tumor biopsy samples should be snap- frozen using liquid nitrogen or a dry ice 
slurry , or embedded in OCT.  The tissue must be processed  as soon as possible aft er 
biopsy to minimize any form of degradation and to avoid risking the viability of the 
tissue.  The following procedures may be used or standard operating procedures (SOPs) for each institution may be used after discussion with the principal investigator.   
 
Snap -Freezing in Liquid Nitrogen:  
• Label cryogenic vial(s) with the subject’s study identification number, 
the date of collection, time point (baseline, day 15, or progression) and the study 
center performing the biopsy.  Ensure that the label adheres to the vial and does not come off when placed in liquid nitrogen.  Labels cannot be adequately affixed to the vials after freezing.  
• Immediately place the freshly obtained tissue into the labelled cryogenic 
vial.  Place the vial with tissue in liquid nitr ogen for 2 minutes or longer to snap-
freeze the tissue.  Tumor cores should be frozen individually in separate cryovials as collected in order to minimize the time between removal and freezing.  
• Remove the cryogenic vial from the liquid nitrogen.  
• Store the sample in a -80°C freezer ( -65°C to - 80°C is acceptable) until 
ready for shipping.  
 
Freezing Procedure with Dry Ice Slurry  
• Materials required include: 5 lbs dry ice, alcohol (ethanol or comparable), 
basin, long forceps  
CONFIDENTIAL 
Version Date: February 12 , 201 6 63  
 • Place at least 5 lbs of dry ice into a basin and pour one liter of alcohol 
over the ice.  
• Label cryogenic vial(s) with the subjec t’s study identification number , 
the date of collection, and the study center performing the biopsy.  Ensure that 
the label adheres to the vial and does not come off when placed in liquid nitrogen.  Labels cannot be adequately affixed to the vials after freezing.  
• Immediately place the freshly obtained tissue into the labelled cryogenic 
vial.  Place the vial with tissue in liquid nitrogen for 2 minutes or longer to snap-freeze the tissue.  Tumor cores should be frozen individually in separate cryovials as collected in order to minimize the time between removal and freezing.  
• Pace the lower half of the sealed cryotube containing tissue into the 
solution for at least 2 minutes until frozen solid.  
• Store the sample in a -80°C freezer ( -65°C to - 80°C is acceptable) until 
ready for shipping.  
 
Archival tumor tissue should be obtained as 10 unstained slides with 5 micron thickness.  
 
7.6.2. Blood Biom arkers 
 
Blood sa mples (3X 10 m l) will be  collected a s indicted in t he Time  and E vents Table  (see 
Section 7.1 ). Blood wi ll be p rocesse d to i solate  both PBMC s and  serum for future 
biomarker analyse s at the  conc lusion of  the stu dy, a s to be  determine d by the 
investi gators based on t he state  of knowl edge at that time, a nd availa ble molecular 
analy sis platfo rms. P ossible analyse s include,  but a re not limite d to, immune cell 
populations, circ ulating free D NA (cfDNA), circu lating  miRNA, and pr oteins/cytokines. 
 
Three 10 ml sodium heparin tubes will be collected from patients prior to treatment, and at day 15.  Samples will be subsequently stored for future correlative studies. The samples drawn prior to treatment can be drawn on C1W1 prior to initiation of study drug.   Process samples in the following manner.  If institutional standards differ for PBMC or 
plasma processing, other processing methods may be acceptable pending discussion with the principal investigator.   • 
Processing – Plasma  
1. Centrifuge the tubes at 609 x g or equivalent speed for 10- 15 minutes with low brake. 
Centrifuge at 4 °C.  
2. Use a transfer pipette to transfer the plasma into cryovials in 1mL aliquots. Store 
cryovials in -80 °C freezer until shipped.  
3. Save remaining sample for PBMC processing.   
Processing - Peripheral Blood Mononuclear Cells  
1. Remove the Ficoll from the refrigerator and aliquot 12mls of Ficoll into two separate 
50mL centrifuge tubes (or prepare Ficoll for underlay using pre -measured transf er 
packs).  
2. Dilute remaining sample from plasma processing above (white and red blood cells) 
with 1:1 1XPBS. Wash the original green- top blood tubes with the diluent prior to 
mixing in the empty 50mL tube. Mix the PBS and blood well.  
CONFIDENTIAL 
Version Date: February 12 , 201 6 64  
 3. Slant the 50mL tube containing Ficoll being careful not to spill. Carefully pour the 
diluted blood on top of the Ficoll so as to not disturb the Ficoll layer. Discard the 
now empty 50mL tubes as well as the original blood tubes.  
4. Spin at 609 x g or equivalent speed for  20 minutes, no brake. Centrifuge at 4ºC.  
5. Aspirate the PBMC layer at the interface above the density gradient (white layer/buffy 
coat) including a small amount of plasma but as little Ficoll as possible.  
6. Transfer to a sterile, 50mL centrifuge tube.  Add sufficient 1X PBS to bring the fluid 
volume to 50mls in each tube. Spin at 343 x g or equivalent speed for 15 minutes.  
7. Pour off supernatant, flick tube to re -suspend cells (repeat steps 7 -8 two more times to 
give a total of three washes.)  
8. Afte r third wash, add 10mL 1X PBS and count cells. Record cell count and cell 
viability.  
9. Spin at 343 x g or equivalent speed for 15 minutes. Pour off supernatant. 
10. Prepare a 10% DMSO in 100% FBS (1:10 dilution) for freezing solution. Ensure the 
FBS is ch illed before adding the DMSO.  
11.  Suspend cell pellet in enough freezing media to ensure 1 mL aliquots of 5.0x106 
cells.  
12.  Make 1mL aliquots into cryovials, and store at -80 °C until shipment.  
 
8. ADVERSE EVENT S AN D SERIOUS ADVERSE EVENTS 
 
The investigator  or site s taff will be responsi ble fo r detecting, doc umenti ng and reportin g 
events that meet the definition of  an adverse even t (AE) or se rious a dverse eve nt (S AE) 
as outl ined in S ection 8.1 and S ection 8.2, re spectively. 
 
8.1. Definition of an AE 
 
Any untowa rd medical occurrence in a subj ect or  clinical investigation su bject, 
tempo rally associ ated wit h the use  of a med icinal produc t, wh ether or not c onsid ered 
related to t he medi cinal produc t. 
 
Note: An a dverse event (AE) can therefore be any unfa vorable a nd unin tende d sign 
(including an abnorma l labora tory finding), symp tom, or d isease (new or exacerb ated) 
tempo rally associ ated wit h the use  of a med icinal produc t.  For marketed medicin al 
produc ts, this also inc ludes fa ilure to produce exp ected  bene fits, abus e, or mi suse. 
Examples of eve nts meeting the d efinition of  an AE include:  
 
• Exacerb ation of  a chronic or inte rmitte nt pr e-existing condition inc luding eithe r an 
increase in f requency an d/or gra de of the condit ion 
 
• Ne w condit ions de tected or diagnosed after study treatme nt admin istration eve n 
though it may ha ve been pre sent prior to the sta rt of the stu dy 
 
• Signs, sy mptoms, or  the clinical sequ elae of a suspected inte raction 
 
• Signs, sy mptoms, or  the clinical sequelae of a suspected ov erdose of either study 
treatme nt or a  conc omitant medication (overdose  per se will not be reported as an 
AE/s erious a dverse event [S AE]). 
 
“Lack of efficacy” or  “failure of exp ected p harm acological acti on” per se is not to be 
reported a s an AE or SAE.  H owever, any sig ns and sy mptoms and/or clinical sequ elae 
resulting from “lack of efficacy” will be reported as an AE or SAE, if  they fulfill  the 
definition of  an AE  or S AE. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 65  
 Events that d o not me et the definition of  an AE  include:  
 
• Medi cal or su rgica l procedure (e.g., endoscopy, append ectomy); the  condit ion tha t 
leads to the p rocedure is an AE. 
 
• Situati ons whe re an unt oward medical occurrence did not  occur (social and /or 
conve nience admission to a hospit al). 
 
• Anticip ated d ay-to-day fluc tuations of p re-existing disease(s) or condit ion(s) present 
or de tected at the start of the stu dy that do not worse n. 
 
• The disease/disorder being studied, or expected p rogre ssion, si gns, or symp toms of 
the dis ease/disorder being studied, unless more  seve re than expected for the subj ect’s 
condit ion. 
 
8.2. Definition of an SAE 
 
A serious a dverse event (S AE) is any untowa rd medical occurrence that,  at any dose: 
 
a. 
Results in d eath 
 
b. Is life-threatening 
 
NOTE:  The  term 'life-threa tening' in t he definiti on of 'se rious' refe rs to an eve nt in 
which the subj ect w as at risk of  death at the ti me o f the event.  It does not refer to a n 
event, which hypotheti cally mig ht ha ve ca used death, if it w ere more severe. 
 
c. Re quires hosp italizati on or prolongati on of  existing hospitali zation 
 
NOTE:  In general, hospital ization si gnifies that the  subj ect has b een detained 
(usually involving a t least an ov ernight stay) at the hospital or  emergency wa rd for 
observati on and/or tr eatment that would not have  been appropriate in the ph ysician’s 
office or out- subject sett ing. Complications tha t occur during hospitalizati on are 
adverse events (AEs). If a c omplication prolongs hospitali zation or  fulfills any other 
serious c riteria, the eve nt is serious.  When in doubt  as to wh ether “hospita lizati on” 
occurred or was nece ssary, the AE should be  cons idered serious.  
 
Hos
pitalization for elective treatme nt of  a pre-ex isting condition tha t did not wo rsen 
from bas eline is not con sidered an AE. 
 
d. Re sults in disabili ty/incap acity, or 
 
NOTE:  The  term disability me ans a substa ntial disruption of a  person’s ability to 
conduct norma l life funct ions.  This de finition is n ot intende d to inc lude expe riences 
of relative ly mi nor m edical significance suc h as uncomplicated h eadache, na usea, 
vomiting, diarrhea, influ enza, and accid ental tr auma (e .g. spra ined a nkle) which m ay 
interfere or prevent everyday l ife functi ons but do not constitu te a substa ntial 
disrupt ion. 
 
e. Is a conge nital anoma ly/birth d efect. Medical or sc ientific  judgment should be 
exerc ised in de ciding whe ther reporti ng is appropriate in other situations, suc h as 
important medical events that m ay not be im mediately life- threatening or result in 
death or hospi talization but may jeopardize the s ubject or m ay re quire  medical or 
CONFIDENTIAL 
Version Date: February 12 , 201 6 66  
  
 
surgica l intervention to preve nt one of the other  outcom es listed in the  above 
definition.  The se should a lso be c onsid ered serious.  Exa mples of su ch eve nts are 
invasive o r maligna nt cancers, intensive tr eatmen t in an emergency room or at hom e 
for allerg ic bronchosp asm, blood dyscra sias or  convuls ions th at do not  result in 
hospitali zation, or deve lopment of d rug dependency or drug a buse.  
 
g. P rotocol-Sp ecific SAEs:  
 
• All ev ents of poss ible stu dy treatment- induced liver inju ry with 
hype rbilirubinemia de fined as a lanine  aminotransferase (AL T) ≥3 times u pper 
limit of nor mal ( ULN) and bi lirubin ≥2  times UL N (>35% direct) (or 
ALT ≥3 t imes ULN and i nternational norm alization ratio (INR) >1.5, if  INR is 
measured) or termed ‘Hy ’s Law’ events (INR m easurement is not r equired and 
the th reshold v alue stated will not apply to patients r eceiv ing a nticoag ulant s). 
 
NOTE:  Bil irubin f ractionati on is perfor med if  testing is av ailable.  I f testing is 
not availa ble, recor d presence of de tectable u rinary bilirubin on dipst ick 
indicating direct bilirubin e levations and sugge sting live r inju ry.  If testing  is 
unavaila ble a nd a subj ect meets the criterion of total bilirubin  ≥2 times ULN, 
then the  event is still reporte d as a serious a dverse event (S AE).  If I NR is 
obtain ed, include  values on the SAE form.  INR elevations > 1.5 sugg est severe 
liver inju ry. 
 
• Any ne w primary cancers 
 
• LVEF that m eets stopping c riteria (see Se ction 3.9.1.1) 
 
• Retina l pigment e pithelial detachm ent (RPED) or re tinal vein o cclus ion 
 
8.2.1. Sent inel Events  
 
A Sentinel Ev ent is a Novartis -defined SAE that is not n ecessa rily drug-rela ted but has 
been associ ated histo rically wi th adv erse react ions for  other drug s and  is there fore 
worthy of heightened pharmacov igilance.  The Me dical Monitor is a ccountable  for 
reviewing all SAEs for possi ble Sentinel Ev ents whi ch is mandated by the Supporter.  
The medi cal mon itor m ay re quest additional cli nical infor mation on an urge nt basis i f a 
possi ble Se ntinel Event is identifie d on S AE review.  The curre nt Novartis -defined 
Sentine l Events are listed b elow: 
 
• Acquired Long Q T Synd rome  
 
• Agranulocytosis/Seve re Neutrop enia 
 
• Anaphylax is & Anaphylac toid Reactions 
 
• Hepa totoxicity 
 
• Ac ute Ren al Failure 
 
• Seizure 
 
• S tevens Johnson sy ndrome/To xic epidermal n ecrosis 
CONFIDENTIAL 
Version Date: February 12 , 201 6 67  
  
 
8.3. Laborat ory and Oth er Safe ty Assessm ent A bnormalit ies 
Reported as AEs a nd SAEs  
 
Any a bnorm al laboratory test r esults (hematolo gy, cli nical chemistry, or urinaly sis), or 
other  safety a ssessments  (e.g., elec trocardiogram [ECGs ], radiological scans, vital si gns 
measurements) i ncluding those  that wo rsen from b aseline, and eve nts felt to be clinically 
significant in the m edical and sc ientific  judgment  of the inv estigator are to  be reco rded as 
an adverse eve nt (AE) or se rious a dverse eve nt (SAE), in a ccordance with  the d efinitions 
provided.  
 
In addit ion, an a ssoci ated AE or SAE is to be  reco rded for  any laboratory test result or 
other  safety assessment that led to a n intervention, including permane nt disconti nuati on 
of stu dy treatment, dose reducti on, a nd/or dose  interrupti on/del ay. 
 
Any ne w primary cance
r must  be reporte d as a SA E. 
 
However, any cli nically sig nificant safety asse ssments tha t are associ ated with the 
underlying disease, unle ss jud ged by the inv estigator to be more se vere than exp ected for 
the subje ct's c ondition, a re not t o be reporte d as AEs or  SAEs. 
 
8.3.1. Card iovascul ar Events  
 
Investigators will  be required to fill out  event spe cific da ta collection tool s for the 
following  AEs and S AEs:  
 
• Myoca rdial infarcti on/unstable  angina 
 
• Congestive heart failure 
 
• Arrhy thmias 
 
• Va lvulopathy 
 
• P ulmonary hype rtension  
 
• Cerebr ovascular events/stroke  and transient is chemic att ack 
 
• Pe ripheral arterial thromboe mbolism 
 
• D eep venous thr ombosis /pulm onary em bolism 
 
• Revasc ularization  
 
This infor mation should be rec orded in t he specific cardio vascular eCRF within one wee k 
of wh en the AE/SAE(s) are first reported. 
 
8.4. Disea se-Rel ated Events and/or Di sease-Relat ed Outcomes 
Not Qualifying as SAEs  
 
An eve nt which is p art of the n atural course of the  disease unde r study (i.e., disease 
progression or  hospitalizati on due  to disease prog ression) doe s not n eed to be re porte d as 
a serious a dverse event (S AE).  Death due to dis ease unde r study is to be recorde d on t he 
Death elect ronic  case repor t form (eCRF).  Ho wever, if the und erlying disease (i.e., 
CONFIDENTIAL 
Version Date: February 12 , 201 6 68  
  
 
progression) is  greater than that whi ch would nor mally be expected for the  subj ect, or if 
the inv estigator consid ers that the re was a ca usal re lationship betw een t reatment with 
study treatme nt(s) or protocol desi gn or procedures and the dis ease progres sion,  then this 
must  be reporte d as a SA E. 
 
8.5. Time Period a nd Frequen cy of D etect ing AEs and SAEs  
 
The investig ator or  site sta ff is responsi ble for detecting, docume nting and re porting 
events that meet the definition of  an adverse even t (AE) or se rious a dverse eve nt (S AE). 
 
AEs wil l be c ollected from the time the  first dose  of stu dy treatme nt is administered unt il 
30 days following  disco ntinuati on of  study treatme nt regardless of init iation of a ne w 
cance r therapy or transfer to hospic e. 
 
SAEs 
will be c ollected ove r the same  time pe riod as stated a bove  for AEs.  In addit ion, 
any S AE assessed as relate d to study pa rticip ation (e.g., pro tocol -mandated procedures, 
invasive t ests, or chan ge in existing therapy), study tr eatme nt or Novartis conc omitant 
medi cation must be rec orded from the time a  subjec t cons ents to particip ate in the study 
up to and inc luding any f ollow-up contact.  All S AEs wil l be re porte d to Coordinating 
Center within 24 hours, as ind icated in  Section 8.5.1.  
 
After discontinu ation of  study treatme nt, the investigator wil l monitor all AEs/ SAEs th at 
are ongoing unti l resolution or stabil ization of  the event or until the subj ect is lost to 
follow -up.  At any ti me after 30 d ays the inv estigator m ay re port any AE t hat they 
belie ve poss ibly re lated to stu dy treatme nt. 
 
8.5.1. Pro
mpt Reporting of SAEs and Other  Events  
 
Serious a dverse events (S AEs), pregnanc ies, and live r functi on abnormalit ies and an y 
other  events meeti ng pre-de fined criteria will be re porte d promptly by the inve stigator on 
a Vanderbilt Serious Adverse Event Form  and the centralized electronic case report form 
called ON -line Clinical Oncology Research Environment = Oncore 
 as des crib e d (Table 18) in the f ollowing  
table once the in vesti gator dete rmine s the eve nt meets the protocol de finition for that 
event. SAEs should also be sent to Novartis and the NCCN as listed below:  
 
Al
l Events must be reported to Novartis within 24 hours of learning of its occurrence . 
Information about all SAEs is collected and recorded on a Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of  each SAE to 
each specific study treatment (if there is more than one study treatment), complete the SAE 
Report Form in English, and send the completed, signed form by fax to  (
within 24 hours to the oncology Novartis DS&E department with the provided FAX 
cover sheets  and to NCCN via email to 

CONFIDENTIAL 
Version Date: February 12 , 201 6 69  
  
 
 
 
Table 18 R ules for Repor ting SAE, C ardiovascular , Pregnancy an d Liver 
Func tion Abnorma lities 
 
  Initial Reports Follow -up In formation on a  Previous  
Report 
Type of Event Time F rame Documen ts Time F rame Documen ts 
All SAEs 24 hours  SAE data collection 
tool 24 hours  Updated  SAE data 
collection tool  
“CV events” and/or 
“death” Initial and 
follow u p 
reports to be 
comp leted 
within one 
week of when 
the 
cardiov ascula r 
event or d eath 
is reported “CV events” 
and/o r “death” 
data collectio n 
tool(s) if 
applicab le Initial and follow 
up reports to be 
comp leted within 
one w eek of when 
the ca rdiov ascu lar 
event or d eath is 
reported Updated “CV 
events” and/or 
“death” data 
collection t ool(s) if 
applicab le 
Pregnan cy 2 Wee ks Pregnan cy 
Notification Fo rm 2 Wee ks Pregnan cy 
Follow-up Form 
Liver  chemist ry abno rmalit ies: 
ALT ≥3 times ULN and 
bilirubin ≥2 times ULN 
(>35% dire ct) (or ALT 
≥3 times ULN and INR 
>1.5, if INR i s 
measur ed)c 24 hour sa SAE data collection 
tool; 
Liver Ev ent eC RF 
and li ver imaging 
and/or b iopsy 
eCRFs if 
applicableb 24 hours  Updated  SAE data 
collectio n too l. 
Updated Li ver Ev ent 
eCRFb 
ALT ≥5 times ULN; ALT 
≥3 times ULN with 
hepat itis or r ash or 3 
times  ULN ≥4 weeks 24 hour sa Liver Event eC RFb 24 hours  Updated  Liver Event 
eCRFb 
ALT ≥3 times ULN and 
<5 tim es ULN and 
bilirubin <2 times ULN 24 hour sa Liver Event eC RF 
does  not need to be 
comp leted u nless 
elevat ions persist 
for 4 w eeks or 
subject ca nnot be 
monitor ed w eekly 
for 4 w eeksb   
a. Coordinating Center is to  be no tified  at onset of liver chemi stry elevations to discuss  subject saf ety.  
b. Liver event documen ts should be com pleted as so on as possible 
c. INR me asuremen t is not required; if mea sured, the thr eshold value  stated will not appl y to subjects receiving 
anticoagulan ts. 
 
CONFIDENTIAL 
Version Date: February 12 , 201 6 70  
  
 
8.5.2. Regul atory re porting requirements for SAEs 
 
Prompt notific ation of s erious a dverse events (SAEs) by the investig ator to the 
Coordinating Center is e ssential so th at legal obligati ons and e thical 
responsibilities tow ards the s afety of subj ects a re met.  All serious adverse events 
must be reported to the Coordinating Center within 1 business day after the treating 
institution becomes aware of the event. Events should be reported using the Vanderbilt Serious Adverse Event Form . 
 
Follow -up information must also be reported within 1 business day of receipt of 
the information by the investigator.  
 
The Coordinating Center  has a legal responsi bility to no tify t he local regulatory 
authority , the FDA  and other re gulato ry agenc ies abou t the safety of a produc t unde r 
clinical investigation.  The Coordinating Center  will c omply with country spec ific 
regula tory requireme nts relating to sa fety reporti ng to the reg ulato ry author ity, 
institutional review  board (IRB)/ethics commit tee (EC) a nd investi gators. 
 
Investigator safety report s are prepare d for  susp ected unexpected s erious adve rse 
reactions a ccording to local regulatory requireme nts and Novartis  policy and a re 
forwa rded to i nvestigators a s necessary. 
 
An inv estigator who receives a n investig ator safety report d escribing a  SAE( s) or other 
specific s afety information (e.g., summary or lis ting of SAEs)  from Novartis wi ll file it  
with the  IB and will  notify the IRB/ EC, if appropriate according to local re quirements.  
 
Food and Drug Administration (FDA)  
 
In this trial, unexpected adverse events believed to be definitely, probably, or possibly 
related to the medications will be reported to the Food and Drug Administration via MedWatch Form 3500A Mandatory Reporting Form (using the online form available at:  
http://www.fda.gov/downloads/Safety/MedWatch/HowToReport/DownloadForms/UCM
082728.pdf  by telephone 1 -800- FDA -1088; or by fax 1-800- FDA -0178 using form 
available at:  
 http://www.fda.gov/Safety/MedWatch/HowToReport/ucm085692.htm .  
The Coordinating Center will be responsible for correspondence regarding adverse events with the FDA for all participating sites.  
 
 
9. LIVER CHE MISTRY FOLLOW-UP PROCEDURES  
 
9.1. Liver  Chemistry Testing Pro cedures 
 
For subj ects meeting any of the  liver chemi stry stopping c riteria in Section 3.10. 1, make 
every atte mpt to carry ou t the liver even t follow-up assessmen ts described be low: 
 
• Viral hep atitis serology, inc luding: 
 
• Hepatiti s A IgM a ntibody 
 
• Hepatiti s B surface a ntigen and H epatiti s B Core Antibo dy (IgM) 
CONFIDENTIAL 
Version Date: February 12 , 201 6 71  
  
• Hepatitis C RNA  
 
• Cy tomega lovirus IgM anti body 
 
• Epstein -Barr vir al capsid  antigen I gM a ntibody (o r if unavaila ble, the n obtain 
heterophile a ntibody or monospot te sting) 
 
• 
 
• Se rum c reatinine phosphokinase  (CPK) and lac tate dehydrogena se (LDH ). 
 
• F ractionate bil irubin, if total bi lirubin  ≥2 X upp er limit of n ormal (ULN ). 
CONFIDENTIAL 
Version Date: February 12 , 201 6 72  
  
 
• Obtain a c omplete blood  count (CB C) wit h differential to assess eosinophilia. 
 
• R ecord the app earance or worsening of cli nical symptoms indicative of hepatiti s 
or hype rsensitivity, such a s fatigue, naus ea, vom iting, rig ht uppe r quadrant pain 
or tend erness, fever, rash or eosinophil ia as relevant on t he AE e CRF. 
 
• R ecord the use  of concomi tant medi cations, i ncluding acetaminophen, herba l 
remedi es or any other  over the counte r (OTC)  medications, or any putative 
hepa totoxins, on the conc omitant medica tion eCRF. 
 
• R ecord alcohol use  on the live r eve nt alcohol in take eCRF. 
 
The following a ssessme nts are require d for subj ects with ALT ≥ 3 X ULN and bi lirubin  
≥2X UL N (>35% direct) but a re opti onal for other abnorma l liver chemi stries:  
 
• Anti-nuclear antibody, a nti-smooth muscle  antibody, a nd Type 1 a nti-live r 
kidney mic rosomal antibod ies. 
 
• L iver imaging (ultr asound, ma gnetic re sonance imaging [MRI] or c ompu ted 
tomography [ CT]) to eva luate  liver disease. 
 
 
 
9.2. Liver  Chemistry Monitoring Criter ia 
 
For subj ects with ALT ≥3 X ULN bu t <5X ULN and bilirubin < 2 X ULN, without 
symptoms indicative of hepatiti s or rash, and who  can be  monitored safety for 4 weeks, 
the following  actions shoul d be taken: 
 
• Notify the Medical Monitor wit hin 24 hours of  learning of the  abnormalit y to 
discuss subje ct safety. 
 
• Cont inue administration of stu dy drug(s). 
 
• Evaluate  liver chemi stries (ALT, AS T, alkaline ph osph atase, bil irubin) we ekly 
until they resolve, stabil ize or re turn to within ba seline levels. 
 
• If a t any time the  subjec t meets a ny of the  liver chemi stry stopping c riteria 1 to 5 
(Section 3.10. 1), then proceed a s des cribed in S ection 9). 
 
• If, a fter 4 wee ks of moni toring, ALT <3X ULN an d bilirubin < 2 X ULN, th en 
monitor subje cts twice monthly until liver chemi stries  normalize or return t o 
within baseli ne values. 
 
9.3. Drug Restart/ Rech allenge Following Liver Events th at are 
Possib ly Rel ated to Study Drug(s)  
 
Approval by the Me dical Moni tor to restart/rechallen ge study drug(s) may b e 
consid ered where: 
 
• The subject is receiving c ompell ing bene fit, the  bene fit exceeds the  risk, and no 
effecti ve alternative therapy is av ailable .  Approva l of restart/rechallen ge by the 
Institutional R eview  Boa rd (IRB) or  Independe nt Ethic s Committee (I EC) must 
be obtain ed, a s required. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 73  
  
 
• If the re start/rechallenge is app roved by Coordinating Center in w riting, then the  
subjec t must be  provided wit h a clear desc ription of the  possi ble b enefits and  
risks of a dministration of  study drug(s), in cluding the pos sibility of a recurren ce, 
a more s evere liver inju ry or de ath. 
 
• The subj ect must also p rovide si gned informe d consent sp ecific ally fo r the study 
drug(s)  restart/rechallenge .  Do cument ation of  the informed consen t must b e 
recorde d in t he subj ect’s study cha rt. 
 
• Study drug (s) must  be admi nistered at the dose sp ecified  by the Me dical 
Monitor.  
 
• S ubjects app roved by the Coordinating Center for re start/rechallenge of  study 
drug( s) must return to t he clinic twice a w eek for evaluati on of  liver chemi stry 
tests un til stable liv er chemi stries h ave been de monstr ated and labora tory 
monitoring  may resume per pr otocol.  
 
9.4. Drug Restart Follow ing T ransien t, Resolving Liver  Events  
Not Rela ted to Study Drug(s)  
 
Approval by the Me dical Moni tor to restart study drug(s ) may be considered wh ere: 
 
• L iver chemi stry abnormalitie s have a clear unde rlying ca use (e.g., bil iary 
obstru ction, hypotension)  and live r chemi stries ha ve impr oved to norm al or are 
within 1.5 X baseli ne and ALT <3X ULN .  App roval of restart by th e 
Institutional R eview  Board (IRB) or  Independe nt Ethic s Committee (I EC) may 
be require d. 
 
• If the re start/rechallenge is app roved by Coordinating Center  in w riting, then the  
subjec t must be  provided wit h a clear desc ription of the  possi ble b enefits and  
risks of a dministration of  study drug(s), in cluding the pos sibility of a recurren ce, 
a more s evere liver inju ry or de ath. 
 
• The subj ect must also p rovide si gned informed consent sp ecific ally fo r the study 
drug(s)  restart/rechallenge .  Do cument ation of  the informed consen t must b e 
recorde d in t he subj ect’s study cha rt. 
 
• S tudy drug (s) must  be admi nistered at the dose sp ecified  by the Me dical 
Monitor.  
 
• S ubjects app roved by the Coordinating Center  for re start/rechallenge of  study 
drug( s) must return to t he clinic once a w eek for evaluati on of  liver chemi stry 
tests un til stable liv er chemi stries h ave been de monstr ated and labora tory 
monitoring  may resume pe r protocol.  
 
• If protocol-de fined stopping criteria for liver chemi stry abnormalitie s are met, 
study drug(s) administration must stop. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 74  
  
 
10. CONCOM ITAN T MED ICATIONS AND NON-DRUG 
THERAPIES  
 
Subjects will  be instructed to info rm the investi gator prior to s tarting any new 
medi cations f rom the time of fi rst do se of stu dy treatme nt until the end of  the study (F inal 
Study Visit).  Any c oncomi tant medi cation(s) , including non-presc ription  medi cation(s) 
and herbal produc t(s), taken during the stu dy will  be recorded in t he electronic case  
report for m (eCRF).  Ad ditional ly, a c omplete list  of all prior  anti-cance r thera pies will 
be recorded in t he eCRF. 
 
If future  change s are made to t he list of p ermitted/prohibited m edications, formal 
document ation will  be provided by the Coordinating Center  and sto red in t he study file.  
Any suc h change s will  be communicated to the inv estigative sites in the form of a  lette r. 
 
As
 trametin ib is metaboli zed predomina ntly via de acety lation likely me diated by 
hydrolytic esterase s, its PK is unl ikely to be affec ted by other agents through met abolic 
interacti ons. Trametinib r epeat-dose exposure  was not af fecte d by co-a dministration with 
a CYP3A4 induce r. 
 
Base d on in  vitro and in viv o data, tra metin ib is unl ikely to significantly affec t the PK of 
other  medi cinal p roduc ts via interacti ons with CYP  enzymes or transporters. 
 
Any que stions r egarding conc omitant medica tions should be  directed to the  Medical 
Monitor for clarification. 
 
10.1.  Permitt ed Medicat ion(s)  
 
Subjects should r eceive  full supportive care  during the stu dy, includi ng transfusion of 
blood and blood produc ts, and tr eatme nt wi th antibiotics, a ntiemetics, a ntidiarrheals, and 
analge sics, a nd hemato poietic growth fac tors as appropria te. 
 
10.2.  Prohibited M edicat ions and Non-D rug Therap ies 
 
The use of ce rtain medicati ons prior to the  first dose  of stu dy treatm ent (refe r to in clusion 
and exc lusion criteria, Section 5.2) and for the  durati on of  the study will not be all owed. 
If a pro hibited m edication is r equired for single use (such as for a procedure ) while 
treatme nt wi th stu dy treatme nt is interrupted, the  Medical Monitor can approv e such  
use. 
 
The following  medications or no n-drug therapies are prohibited: 
 
• Antic ancer agents: Addit ional investi gational or c ommerc ial anticancer age nts 
such as chemotherapy, imm unothe rapy, targeted therapy, biological response 
modifiers, or endoc rine therapy will  be prohibited. 
 
• He rbal thera pies: S ubjects will  abstain f rom using he rbal 
preparati ons/medi cations within 14 day s prior  to the first dose  of Tra metin ib and 
throu ghout t he study until the end of tr eatme nt visit. These herbal medi cations 
includ e, but a re not limite d to, S t. John’s wor t, kava, e phedra ( ma h uang ), ging ko 
biloba, dehyd roepiandrosterone (D HEA), yohimbe, saw palmetto, and g inseng. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 75  
  
 
The investig ator should c ontact the Medical Moni tor be fore initiating 
treatme nt wi th any he rbal pr eparati on. 
 
11. LIFESTYLE A ND/OR DIETARY RESTR ICTIONS 
 
11.1.  Contraception  
 
11.1.1. Female Subjects 
 
A female of  non-chi ldbearin g pote ntial (i.e., phy siologically incapable of  becoming 
pregna nt) is d efined as any fe male  who has had a hysterectomy, bilateral oophor ectomy 
(ovariectomy) or bila teral tubal ligati on, or  is pos t-menop ausal. 
 
A practical definition acce pts menopa use aft er 1 year wit hout menses with a n appropria te 
clinical profile, e.g., age appropri ate, >45 yea rs in the absence of hormone  replacement 
therapy (HRT).  In que stionable case s, the subje ct must  have a follicula r stimulating 
hormone (FSH) va lue >40 mIU/mL a nd an estradiol value <  40pg/mL (<14 0 pmo l/L). 
 
A female of  childbearin g pote ntial is defined as any fe male  who doe s not  meet the 
criteria of non-c hildbeari ng potential a s descr ibed in the previous pa ragraph. 
 
Female  subjec ts of c hildbearing potential must  not be come p regnant during the stu dy and 
so must be s exually inactive by a bstinence or u se contrac eptive methods w ith a 
failure rate of <1 %. 
 
Abstinen ce 
 
Sexual inactivity by ab stinence mu st be c onsistent with the preferred an d usua l lifestyle 
of the subje ct. Periodic abstinence (e.g., ca lendar, ovu lation, sy mptother mal, post-
ovulation methods) and w ithdrawa l are not acc eptable methods of con traception. 
 
Comp lete abstinence from se xual intercourse for 14 d ays prior to first do se of stu dy 
treatme nt, throug h the d osing period, and for at least four mon ths after the last do se of 
study treatme nt. 
 
Contraceptive Meth ods w ith a Failure Rate of <1% 
 
• O ral contr acept ives (eithe r combined or proge sterone only) if not cont raindicated for 
this sub ject population or pe r local p ractice. 
 
• Estro genic vagina l ring if  not cont raindicated  for this subject population or pe r local 
practi ce. 
 
• Perc utaneous c ontraceptive patches if not c ontraindicated for this sub ject p opulation 
or pe r local practice. 
 
• I mplants of levon orgestrel if not cont raindicated  for th is subj ect population or p er 
local practice. 
 
• I njectable  proge sterone if not cont raindic ated for this subject populati on or  per local 
practi ce. 
CONFID ENTI AL 
Ver s ion Dat e:  Feb rua r y  12,  201 6 76  
  
 
•  I n t r a u t e r i n e  de v i c e  or  i n t r a u t e r i n e  s y s t em  t h a t  m e e t s  t h e  <1%  f a i l ur e  r a t e  a s  s t a t e d  i n  
t h e  p r o d uc t  l a be l  
 
•  M a l e pa r t n e r  s t e r i l i z a t i on  (v a s e c t o my  w i t h  d o c ume n t a t i on  o f  a z o o s pe rm i a )  p r i o r  t o  
t h e  f e m a l e sub j e c t ' s  e n t r y  i n t o  t h e  s t u dy ,  a nd  t hi s  m a l e  i s  t h e  so l e  p a r t n e r  f o r t h a t  
su b j e c t .   Fo r t h i s  d e f i n i t i o n ,  “ d oc um e n t e d”  r e f e r s  t o  t h e  o u t c om e  o f  t h e  
i nv e s t i g a t o r ' s / de s i g ne e ’ s  m e d ic a l  e x a mi na t i on  o f t h e  s u b j e c t  o r  r e v i ew  o f  t he  
su b j e c t ' s  m e di c a l  h i s t o r y  f o r  s t u dy  e l i g i b i l i t y ,  a s  ob t a i ne d  v i a  a  v e rb a l  i n t e r v i ew  w i t h  
t h e  su b j e c t  o r  f r om  t h e  s ub j e c t ’ s  m e d i c a l  r e c o r d s .  
 
•  D o u b le - ba r r i e r  m e t ho d :  c o n d om  a nd  oc c l u s i v e  c a p ( d i a p h r a g m  o r c e rv i c a l / va u l t  
c a p s )  p l u s  v a g i n a l  sp e rm i c i d a l  a g e n t  ( f o a m/ g e l / f i lm / c r e a m/ sup p o s i t o r y )  
 
The s e  a ll o we d me tho ds  o f  c ont r ac e pt i on  a r e  onl y  e f f e c t i v e  whe n us e d c o ns i s t e nt l y ,  
c or r e c t l y  and  in  ac c or danc e  wi th  t he  pr oduc t  l abe l .   The  i nv e s t i ga t o r  i s  r e s pons i bl e  f o r  e ns ur i ng  subj e c t s  u nde r s t and  ho w t o  pr ope r l y  us e  t he s e  me tho ds  o f  c ont r ac e pt i on .  
 
11. 1. 2.  Male  Subj ects  
 
T o  pr e v e n t  p r e g na nc y  i n  a  f e m a l e pa r t n e r ,  m a l e  su b j e c t s  mu s t  us e  on e  o f t h e  f o l l ow i ng  c o n t ra c e p t i v e  m e t ho d s  fr om  t h e  b e g i nn i ng  o f t h e  s t u dy  un t i l  90  d a y s  a f t e r  th e  l a s t  do s e  o f  s t u dy  t r e a t me n t : 
 
 A b s t i ne nc e ,  de f i n e d  a s  s e x u al  i n a c t i v i ty  c ons i s t e n t  wi t h  t he  pr e f e r r e d a n d u s u a l  
l i f e s t y l e  of  t he  s u bj e c t .  P er i odi c  a b s t i ne n c e  ( e . g .  c a l e nda r ,  ov ul a t i o n,  s y m pt ot he r m al ,  pos t - ov ul a t i on  m et ho ds )  a n d  wi t hdr a wa l  a r e  not  a c c e pt a bl e  m et hods  o f  c ont r a c e p t i on.  
 
 C on d om ( du r i ng  n o n - v a gi na l  i n t e r c ou r s e  w i t h  a n y  p a r t n e r -  m a l e o r  f e m a le )  OR 
 
 D o u b le - ba r r i e r  m e t ho d :  c o n d om  a nd  oc c l u s i v e  c a p ( d i a p h r a g m  o r c e rv i c a l / va u l t  
c a p s )  p l u s  s pe rm i c i d a l  a g e n t  ( f oa m/ g e l / f i lm / c r e a m/ sup p o s i t o r y )  ( du r i n g  se x u a l  
i n t e r c ou r s e  w i t h  a  f e ma le )  
 
11 .2 . Lac ta t ion Rest r ic t i ons 
 
F em a l e su b j e c t s  w ho  a r e  l a c t a t i ng  m u s t  d i s c on t i n u e  n u r s i ng  pr i o r  t o  t h e  f i r s t  do s e  o f  s t u dy  
t r e a t me n t  a nd  m u s t  r e f r a i n  f r om  nu r s i ng  t hro ug h ou t  t h e  t r e a t me n t  p e r i o d  a n d  f o r  f o u r  m ont h s  f o l l ow i ng  t h e  l a s t  d o s e  o f  s t u dy  t r e a t me nt .  
 
 
 
12 . DATA MANAGEMENT 
 
E a c h  p a r t i c i p a t i ng  i n s t i t u t i o n w i l l  b e  c o l l a b o r a t i ng  w i t h  V a n d e r b i l t  o n  p a t i e n t  a c c r u a l .  
D a t a  w i l l  b e  c o l l e c t e d  u s i ng  a  c e n t r a l i z e d  e l e c t r o n i c  c a s e  r e p o r t  f o rm  c a l l e d  ON- l i n e  C l i n i c a l  O n c o l og y  R e s e a r c h  E nv i r o nm e n t  =  O n c o r e  
O n c o r e  i s  a  h i g h ly  s e c u r e ,  w e b  b a s e d ,  
c a n c e r  s p e c i f i c ,  a n d  c u s t om i z a b l e  sy s t em  t h a t  p r ov i d e s  f u l ly  i n t e g r a t i v e  c l i n i c a l  d a t a  m a n a g em e n t  a n d  s t u dy  a dm i n i s t r a t i o n  c a p a b i l i t i e s  d e v e l o p e d  i n  a n  o ng o i ng  c o l l a b o r a t i v e  e f f o r t  w i t h  NC I  d e s i g n a t e d  C om p r e h e n s i v e  C a n c e r  C e n t e r s .  I t  f u l ly  i n t e g r a t e s  s t u dy  a dm i n i s t r a t i o n  f u n c t i o n a l i ty  i n c l u d i ng  p r o t o c o l  t r a c k i ng ,  p a t i e n t  r e g i s t r a t i o n ,  NC I  r e p o r t i ng ,  r e v i ew  c omm i t t e e  t r a c k i ng ,  a n d  SAE  t r a c k i ng ,  w i t h  c l i n i c a l  d a t a  m a n a g em e n t  

CONFIDENTIAL 
Version Date: February 12 , 201 6 77  
 functionality including electronic case report forms (eCRF) design, clinical data capture, 
protocol and regulatory compliance monitoring. Also the system is capable in storing basic protocol in formation (e.g., IRB approval dates, dates for annual renewals, etc.) and 
clinical trials research data. Oncore allows the investigator to define specific protocol requirements and generate data collection forms. Creation of the data collection form is done with a single button click after the parameters of an individual protocol have been specified. Oncore permits specification of study protocols, management of patient enrollment, clinical data entry and viewing, and the generation of patient or study -specific 
reports based on time stamping. OnCore is embedded with a comprehensive domain repository of standard reference codes and forms to promote standardization. The sources for the repository include CDUS, CTC, CDEs from NCI, ICD, MedDRA and various best practices from contributing NCI -designated Comprehensive Cancer Centers. OnCore 
provides several reporting features specifically addressing NCI Summary 3 and Summary 4 and other reporting requirements. Data may also be exported in a format suitable for impo rt into other database, spreadsheets or analysis systems (such as SPSS). This system  
will be used to manage all VIC C clinical trials data. OnCore is maintained and supported 
in the VICC Clinical and Research Informatics Resource.  
 Specified members at each  participating site will submit all pertinent regulatory 
documents to the Coordinating Center team member , who will upload it on Oncore. 
 
The Principal Investigator or designee will inform the sponsor within 24 hrs of any serious 
adverse event, and will inform the IRB in accordance with each institution’s IRB policy. The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an AE or SAE, as provided in this protocol. During the study when there is a  safety evaluation, the investigator or site staff will be responsible for 
detecting, documenting, and report AEs and SAEs, as detailed in the protocol. Furthermore, the investigator will be required to provide periodic (monthly) safety updates on the conduct of the study at his/her site and notification of study closure to the SRC/IRB. If any problem is identified related to the conduct of this research, the VICC Data Safety and Monitoring Committee (DSMC) will be formally asked to review the study and the  
situation that required DSMC intervention.   
 
13. DATA ANAL YSIS AN D STATIST ICAL CONSIDERATIONS 
 
13.1.  Hypothesis  
 
The primary objective is to determine wither  trametin ib is an effective ta rgeted th erapy in 
BRAF  nonV600MUT melanom a. The  hypothesis  desc ribed below will  apply to coho rt A 
(“high activity” mutations a nd fusion ev ents). The null hy pothesis is that the  obje ctive 
response ra te (ORR; percentage of patie nts achieving a confir med CR  or PR  is not 
attracti ve (defined as ≤5%). T he alternative hy pothe sis is that the response ra te is of  
interest for  further  devel opment (de fined as ≥25%). 
 
The 
final analy sis of the  overall response rate will be perfo rmed usi ng one sided test with 
α=0.05.  It is calculate d that at least 4 response s are needed out of  a total of 25 patients to 
reject the null hy pothesi s. 
 
To all ow early te rmin ation of  the tr ial due  to lack of efficacy, the trial will be conduc ted 
in two sta ges per Simon’s Minimax De sign. If no re sponses are de monstr ated in t he first 
15 patients, then the t rial will be termina ted early for f utility. I f ≥1 response s are obse rved, 
CONFIDENTIAL 
Version Date: February 12 , 201 6 78  
 enrollm ent wi ll continue to 25 patie nts. 
 
For the expe rimental arm (cohort B ), the  trial will a lso be conduc ted in two  stages. If no 
responses a re demonst rated in the first 15 patients,  then the  cohort wil l be te rmin ated 
early for futil ity. If ≥1 responses a re obse rved, enrollment will  continue to a maximum of  
25 patients. Addit ionally, when cohort A acc rual has complet ed, coho rt B will close  and 
not a ccrue fur ther patient s. 
 
Given the ra pid c hange s in mel anoma th erapies, we wi ll also h ave the optio n of closing 
eithe r cohort if the  clinical activity is low. If one or two re sponses o ccur in cohort A f rom 
the first 15 patients, the  principal investig ators and Coordinating Center will h ave the 
option of  closing the tr ial at the interim analy sis. The principal investigators must be  in 
unive rsal agreement for  this to o ccur. 
 
13.2.  Sample Size Assumptions  
 
To determine the o verall sample size and the inte rim sample si ze, a two st age Sim on’s 
Minimax desi gn was evalua ted. To t est the hypotheses (ORR= 5% vs. 25%), 1 
response f rom the first 15  subj ects would be  required to pr ogress to stage 2 and a to tal 
of 25 subj ects will  be needed to achieve  the de sired type I (<5%) and type II error rate 
(Pow er>90%). T he risk of  inco rrectly stoppi ng the trial a fter stage I if the  drug is 
effecti ve is <1.5 %. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 79  
 Table 20: Sa mple size ca lculati ons 
 
If the True Response Rate to 
trametinib is: (%) Probability of Early Termination 
after Stage I Probability of Rejecting the Null 
Hypothesis 
5% 0.463 0.034 (type 1 error) 
10% 0.206  0.234  
15% 0.087  0.525  
20% 0.035  0.762  
25% 0.013 0.901  
30% 0.005 0.965  
 
 
13.3.  Data Analysis Cons iderations  
 
Data will be listed a nd summa rized accor ding to Novartis  integrated d ata standa rds 
library (IDSL ) reporting  standards wh ere appli cable. C omplete details will be provided 
in the R eporting  and An alysis Plan (RAP). Analyse s will be perfor med for each cohort. 
 
13.3.1. Interim  Analysis 
 
An inte rim analy sis will be perfo rmed for  each cohort a fter 15 subjec ts have completed 
their first po st-dose disease assessment a t 8 w eeks. The primary analy sis of this includes 
a boundary fo r early d ecision on futili ty. 
 
By the S imon Opt imal d esign, it is calcula ted th at at least 1 response o f 15 subj ects a re 
needed to f urther progress enrolment. There is no early stopping  boundary for ef ficacy, 
howeve r if ≥4 patie nts experience CR or P R, then further planni ng of addit ional 
deve lopment may occur. 
 
Core m
embers of the  Novartis cli nical team wi ll be n otified of the  results of t he 
interim analy sis. Investigators w ill be informed a s to wh ether or not the stu dy will be 
stopp ed prematu rely. 
 
13.3.2. Final Analysis 
 
13.3.2.1. Prima ry Analy sis 
 
The primary c omparison  of in terest (and p rimary endpoint ) is to dete rmine  whether the 
objective re sponse ra te to trametin ib in cohor t A (“hig h affinity” group) is le ss tha n or 
equa l to a null hy pothesized response rate of 5%  versus a n alternative response ra te of 
25%.  No compa risons  between tr eatme nts will be perfor med as the re is a sin gle arm in 
each c ohort. The  primary analy sis of ORR will  be perfor med following  treatme nt of  all 
patient s for at least 8 wee ks or h ave discontinu ed therapy. 
 
13.3.2.2. Secondary Analyses  
 
13.3.2.2.1. Coh ort B 
 
Overall response ra te wil l be a ssesse d in coh ort B a s defined by RECIST 1.1 criteria and 
will be reporte d in a descriptive  fashion. No statis tical comp arisons will be  performe d. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 80  
  
 
13.3.2.2.2. Overal l Surviv al and Prog ression-F ree S urvival for both cohort A a nd B  
 
Overall surviva l, defined as the time f rom Day 1 of the trametin ib the rapy to death f rom 
any cause. Prog ression free surviva l, defined as the time from Day 1 of t rametin ib 
therapy to progre ssion of  disease as de fined by RECIS T 1.1 c riteria or death, will be 
reporte d for each arm. We will  also perfor m subs et analy sis for PFS str atified by 
baseli ne cha racteristics in cluding LD H level, metastatic st age, a nd previous th erapy 
(particularl y wh ether a sub ject has rece ived immune-base d therapy). 
 
13.3.2.2.3. Safety  
 
Adverse events (A Es) will be code d using  the sta ndard Med DRA and g rouped by sy stem 
organ class.  Ad verse events (A Es) will be graded by the inve stigator accor ding to the 
National Cancer I nstitute- Com mon Toxi city Criteria for Adverse Events (NCI- CTCAE), 
(version 4.0 ). 
 
Events will  be summa rized by frequency a nd proporti on of  total sub jects, by  system 
organ class an d pref erred term.  Separate summa ries will  be given for all AEs, treatment- 
related AEs, se rious ad verse events (SAEs) and A Es le ading to disconti nuati on of  study 
treatment.  Adve rse even ts (A Es), if listed in the  NCI- CTCAE (ve rsion 4 .0) wil l be 
summarized by the m axim um grade .  Oth erwise,  the AEs will  be summa rized by 
maximum intensity. 
 
Characte ristics (e.g. numbe r of occurrences, actio n tak en, grade, et c.) of the  following  
AEs of  special in terest will be summ arized separately. 
 
The incid ence of de aths and the p rimary ca use of death wi ll be summ arized. 
 
13.3.2.2.4. Bi omarke rs and Pharmacodyn amic Analys es 
 
The study will analyze tu mor tissue a nd/or blood to und erstand genetic mechanism  of 
MEK inhib itor response a nd resistance. As da ta warrant, corre lation an alysis will  be 
perfor med to  explore  the relationship betw een patie nt’s bio marker and PD da ta (e.g. 
change f rom b aseline ) to p atient’s tumor response. As data war rant, addit ional analy sis 
will be conduc ted on cfDNA data. Full details will  be provided in RAP prior to stu dy 
initiation. 
 
Molecular  characterizati on of  tumor tissue wil l be p erformed to ide ntify markers tha t 
correla te with clinical responsivene ss to treatme nt with tra metin ib.  An alysi s will 
incorpora te de tection of  DNA-base d alterati ons in other  gene s known to be altere d in 
melanoma, in cluding (b ut not  limited to)  gene s in the MAPK p athway (i.e. MEK1/2, 
NF1), PI3K-AK T pathway ( i.e. PIK3CA, A KT, P TEN), ce ll cycle regulators (i.e. 
CDKN2A, CDK4, CCND1), a nd/or b roade r mol ecular testing.  Analy sis of RNA  and 
protein m ay also be perfo rmed for  tumors with su fficient mate rial availa ble to ass ess 
functional netwo rks and pa thways.  The  exact methodolog ies us ed will  be selected base d 
on the DNA/RNA /protei n amoun ts, technolog ies, and infor mation av ailable a t the time 
the analyse s will  be perfo rmed .  An alyse s will  be perfor med on pre-treat ment and/or 
archival s amples to identify pre dicto rs of t reatmen t outcomes.  Optional on-treatme nt 
biopsies wil l be us ed to ev aluate  pharm acodynamic a nd other  molecular effects of  
CONFIDENTIAL 
Version Date: February 12 , 201 6 81  
  
 
treatme nt, which will be compa red to clin ical outc omes.  O ptional pos t-progre ssion 
samples will  be analyzed to ide ntify me chanisms of resistance. 
 
13.3.3. W ithdr awal  
 
Reason for  subj ect withdrawa l will be listed.  
 
13.3.4. Mi ssing D ata 
 
Miss ing data will not be imputed.  Whe re appropriate, availa ble da ta will be summa rized 
over specified intervals (e.g., fr om s tart of treatment un til withdr awal from s tudy) using 
suitable summ ary statistic s. 
 
13.3.5. Protocol Violations  
 
A summ ary a nd listing of proto col violations will  be provided.  
 
13.3.6. A ssess ment Windows 
 
Safety a ssessments th at occur prior to t he administration of  study drug will  be consid ered 
scree ning assessments.  Safety a ssess ments that occur afte r dosi ng ha s begun will  be 
consid ered a s having occurre d while on t reatme nt. 
 
Dis
ease asse ssments will  be distinguished a s belonging to either  screening, conti nued 
therapy or post-study phase s of the  study. 
 
13.3.7. Other Issues 
 
Data from pa rticip ating ce nters will  be pooled prio r to analy sis. It is anticipa ted th at 
subject accrual may be limited across ce nters and sum maries of d ata by center would 
likely not be in formative . Therefore , these summa ries will not be provided.  
 
Demogr aphic and baseline char acteristics will  be summa rized. 
 
13.4.  Key Elements of Analysis Plan  
 
Data wil l be listed and summa rized accor ding to the Novartis  reporting  standards, wher e 
appli cable.  Complete  detail s will  be document ed in t he Reporting a nd Analys is Plan 
(RAP) .  Any de viations from, or  addit ions t o, the o riginal analy sis plan desc ribed in t his 
protocol will  be documented in the RAP and final stu dy report. 
 
As
 it is antic ipate d that accru al will be sp read thinly ac ross ce nters and su mmaries of  data 
by ce nter would be unlikely to be in formation, data f rom a ll participati ng centers will be 
pooled pr ior to analy sis. 
 
All data  up to t he time of  study completion/wi thdrawa l from s tudy will be included in the 
analy sis, regardless of  durati on of  treatm ent. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 82  
  
 
13.4.1. Pharmacodynamic Analyses 
 
13.4.1.1. Translational Resea rch Analyses  
 
The results of t ranslatio nal researc h investigations may be repo rted separately f rom the 
main cli nical study repor t (CSR).  All endpoints o f intere st from all com parisons  will be 
descriptively a nd/or  grap hically summa rized as appropria te to the d ata. 
 
Further details on the t ranslation al researc h analyse s will  be addresse d in t he Reporting 
and An alysis Plan (RAP). 
 
13.4.1.2. Nov el Biomarke r(s) Analyses  
 
The results of th ese biomarker investigations may be reporte d separately from the main 
clinical study report.  A ll endpoint s of inte rest from all comp arisons will be d escriptiv ely 
and/or g raphically summarized as appropriate to the data. 
 
Addit ional explor atory analyse s may be performe d to fu rther characterize the nove l 
biomarker. 
 
14. STUD Y CONDUCT CONSIDERATIONS 
 
14.1.  Posting of Infor mation on Clinicaltr ials.gov 
 
Study in formation f rom this protocol will  be poste d on publ icly availa ble cl inical trial 
registers before enr olment of subje cts begins. 
 
14.2.  Regulatory and Ethical Cons iderations, Including the  
Informed Cons ent Proce ss 
 
Prior to initiation of a  study site, the Coordinating Center will  obtain  approval from the 
appropri ate regulato ry agency to co nduct the stu dy in accordance with  International 
Conference on H armoni zation Good Cl inical Practice (I CH GC P) and appli cable 
country- specific re gulato ry requirements.  
The study will be conduc ted in accordance with a ll applic able regula tory requirements. 
The study will be conduc ted in accordance with  ICH GCP, a ll applicable subje ct priv acy 
requireme nts, a nd the eth ical prin ciples that a re outl ined in the Decla ration of  Helsinki 
2008, including, but not limi ted to:  
 
• I nstitutional re view  boar d (IR B)/ethics committee (EC) re view  and app roval of stu dy 
protocol and any subseq uent am endments  
 
• S ubject infor med conse nt 
 
• Inve stigator reporting r equirements  
 
The Coordinating Center  will provide full de tails of the  above  procedures, eith er verbally, 
in writing, or both.  
CONFIDENTIAL 
Version Date: February 12 , 201 6 83  
  
 
Written info rmed consent must be obt ained from each subj ect prior to pa rticipation i n the 
study. 
 
Protocol Review and Amendments  
Information regarding study conduct and progress will be reported to the Institutional 
Review Board (IRB) per the current institutional standards of each participating center.  
 Any changes to the protocol will be made in the form of an amendment and must be 
approved by the IRB of each institution prior to implementation.   
 
The Protocol Chair (or his designee) is responsible for the coordination and development 
of all protocol amendments, and will disseminate this informat ion to the participating 
sites. 
Before implementing this study, the protocol, the proposed informed consent form and other information to subjects, must be reviewed by a properly constituted Institutional Review Board/Independent Ethics Committee (IRB/IEC/REB). A signed and dated statement that the protocol and informed consent have been approved by the IRB/IEC/REB must be given to the Coordinating Center before study initiation. Any amendments to the protocol, other than administrative ones, must be approved by this committee.  
Amendments significantly affecting the safety of subjects, the scope of the investigation or the scientific quality of the study, require additional approval by the IRB/IEC/REB. A copy of the written approval of the IRB/IEC/REB, must be sent to the Coordinating Center.  
Amendments affecting only administrative aspects of the study do not require formal protocol amendments or IRB/IEC/REB approval but the IRB/IEC/REB of each site  must 
be kept informed of such administrative changes.  
 Protocol Deviations  
 
The Coordinating Center is responsible for implementing and maintaining quality assurance and quality control to ensure that studies are conducted according to the protocol, GCP, and all applicable regulatory requirements. A protocol deviation is any noncompliance with the protocol. Noncompliance can be on the part of the study 
participant, the Investigator, or the study site staff. Deviations to the protocol are not permitted except when necessary to eliminate an immediate hazard to study subjects.  
 
 
14.3.  Urgent Safety M easures  
 
If an eve nt oc curs that is related to t he conduc t of the stu dy or the  deve lopment of  the IP, 
and th is new  event is likely to affect the study of subjects, the Coordinating Center , and 
the investi gator wil l take appropriate urge nt safety mea sures to prot ect sub jects agai nst 
any immedi ate hazard. 
 
The Coordinating Center will work wit h the  investi gator to ensure the  Institutional re view 
board (IRB )/ethics committee (EC) is no tified.  
 
CONFIDENTIAL 
Version Date: February 12 , 201 6 84  
 14.4.  Quality Control (Study Monitoring)  
 
In accordance with appl icable re gulations,  Good Cl inical Practice (G CP) and t he 
Coordinating Center pro cedures, the si te will be contacted prior  to the start of the  study 
to review with the site sta ff the protoc ol, study re quirements, a nd their  responsi bilities to 
satisfy reg ulato ry, ethical, and t he Coordinating Center re quirements.  When reviewing 
data collection procedures, the discussion will  include  identification, ag reement and 
document ation of  data items for whi ch the elec tronic  case report for m (eCRF) will  serve 
as the so urce docu ment.  
 
During the course of the study, the Coordinating Center will routinely monitor sites for 
protocol compliance, compare CRFs with individual subjects’ original source documents, assess drug accountability, and ensure that the study is being conducted according to the pertinent regulatory requirements. The review of subjects’ medical records will be performed in a manner to ensure that subjects’ confidentiality is maintained. Investigators must agree to cooperate with the Coordinating Center to ensure that any  problems detected 
are resolved.   
 
Quarterly safety and monitoring reports are available to the Data and Safety Monitoring Committee (DSMC). The DSMC reviews all serious adverse events reported during the previous quarter for all clinical trials active at the VICC and makes recommendations to address concerns of patient safety.  
 A Quality Assurance auditor under the direction of the DSMC will audit this clinical trial quarterly for compliance with adverse event reporting, regulatory and studies requirements, and data accuracy and completion. Audit reports detailing the findings are provided to the DSMC. 
 
14.5.  Quality As surance  
 
To ensure  compliance wi th International Conference on H armoni zation Good Clini cal 
Practice (IC H GCP) and a ll applicable re gulato ry requirements, the Coordinating Center 
may conduc t quality a ssurance audit s of the  site.  Regulatory agenc ies m ay conduc t a 
regulato ry inspe ction at any time du ring or after completion of the stu dy.  I n the eve nt of 
an audit or inspe ction, the inv estigator (and inst itution) must  agree to grant the auditor (s) 
and inspe ctor(s) direct access to all r elevant docum ents and  to alloc ate their time a nd the 
time of their  staff to discuss any f indings/relevant issues.  
 
Study Documentation  
 Each participating site is responsible for submitting copies of all relevant regulatory documentation to the Coordinating Center. The required documents include, but are not limited to the following: local IRB approvals (i.e., protocol, consent form, amendments, patient brochures, recruitment m aterial, etc.), each participant’s informed consent, 
enrollment form, eligibility checklist, summary of unanticipated problems or protocol deviations, and documentation of expertise of the investigators. The Coordinating Center will provide each participating site with a comprehensive list of the necessary documents. It is the responsibility of the participating sites to maintain copies of all documentation submitted to the Coordinating Center.  
 
 
 
CONFIDENTIAL 
Version Date: February 12 , 201 6 85  
 14.6.  Study and Site Closure  
 
The end of  the stu dy will be defined as the d ate of the la st visit of the  last sub ject 
enrolled. 
 
Upon c ompletion or  termination of the  study, the monitor will conduc t site closure 
activit ies with the inv estigator or site sta ff (as appropriate), in a ccordance with applic able 
regulations,  International Conference on Ha rmoni zation Good Clini cal Practice (I CH 
GCP), and the Coordinating Center S tandard Op erating P rocedure s. 
 
The Coordinating Center re serve s the rig ht to tempo rarily suspend or  termin ate the  
study at any time for reasons inc luding (but n ot limite d to) unsatisfactory enrollment, 
GCP noncompliance, inaccurate or incomplete data collection, falsification of records, 
safety issues, e thical issues, or  nonc ompliance.  If t he Coordinating Center determine s 
that such acti on is r equired, the Coordinating Center will discuss the r easons f or taking 
such action wit h the inv estigato r or head of the medi cal institution (where appli cable).  
When feasible, the Coordinating Center will provide a dvance notice to the investigato r 
or head of t he medi cal institution of the  impe nding acti on. 
 
If a
 study is suspended or termina ted for sa fety reasons, the Coordinating Center will 
prompt ly inform all investi gators, h eads of t he medi cal institutions (whe re 
applicable),and/or i nstitutions conducti ng the stu dy.  The Coordinating Center wil l also 
prompt ly inform the relevant regulatory a uthorities of  the susp ension/ termin ation along 
with t he reasons for  such  action.  Where require d by applicable re gulations, the 
investigato r or head of the m edical institution must infor m the IRB/ EC prompt ly and 
provide the  reaso n(s) for the suspension/te rmination. 
 
The Coordinating Center may a lso close stu dy sites which  fail to recru it subj ects 
within a prede fined timeframe. 
 
 
14.7.  Recor ds Retention  
 
U.S. FDA regulations (21 CFR §312.62[c]) require that records and documents pertaining 
to the conduct of this study and the distribution of investigational drug, including CRFs, 
consent forms, laboratory test results, and medication inventory records, must be retai ned 
by each Principal Investigator for 2 years after marketing application approval. If no application is filed, these records must be kept 2 years after the study is discontinued and the U.S. FDA and the applicable national and local health authorities ar e notified.  
Following closure of the study, each participating center will maintain a copy of all site study records in a safe and secure location. The Coordinating Center will inform the Investigator at each site at such time that the records may be destr oyed.  
 
The investig ator must  notify the Coordinating Center of  any changes in the archival 
arrangeme nts, including, but not limi ted to arc hival of  records a t an o ff-site facility o r 
transfer of owne rship  of the r ecords in the  event tha t the investi gator is no longer  
associ ated with t he site. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 86  
  
14.8.  Provisi on of Study Results to Investigators, Posting of 
Information on Publicly Available Clinic al Trials Registers 
and Publication 
 
Whe re require d by applicable regulatory requireme nts, an inv estigator signa tory will  be 
identifie d for  the app roval of the  clinical study repor t.  The  investig ator wil l be p rovided 
reasonable ac cess t o statistical tables, figures, and re levant reports a nd will  have the 
oppor tunity to review the  complete stu dy re sults at a Novartis  site or  other  mutually- 
agreeable lo cation. 
 
Novartis  will also provide the  investi gator with the fu ll summa ry of the  study re sults.  
The investi gator is e ncourage d to sha re the summ ary re sults with the stu dy subj ects, as 
appropr iate. 
 
The results summary will be poste d to t he Novartis  Clinical Study Reg ister no la ter than 
eight months a fter the final prim ary c ompletion da te, the  date that the final sub ject w as 
examined or received an in tervention for the  purposes of  final c ollection of data for the 
primary outcom e.  In addit ion, a m anuscript will  be submi tted to a  peer reviewe d journa l 
for publi cation no lat er than 18 mont hs after the la st subject’s last visit  (LSLV ).  Wh en 
manus cript public ation in a peer reviewe d journa l is not fea sible, a statemen t will be 
adde d to t he register to explain the reason for  not publi shing. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 87  
  
 
15. REFERENCES 
 
Bahadoran, P., M. Allegra, e t al. (2013). "Ma jor C linical Response to a  BRAF Inhibi tor 
in a Patient With a BRAF L597R- Mutated M elanoma."  J Clin On col. 
Balag ula, Y., K. Ba rth Huston, e t al. (2011). "Der matolo gic side  effec ts associated wit h 
the MEK  1/2 i nhibi tor selumetinib (AZD6244, A RRY-142886) ." Invest New  
Drugs 29(5 ): 1114-1121. 
Berge r, M.  F., E. H odis,  et al. (2012). " Melanoma  genome seq uencing reveals frequent 
PREX2  mutations." Na ture 485(7399): 502 -506. 
Botton, T., I. Ye h, et al. (2013). "Recurre nt BRAF kinase  fusions in melanocytic tu mors 
offer a n oppor tunity for targe ted th erapy." Pigmen t Cell Melanoma R es. 
Ciampi, R., J. A. Knauf, e t al. (2005). " Oncoge nic AKAP9-BRAF f usion is  a nove l 
mechanism  of M APK pathway activati on in thyro id cancer." J Clin Invest 115(1 ): 
94-101. 
Dahlman, K.  B., J. Xia, e t al. (2012). "BRAF L59 7 mu tations in mel anoma a re associated 
with s ensitivity to M EK inhibitors."  Cance r Discov. 
Davies, H., G. R. Bignell, e t al. (2002). " Mutations of the BRAF ge ne in human cancer. " 
Nature 417(6892): 94 9-954. 
Eisenh auer, E. A., P. Thera sse, e t al. (2009).  "New response eva luation c riteria in sol id 
tumours: re vised RE CIST guideline  (version 1.1 )." Eur  J Can cer 45(2): 228-247. 
Falchook, G. S., K. D. Lewis, e t al. (2012). "Activity of the  oral MEK inh ibitor 
trametin ib in patients with a dvanced mel anoma: a  phase 1 dos e-escalation trial." 
Lancet O ncol 13(8 ): 782-789. 
Flaherty, K. T., J. R. Infante, e t al. (2012). " Comb ined BRAF a nd MEK  Inhibition in  
Melanoma with BRAF V600 Mutati ons." N E ngl J Med. 
Flaherty, K. T., C. R obert, et al. (2012). "I mprov ed surviva l with MEK inhib ition in  
BRAF-mutated m elanoma." N Eng l J Med 367(2 ): 107-114. 
Gilmartin, A. G., M. R. B leam, et  al. (2011). "GSK1120212 (JTP-74057) is an inhibi tor 
of MEK ac tivity a nd activati on with f avorable p harmacokinetic p roperties for 
susta ined in vivo pathw ay inh ibition." Cl in Can cer Res 17 (5): 989 -1000. 
Huncharek, M., J. F . Caub et, et al. (2001). "S ingle-agent DTIC versus com bination 
chemotherapy with or w ithout  immunotherapy in metastatic m elanom a: a meta- 
analy sis of 3273 patie nts from 20 r andom ized trial s." Melanoma Res 11 (1): 75- 
81. 
Hutchinson, K. E., L ipson D, Stephe ns PJ, e t al. (2013). "B RAF Fusions Define a 
Distinct Molecular  Subse t of M elanom as with Potential Se nsitivity to M EK 
Inhibiti on." Clinical Cancer Research 19(24): 6696- 6702.  
Infante, J. R., L. A. Fecher, e t al. (2012). "Safety, pha rmacokinetic, p harmacodynamic, 
and effi cacy da ta for the oral MEK inh ibitor trametin ib: a pha se 1 dos e-esca lation 
trial." Lancet O ncol 13(8): 773-781. 
Jing, J., J. G reshock, et al. (2012). " Comp rehensive pre dictive biom arker analy sis for 
MEK inhib itor GSK1120212." Mol C ancer Ther 11(3): 720-729. 
Jones, D. T., S. Koc ialkowski, et al. (2008). "Tande m dup lication producing a nove l 
oncogenic BRAF fusion gene de fines the majo rity of pilo cytic a strocytomas." 
Cancer R es 68 (21): 867 3-8677. 
Kim, K. B ., R. K efford, et al. (2013). "Phase II study of the  MEK1/ME K2 inhibitor 
Trametin ib in patients with meta static BRAF-mutant cut aneous m elanoma 
CONFIDENTIAL 
Version Date: February 12 , 201 6 88  
  
 
previous ly treated wit h or without a BRAF inh ibitor." J Clin On col 31(4 ): 482- 
489. 
Korn, E. L., P. Y. L iu, et al. (2008). " Meta-analysi s of ph ase II cooperative group tr ials in 
metastatic stage I V mela noma to d etermine progre ssion-free a nd overall survival 
benc hmarks for f uture pha se II trials." J Clin On col 26(4): 527-534. 
Krauthamme r, M., Y. Kong, et al. (2012). "Exome s equencing identifie s recurre nt 
somat ic RAC1 mutations  in melanom a." Na t Genet 44(9): 1006-1014. 
Lacoutur e, M. E., M. J . Anadkat, et al. (2011 ). "Cli nical practice g uideli nes for the 
prevention and tr eatme nt of EGFR inh ibitor-a ssociated dermatologic toxicities." 
Suppor t Care Cancer 19(8) : 1079-1095. 
Palanis amy, N., B. Ateeq, e t al. (2010). "Rear rangements of the  RAF  kina se pa thway in 
prostate  cancer, gastric cancer and mel anoma ." Nat Med  16(7 ): 793-798. 
Smalley, K. S., M. Xia o, et al. (2009). " CRAF  inhibition indu ces ap optos is in mel anoma 
cells with no n-V600E BRAF  mutations." On coge ne 28(1): 85-94. 
Wan, P. T., M. J. Ga rnett, e t al. (2004). "Mecha nism of activati on of  the RAF- ERK  
signaling pa thway by onc ogenic mutations of B-RAF." Cell 116(6): 85 5-867. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 89  
  
 
APPEND ICES 
 
Appendix 1 BRAF m utations by Cohort  
 
Cohort A – “High 
Activity”* Cohort B – “Low 
Activity/Unknow n” Excluded 
R462I G466E Concurrent BRAF V600E 
mutation 
I463S G466V Concurrent NRA S codon 
12, 13, or 61 mutation 
G464V D594V  
G464E G596R  
G466A All other  BRAF mutations  
G469A   
G469E   
N581S   
E486K   
F595L    
L597V    
L597S    
L597R    
L597Q    
T599I   
K601E   
A728V   
BRAF fusions/truncations   
*Defined by affinity for MEK phosphorylation in Wan et  al, Cell 2004. Mutations with 
documen ted responses to MEK inhibitors are also included 
CONFIDENTIAL 
Version Date: February 12 , 201 6 90  
  
 
Appendix  2 :  NYHA Functional  Classification System 
 
The New York Hea rt Associa tion (NY HA) Functional Classi fication: Class I, II, III 
or IV H eart Failur e [NYHA, 1994]  provides a  simple way o f classifying the extent of 
heart failu re.  It places subjects in one  of 4 categor ies based on the l evel of lim itation 
expe rienced during physi cal activity: 
 
Class  Symptoms 
Class  I 
(Mild)  No li mitation of  physical activity.  Ordinary physical activity 
does not cause undue fatigue, pa lpitation or dy spnea (shortne ss 
of breath). 
Class  II 
(Mild)  Slight limitation of  physical activity.  Co mfortable at rest, but  
ordinary phy sical activity results in f atigue, pa lpitation or 
dyspnea. 
Class  III 
(Mod erate) Marked limitation of p hysical activity.  Co mfortable at rest, but  
less than o rdinary phy sical activity re sults in f atigue , palpitation 
or dyspnea. 
Class  IV 
(Severe) Unable to carry out a ny physical activity without  discomfo rt. 
Symptoms of  cardi ac in sufficiency at rest.  If any phy sical 
activity is und ertaken, discomfo rt is increased. 
 
Refer ence: 
 
The Crite ria Committee of the  New York Heart Associ ation (NYHA).  No menclature and 
Crite ria for Diagnosis of  Dise ases of the  Heart and G reat Ve ssels. 9th Ed. Boston, Ma ss: 
Little , Brown  & Co.;  1994:253-256. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 91  
  
 
Appendix  3 :  COC KCROF T-GA ULT FOR MULA  
 
ClCr (mL/min) = Q x (140 - age [yr]) x i deal body weight [kg ]* 
72 x se rum c reatinine [ mg/dL] 
Q = 0.85 for females 
Q = 1.0 for males 
 
OR 
 
ClCr (mL/min) = K x (140 - age [yr]) x i deal body weight [kg ]* 
Serum creatin ine [umo l/L] 
K = 1.0 for fema les 
K = 1.23 for ma les 
 
 
 
*Calculation of Ideal Body Weight Using the Devine Formula [Devine, 1974] 
Ideal body weight: 
Males = 50.0 kg + (2.3 kg x each inch over 5 feet) or 50.0 kg + (0.906 kg x each cm over 
152.4 cm) 
Females = 45.5 kg + (2.3 kg x each inch over 5 feet) or 45.5 kg + (0.906 kg x each cm over 
152.4 cm) 
Example: Male, actual body weight = 90.0 kg, height = 68 inches 
Ideal body weight = 50.0 + (2.3) (68-60) = 68.4 kg. 
This s ubject’s actual body weight is >30% over ideal body weight. Therefore, in this case, the 
subject’s ideal body weight of 68.4 kg should be used in calculating estimated CrCl. 
 
Refer ence 
 
Devine,  BJ.  Case Numb er 25 Ge ntamicin T herapy: Clinical Pha rmacology Ca se Studies. 
Drug Intelligence a nd C linical Pha rmacy. 1974; 8:650-655 
CONFIDENTIAL 
Version Date: February 12 , 201 6 92  
  
 
Appendix  4:  ECOG Pe rformance Status  
 
Grade Descriptions  
 
0  
Normal ac tivity.  F ully active, a ble to carry on all pre- disease 
perfor mance without  restriction.  
 
 
 
1  
 
Symptoms, but ambulat ory.  Restr icted in p hysically strenuous 
activity , but ambulatory and a ble to carry out wor k of a  light or 
sedentary na ture (e.g., light house work, office wo rk). 
 
2 In bed <50% of the time.  Ambulato ry and capable of all self- 
care, but una ble to carry out a ny wo rk activit ies.  Up and about 
more  than 50%  of waking hour s. 
 
3  
In bed >50% o f the time.  Capable of  only limi ted self-care, 
confine d to bed or  chair more  than 50%  of waking hour s. 
 
4  
100% bedridden.  Co mpletely disab led.  Cannot carry on an y 
self-care .  Totally con fined to bed or  chair. 
5 Dead. 
 
 
Refer ence: 
 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J ., Davis, T.E., McFadden, E.T., 
Carbone, P.P .: To xicity And Response Crite ria Of The Eastern Co operative On cology 
Group. Am J  Clin On col 5:649-655, 1982.  
CONFIDENTIAL 
Version Date: February 12 , 201 6 93  
  
 
Appendix  5:  Liver Safety Drug Re start Guid elines  
 
Drug restart may be cons idered for  a subj ect exhi biting compell ing bene fit for a c ritical 
medi cine following  drug- induc ed live r inju ry, if the re is f avora ble bene fit: risk ratio and 
no alte rnative medi cine availa ble. 
 
Backgro und Information on  Dru g Restart/Rechallenge 
 
Following  drug- induc ed liver injury, dru g restart or  rech allenge is associa ted with a  
13% mor tality a cross a ll dru gs in  prospective  studies .1  Clinical outcomes v ary b y 
drug, with ne arly 50% fatali ty with halothane  readmi nistered in one month of init ial 
injury. However, some d rugs seldom  result in recurre nt liver injury or fatality.  Ri sk 
factors for a fatal drug restart/rechallen ge outcome includ e: hyperse nsitivity1 with i nitial 
liver inju ry (e.g. feve r, rash, eosinophil ia), jaundice or bilirubin>2xUL N or INR>1.5 
suggesting severe liver injury, prior IP-rela ted severe or fa tal drug restart/rechallenge2,3 or 
eviden ce of drug-re lated pre clinical liability / mitochondr ial impairment3. 
 
Drug Restart/Rechallenge Proce ss (also see Figure 1)  
 
1. Principal Inve stigator (PI) requests considerati on of drug restart for a subj ect 
receiving c ompelling bene fit from a critical or lif e-saving drug , who exhibits liver 
chemi stry elevation me eting subject stopping criteria, with no alte rnative treatme nt. 
 
2. Medical Moni tor & Cli nical Safety Phy sician.to r eview  the subj ect’s 
restart/rechallenge risk fac tors & c omplete ch ecklist (Table 1 ). 
 
Table 1. Checklist for drug restart/rechallenge for critical medi cine 
 
(Following drug-ind uced liv er injury, drug r echallenge is associat ed with 13% morta lity 
across  all drugs i n prospective studies) 
 Yes No 
Comp elling b enefit of the investigational product (IP) for this subject 
and no alternative therapy .  Provide brief explan ation:   
Relative benefit-risk favorable for drug  restart/rechallenge, after 
consideri ng the followin g high risk fact ors:   
• Initial liver injury event included:   
– fever, rash, eosinophilia, or hypersensitivity   
– or bilirubin>2xULN (direct bilirubin >35% of total)   
• Subject currently exhibits ALT >3xULN, bilirubin >2xULN (direct 
bilirubin >35% o f total, if available), or INR>1.5   
• Severe or fatal restart/rechallenge has  earlier been observed 
with IP If yes, please provi de br ief explanation :   
CONFIDENTIAL 
Version Date: February 12 , 201 6 94  
  
 
• IP ass ociat ed with know n preclinical h epatic liability/ inj ury 
 
 
 
 
3. If the Coordinating Center  provides w ritten a pproval for restart/rechallenge 
following  the above review, the Prin cipal I nvestigator (PI) must ensu re the  
followin g: 
 
• The PI is to obtain  Ethics Com mittee or  Institutional R eview  Board review  of 
drug re-initiation, a s required. 
 
• PI must  discuss the  possi ble b enefits and risks of drug re-initiation with t he 
subject. 
 
• The subj ect must sign in formed consent with a  clear description of possi ble 
bene fits and risks of dru g administration, includi ng recurre nt liver injury or death. 
Conse nt specifically f or the IP re start must be r ecorded in t he study cha rt. 
 
• The drug must  be reinitiated a t approved dos e(s). 
 
• S ubjects app roved by the Coordinating Center  for restart of IP must  return to the  
clinic twice a w eek for  liver chemi stry tests u ntil stable, liver  chemi stries h ave 
been demonstr ated and then l abora tory monitoring may re sume a s per protocol.  I f 
protocol de fined stopping c riteria for liver chemi stry elevations a re met, stu dy 
drug must  be stoppe d. 
 
• The Ethic s Committee or  Institutional R eview  Board is to be info rmed of  the 
subject’s outcom e, as req uired. 
 
• T he Coordinating Center  is to be notified of  any a dverse eve nts, as p er Section 
8.5.1.  
CONFIDENTIAL 
Version Date: February 12 , 201 6 95  
 
 
  
 
Novartis  proc ess for dr ug restart after possible drug- induc ed liver injury  
 
  
Subject exhibits liver injury on 
drug , while disease condition 
stable or improvin g 
 
Principa l Inves tigator reque sts the 
Coordinating Center ap prove drug readmin. 
with inves tigational product (IP) 
 
Medical Moni tor & C linical S afety Physicia n(s) to disc uss benefit: risk and : 
1 
Any fever, r ash or eosinophilia/h ypersen s. with init ial liv er inju ry 
subject? in this 
Bilirub in >2xULN  or INR>1.5  in this subject, suggesting failing liver? 
3 
Any prior severe/ fatal outcomes  reported on drug restart  with this drug? 
Any evidence of preclinical hepat ic liability/injury with this drug? 
Agree to allow IP reiniti ation wit h 
endo rsement  of  senior S afety an d 
Medicine s Development Phy sicians; 
Hepatotoxic ity Pan el available f or 
input 
 
Principa l Investigator promp tly infor med in writi ng of  
the Coordinating Center  decisi on to restart 
IP & dosing regimen 
PI to request drug restart a pprov al with Ethics Co mm. 
or In stitutional Review  Board, as required 
PI to discuss wit h subject the bene fits/risks of drug 
restart; subject con sent must be recor ded in chart 
Liver chemist ries obtaine d twice weekly until 
normal/stable 
PI to pr ovide restart o utcome  to Ethics Co mm. /IRB  
 The Coordinating 
Center  does not allow 
drug re initiation 
 
  
Principal 
Investigat or 
prompt ly informe d 
of decisio n to not 
restart 
investigati onal 
product 
 
 
References: 
 
1. Andrade RJ, Robles M, L ucena  MI. Rechallen ge in drug- induced l iver injury: the attractive hazar d. Expert Opin  
Drug Saf 2009;8:709–714. 
2. Papay JI, Cl ines D, Rafi R, Yuen N, Britt SD, Walsh JS, et al. Drug-induced liver injury following posi tive drug 
rechalleng e. Regul Toxicol Pharm acol 2009 ;54:84-90. 
3. Hunt  CM. Mitoch ondrial and immunoa llergic  injury increase r isk of positive  drug rechallen ge after drug- induced 
liver injury: a system atic rev iew. Hepatology  2010;52:2216– 2222  
CONFIDENTIAL 
Version Date: February 12 , 201 6 96  
  
 
Appendix  6 : QT interval on electrocardiogram corrected us ing the  Bazett’s 
formula  (QTcB) 
 
Bazett's formula used  to correct QT interva l for heart ra te is:  
 
QTcB =  QT 
RR 
 
where QTcB  is the QT i nterval correcte d for  heart rate, RR  is the interval from the onse t 
of one QRS  complex to the onse t of the  next QRS  complex, measured in s econds , often 
derived from the heart rate (HR) a s 60/HR, and Q T is the QT inte rval meas ured in 
milliseconds . 
 
Reference  
 
Baze tt HC.  An analy sis of the ti me-relations of  electrocardiograms.  Hea rt 1920; 7: 353- 
370. 
CONFIDENTIAL 
Version Date: February 12 , 201 6 97  
  
 
 
   
 
     
Appendix 7 – Medication Diary  
 
 Patient Name: _________________  Study ID : __________________  MRN:__________ 
Number of Trametinib Tablets Given: __  _     Pill Bottle(s) returned: Circle Yes  or No 
Total Daily Dose of Trametinib: ______    Number of Trametinib tablets returned ______ 
 
PLEASE FILL OUT AND BRING THIS SHEET AT YOUR N EXT VISIT  
 SPECIAL INSTRUCTIONS  
1. Trametinib should be taken by mouth on an empty stomach one hour before a meal or two hours after a meal with water only.  
2. Trametinib tablets should be refrigerated.  
3. If a dose of Trametinib is missed for more than 12 hours after a scheduled dose, wait until the next scheduled dose. Doses can be “made up” prior to the 12 hour limit.  
  
Cycle #: _________  # of Weeks _________ 
Day Medication  Date  Time  # of 2mg 
tablets 
taken # of 0.5mg 
tablets taken  Comments  
Example  Trametinib  01/01/2014  9:00 AM  1 0  
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
17       
18       
19       
20       
21       
22       
23       
24       
25       
26       
27       
28       
 Patient Signature: _________________________________________    Date: __________ 
CONFIDENTIAL 
Version Date: February 12 , 201 6 98  
  
Consenting Professional/Research RN Signature _________________   Date: ___________  
Consenting Professional/Research RN Comments:  
__________________________________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ __________________________________________________________________________  